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~ Abstract ~ 
 
Snake venoms are a rich and complex source of bioactive proteins and peptides. The 
proteomic variability of snake venoms introduces fascinating and complex investigations from 
a venom adaptational perspective, and the potency and specificity of these venom proteins lend 
promising potential for therapeutic applications. However, a significant knowledge gap exists 
in the proteomic and higher-order structural understanding of venom proteins, which poses a 
challenge for successful applications. The research in this thesis is focussed on probing 
ecological and structural biology questions surrounding snake venoms of medical importance 
from a fundamental protein structural level using mass spectrometry (MS)-based proteomics 
and native MS. This work contributes towards bridging the knowledge gap between venom 
protein structure and potential applications, and further expands knowledge of venom diversity.  
 
The venom composition of the Australian tiger snake Notechis scutatus was studied 
using a shotgun proteomics approach from five different geographical populations in response 
to the polymorphic and widespread geographical diversity exhibited by this species. Analysis 
of the five venom proteomes established a high degree of diversity in the various toxin groups 
identified in each population, and in particular, significant variations in relative abundance of 
3 finger-toxins appeared to be the greatest distinction across the five venoms. Venom 
proteomic variations between populations may be due to a diet prey-type influence although 
climate, seasonal, and intrinsic variabilities must also be considered.  
 
Quaternary structures of various venom proteins from a repertoire of medically 
significant venoms including Collett’s snake Pseudechis colletti, the forest cobra Naja 
melanoleuca, and the puff adder Bitis arietans were explored for the first time. Using a 
combined approach of proteomics, native and denatured MS, a 117 kDa non-covalent dimer of 
a minor toxin component L-amino acid oxidase in the P. colletti venom and a 60 kDa tetramer 
of a major toxin group C-type lectin in the B. arietans venom were identified amongst other 
components.  
 
A targeted, higher-order structural characterisation of phospholipase A2s (PLA2) in P. 
colletti venom by combined native and denatured MS analyses revealed a variety of monomeric, 




in P. colletti venom for the first time by MS, and these PLA2 species were also found to adopt 
a highly compact and spherical geometry based on ion mobility measurements of collision 
cross section. Importantly, further exploration of the catalytic efficiencies of the monomeric 
and dimeric forms of PLA2 using a MS-based PLA2 enzyme assay revealed that dimeric PLA2 
possessed substantially greater bioactivity than monomeric PLA2. This highlights the 
significance of quaternary structures in augmenting biological activity, and emphasises the 









1.1. Proteinaceous composition of snake venoms  
 
Snake venoms are complex, sophisticated, and largely unexplored cocktails of 
pharmacologically active proteins and peptides [1-7] that serve as a snake’s primary hunting 
tool, facilitating the immobilisation, killing, and digestion of prey [5, 8, 9]. For these purposes, 
venom proteins are often extremely stable (commonly due to unusually high numbers of 
disulphide bonds maintaining structural integrity), potent and specific even at low doses [1, 5-
7, 10, 11]. The proteins that constitute venoms can be generally categorised into two classes: 
enzymatic toxins and non-enzymatic toxins (Table 1.1). The former class contributes towards 
debilitating and often lethal effects of the venom as well as a speculated role in prey digestion. 
These enzymatic components often include toxin superfamilies such as phospholipase A2s 
(PLA2s), snake venom serine proteases (SVSPs) and metalloproteinases (SVMPs), L-amino 
acid oxidases (LAAOs), acetylcholinesterases (AChE), and various nucleotidases [5]; they are 
generally known to participate in disruption of cellular pathways involved in haemostasis, 




On the other hand, the class of non-enzymatic toxins is thought to be mainly responsible 
for prey immobilisation [7]. These include a diverse range of superfamilies such as 3-finger 
toxins (3FTxs), C-type lectins (CTLs), proteinase inhibitors (PIs), nerve growth factors (NGFs), 
natriuretic peptides (NPs), bradykinin-potentiating peptides (BPPs), cysteine-rich secretory 
proteins (CRISPs), vascular endothelial growth factors (VEGFs), and disintegrins (DIS) to 
name a few, all of which play different roles by interfering with the cardiovascular and 
neuromuscular systems [7, 12]. Venom composition is highly variable across different families 
of snakes, with viperid venoms known to be more abundant in enzymes while non-enzymatic 
toxins are more prevalent in elapid venoms [4]. However, it is the combination of these various 







Table 1.1. Protein families found in the majority of snake venoms, their abbreviations, and 
general function [2, 6, 13-19]. 
Protein Family Abbreviation General function 
Phospholipase A2 PLA2 Neuro- and myotoxin  
Snake venom serine protease  SVSP Haemorrhagin  
Snake venom metalloproteinase  SVMP Haemorrhagin 
L-amino acid oxidase  LAAO Cytotoxin 
Phospholipase B PLB Haemolysin  
Phosphodiesterase  PDE Speculated as a 
hypotension initiating 
enzyme 
Acetylcholinesterase  AChE Neurotoxin  
5ʹNucleotidase  5ʹNUC Platelet aggregation 
antagonist  
Hyaluronidase  HYAL Venom spreading 
factor (tissue 
destruction) 
3-Finger toxin 3FTx Neurotoxin  
Cysteine-rich secretory protein  CRISP Ion channel inhibitor 
Kunitz-type serine protease 
inhibitor  
KUN Anticoagulant protein 
C-type lectin CTL Platelet aggregation 
agonist and antagonist 
Disintegrin  DIS Platelet aggregation 
agonist and antagonist 
Nerve growth factor NGF Neurotrophic factor 
(neuronal 
maintenance) 
Venom factor VF Complement-
activating protein  
Complement protein Cʹ  Complement-
activating protein 




Bradykinin potentiating peptide BPP Hypotensive peptide 
Phospholipase A2 inhibitor  PLA2 INH PLA2 enzyme 
inhibitor 
Cystatin  CYS Speculated as a 
regulatory protein 
Vespryn  VESP Hyperalgesia-
stimulating protein 
Waprin  WAP Unknown function 
 
 
1.2. Pharmacological interest in snake venoms  
 
The potent pharmacological activities of snake venom proteins translate remarkably 
well into a therapeutic context; snake venoms have been regarded with fascination as a 
therapeutic source for traditional medicine and healing since Ancient Rome [12, 20-23]. 
However, it wasn’t until the late 19th century that growing endeavours to probe the composition 
of snake venoms truly commenced; this led to a paradigm shift from the previous notion of 
using whole venoms non-specifically to a more targeted approach towards understanding the 
proteinaceous nature of venoms [12]. Various venom proteins were noted to exhibit strong 
analgesic, antitumoral, antimicrobial, anticoagulant and procoagulant properties [1, 24]. Since 
then, research efforts have been underway to understand the toxicology of these venom 
constituents as well as their biochemical and pharmacological properties, and essentially 
harness their incredible therapeutic potential.  
 
Captopril is indisputably the first and most successful breakthrough in terms of a venom 
protein informing the design of peptide-mimetic therapeutic agents, and is unanimously 
acknowledged as the pioneer venom-derived drug since its release on the market in 1981 [7, 
20, 23, 25]. Heavily based on the bradykinin-potentiating peptide (BPP) found in the Brazilian 
pit viper (Bothrops jararaca) venom, Captopril was designed to treat hypertension and lower 
blood pressure by inhibiting the angiotensin-converting enzyme (ACE) that is responsible for 
the production of angiotensin which stimulates vasoconstriction [20, 25-27]. The success of 
Captopril inspired the search for more drug candidates in snake venoms; in 1998, disintegrins 
from the venoms of the south-eastern pigmy rattlesnake (Sistrurus miliarius barbouri) and saw-




Eptifibatide and Tirofiban, which are used to treat acute coronary syndrome by binding to 
GPIIB/IIIA integrin receptors present on blood platelets and preventing thrombus formation [7, 
20].  
 
The initial successes of these drugs have led to a growing influx in venom-derived drug 
candidates over the past ten years, where many studies have probed at the venom components 
that are responsible for the myriad of biological effects (with potential therapeutic applications) 
that are well-recognised in various snake venoms [1, 24]. Examples include the antitumoral 
properties elicited by 3FTx proteins from cobra venoms [28], and antimicrobial activities 
exhibited by PLA2, SVMP, and LAAO proteins from various snake venoms [29]. Notably, 
3FTxs known as mambalgins from the black mamba (Dendroaspis polylepis polylepis) have 
also demonstrated potent analgesic properties [30]. Many of these proteins show great promise 
in a pre-clinical trial context, however, the significant challenge of ensuring that the success of 
these venom-derived drug candidates carries through clinical trials and into the market remains 
to be overcome. 
 
 
1.3. Ecological interest in snake venoms 
 
While snake venoms garner tremendous pharmacological interest, the ecological 
premise for studying venoms is also significant as it relates back to the original predatorial 
purpose of snake venoms as a foraging tool; venom diversity is of particular interest. As a 
predatory venom, the composition of snake venoms is highly complex and variable; this often 
results in extraordinary diversity in venom toxicity at different levels of taxa [31]. Increasing 
advances in the “venomics” field which integrates genomic, transcriptomic, and proteomic 
approaches to studying whole venom profiles have enabled better understanding of venom 
variability in response to the various ecological factors and selection pressures that are thought 
to drive venom adaptation [11, 32].  
 
Geographical distribution is known to have an influence on venom variability [33, 34]. 
Similarly, the sex of the snake can also affect venom compositions even within the same species 
[35], as can age where variability is noted between juveniles and adult snakes [34, 36]. Notably, 
diet has also been shown in some cases to act as a strong selection pressure where venoms have 
been optimised for different prey acquisition [32, 37]; from simply an overall enhanced venom 




mangrove snake (Boiga dendrophila) for its bird-specific diet, numerous studies have 
illustrated the variable degree of venom adaptation that is present in nature [37]. These 
geographical, sex-, age-, and diet-related variations can all impart influence on the diversity of 
snake venoms [31, 33-37].   
 
Implications of such venom diversity are severe when considering the efficacy of 
human antivenom, and thus drive characterisation of venom variability and its associated 
factors. As antivenom consists of antibodies purified from blood plasma of animals that have 
been hyperimmunised with a specific snake venom, the efficacy of the antivenom is largely 
restricted towards the species of snake it was raised against [31]. Since the antivenom only 
neutralises critical epitopes or recognition sites on the venom components that initially 
triggered a strong immune response in the animal, antivenom treatment is thus rendered 
essentially ineffective even for very similar species of snakes if venom variability alters the 
critical epitopes. Given the fact that snake envenomation is responsible for at least 94 000 
deaths and many thousands more cases of morbidity annually worldwide [38], a comprehensive 
understanding of the variability in venom compositions is critical in order to support better 
development of effective antivenoms.  
 
 
1.4. Challenges from pharmacological and ecological aspects 
  
In spite of the research endeavours occurring in both pharmacological and ecological 
areas, significant roadblocks exist in both fields. From a pharmacological perspective, the 
majority of the drug candidates that may have appeared promising in pre-clinical studies are 
unable to successfully pass evaluation during clinical trials and consequently, are not released 
into the market  [20]. A myriad of contributing factors can be considered but the discontinuation 
of many of these pharmacological investigations is mainly due to the reported high levels of 
toxicity and lack of efficacy, drug stability as well as low bioavailability [1, 20]. These issues 
ultimately stem from insufficient knowledge of the pharmacological and biochemical effects 
of these venom components. This can be further traced back to a distinct knowledge gap in the 
fundamental understanding of the structure-function relationships between these venom 
components, in particular higher-order synergistic interactions of venom proteins that are 





From an ecological perspective, while efforts to catalogue the venom proteomes of 
certain species are admirable, there is still a tremendous knowledge disparity in the current 
understanding of venom composition and the ecological factors speculated to influence venom 
variability. The sheer number of different venomous species and the great array of protein 
variants coupled to the finer ecological pressures render venomic characterisation to be a 
difficult, labour-intense challenge [32].  
   
The issues here can be further distilled down to a lack of understanding of snake venoms 
from a fundamental protein structure perspective. There are four fundamental levels of protein 
structure (Figure 1.1): the primary structure which is the amino acid sequence that dictates the 
protein identity and the manner it will fold, secondary structure in which hydrogen bonding 
within the protein backbone gives rise to beta sheets, alpha helices and turns. Tertiary structure 
is the three-dimensional folding that arises from interactions between amino acid functional 
groups, and quaternary structure which is the higher-order association between smaller protein 
subunits to form larger protein complexes that are held together by either non-covalent or 
covalent interactions such as disulphide bonds [40].  
 
 
Figure 1.1. The four levels of protein structure: primary structure is the amino acid sequence 
that dictates the protein identity and fold. Secondary structure arises from protein backbone 
hydrogen bonding to form α-helices, β-sheets and turns. Tertiary structure arises from three-
dimensional folding of the protein due to interactions between the amino acid functional groups, 
and quaternary structure is the association of protein subunits into larger complexes. Figure is 
modified from [40]. 
 
The aforementioned ecological and pharmacological issues regarding the lack of 
understanding of snake venom proteins arise predominantly at either ends of the protein 




the primary structure level where existing catalogues of amino acid sequences are limited and 
insufficient to generate a comprehensive understanding of venom proteomes from snake of 
interest. In addition, many of these proteins are known to possess complex, variable post-
translation modifications (PTMs) such as glycosylation, which offer great diversity to protein 
function and further contribute another complicated aspect to venom proteins that requires 
characterisation [41, 42]. The advent of “omics” technology has certainly enabled a more 
thorough understanding of venom proteomes by facilitating high-throughput identification of 
various venom protein amino acid sequences and quantification of venom protein abundance 
[1, 22]. There remains, nonetheless, an immeasurable array of proteins yet to be characterised 
in order to enable our understanding of the venom diversity exhibited by many venomous snake 
species along with the possible ecological factors driving these changes.  
 
At the quaternary structure level, many of the higher-order protein complexes that are 
increasingly speculated to play a dominant, synergistic role in directing venom potency and 
specificity remain largely unexplored for many venoms [6]. Recognition of this knowledge gap 
has driven limited research efforts to study these often non-covalent interactions in venoms; 
the heterodimeric PLA2 crotoxin [43], dimeric 3FTx κ-bungarotoxin [6, 44], and 
heteropentameric PLA2 complex textilotoxin are some celebrated examples of successful 
higher-order structure elucidation [2, 6]. Despite these successes, however, characterisation of 
these interactions is still in the early developmental stages considering the plethora of venom 
proteins in the sheer number of medically significant snakes that require characterisation. 
Moreover, high-resolution techniques such as x-ray crystallography and nuclear magnetic 
resonance (NMR) spectroscopy have been the predominant structure elucidation methods used 
in these studies [45]; while these techniques yield structural information at an atomic-level 
which has been considered very useful in structure-based drug design, they may have difficulty 
capturing the often dynamic and heterogenous nature of larger oligomeric venom proteins that 
may exist at low abundances, particularly in a high-throughput manner [46-49]. Thus, new 
approaches towards understanding the quaternary structure of these venom proteins are also 








1.5. Methodology  
 
Mass spectrometry (MS) based techniques such as shotgun proteomics and native ion 
mobility-mass spectrometry (IM-MS) have emerged as powerful analytical tools for the 
investigation of many biological questions. Due to the powerful analytical contributions of 
these two techniques in proteomic sequencing and higher-order protein structure determination, 
MS based methods are utilised here to address knowledge gaps identified in the respective 
ecological and pharmacological contexts regarding snake venoms. Fundamentally, MS is a 
technique that generates, differentiates, and measures ions in the gas phase, and enables 
determination of molecular mass and structural information of molecules in a sensitive and 
high-throughput manner.   
 
1.5.1. Electrospray ionisation  
 
Electrospray ionisation (ESI) is the key ionisation technique utilised in the work in this 
thesis to introduce protein samples from liquid to gas-phase in the mass spectrometer.  The 
sample is pulled from the tip of a conducting capillary by an applied potential difference 
towards the inlet of the mass spectrometer as a fine mist of charged droplets. These charged 
droplets shrink in size as solvent is evaporated by heating and drying gas until the surface 
tension holding the charged droplet together is overcome by the Coulombic repulsion between 
the charges on the droplet surface, and the droplet fissions [50]. The result of repeated fission 
events and solvent evaporation is the generation of an analyte ion (Figure 1.2). A combination 
of organic solvents, acids and high temperatures is typically used to assist desolvation and ion 
generation; however, these conditions can be quite harsh and not necessarily compatible for 
native MS studies that aim to capture non-covalent protein complexes [51]. Nanoelectrospray 
ionisation (nanoESI) is the variation of ESI that is often employed for native MS analysis of 
intact proteins in their native-like, folded and functional state [48, 51]. NanoESI allows the use 
of smaller sample volumes and reduces flow rate which generates smaller initial sample droplet 
sizes. Subsequently, sensitivity is increased and allows the proteins to be analysed in neutral 
aqueous buffers such as ammonium acetate that further preserves the proteins in their native-
like state. Importantly, this retains any non-covalent interactions present, as opposed to the 






   
 
Figure 1.2. Electrospray ionisation process of an analyte. The analyte is pulled from the tip of 
the capillary by an applied electrical potential to form a charged droplet containing analyte ions 
which shrink as solvent is evaporated. Coulombic repulsion overcomes the surface tension of 
the droplet and results in droplet fission; an analyte ion is generated after multiple droplet 
fission events and solvent evaporation.  
 
Different and often hybrid mass analysers are coupled to ESI to differentiate and detect 
the generated ions. The linear trap quadrupole Orbitrap (LTQ-Orbitrap) and quadrupole-ion 
mobility-time of flight (Q-IM-TOF) mass spectrometers are highlighted as two key examples 
of the various instrument configurations that are frequently used for different types of MS 
based analyses; they are also the predominant instrumentation employed for work described in 
this thesis.  
 
1.5.2.  LTQ Orbitrap mass spectrometer  
 
The LTQ-Orbitrap mass spectrometer is a powerful tool that offers high resolution, 
sensitivity, and mass accuracy (Figure 1.3) [53, 54]. A key component is the hybrid LTQ-
Orbitrap mass analyser; ions are first accumulated by the linear trap quadrupole (LTQ) sector 
where a set of four parallel rods known as a quadrupole confines the generated ions radially by 
application of a 2D radio frequency (RF) field as well as axially by stopping potentials applied 
to the electrodes [55]. Ions are then injected into the Orbitrap mass analyser which is composed 
of a central spindle-like electrode surrounded by two bell-shaped outer electrodes. Ions are 
electrostatically confined to orbit the central electrode; depending on the electric field applied, 
the ions will oscillate harmonically and separate into rings along the electrode based on their 







Figure 1.3. Schematic representation of the LTQ XL Orbitrap mass spectrometer. Samples are 
introduced into the mass spectrometer by electrospray ionisation (ESI); the generated ions are 
trapped by the LTQ component, separated and analysed in the orbitrap sector based on the m/z 
ratios of the ions. Fragmentation of ions by collision induced dissociation (CID) can occur in 
the collision cell for tandem mass spectrometry.  
 
The high resolution, sensitivity and mass accuracy of LTQ Orbitrap mass analysers 
often make these instruments desirable for performing tandem MS (MS/MS) experiments to 
further acquire more detailed structural information, where separated mass-selected ions 
undergo fragmentation by collision-induced dissociation (CID) with noble gas molecules in the 
collision cell of the instrument. The precursor ions (MS1) are subsequently cleaved into 
fragment ions (MS2), which are measured by their m/z values at the detector [56]. 
Fragmentation patterns of the precursor ion can impart further structural information for the 
molecule; in the context of proteins and peptides, amino acid sequences can be determined in 
this manner based on sequential mass loss corresponding to amino acid residues, and this 
establishes the basis of MS based proteomics such as bottom-up proteomics approaches, used 
to identify and quantify proteins in biological samples.  
 
 
1.5.3. Shotgun proteomics  
 
Shotgun proteomics is a variant of bottom-up proteomics that enables protein 
identification and possible quantification of relative abundance without the need to use 
chemical labelling [57]. The general workflow of the proteomic experiment is illustrated below 
(Figure 1.4), where the protein mixture of interest is isolated from the biological source and is 




arginine and lysine amino acid residues [58-60]. Digested peptides are then separated by liquid 
chromatography (LC) before analysed by MS/MS as described above.  
 
The protein identities and their relative abundances can then be determined by 
performing a protein database search using a bioinformatic pipeline where an in silico 
proteomic workflow is performed for each protein in an existing database to afford a theoretical 
peptide list with corresponding fragment ions for each protein. The experimentally acquired 
peptide sequences are compared to those that are theoretically acquired based on the precursor 
mass and fragment ion list; a protein match is evaluated as a statistically valid hit by how well 
the experimental spectral data matches the theoretical [59].  
 
Figure 1.4. A general bottom-up proteomics workflow as applied to snake venom. Proteins are 
digested into peptides by the enzyme trypsin before being separated by liquid chromatography 
and analysed by tandem mass spectrometry. Protein identification and label-free quantification 
are performed by matching experimentally determined protein sequences to existing sequence 
libraries in a database using a bioinformatic pipeline.  
 
 
Aside from protein identification, shotgun proteomics also enables quantification of the 
relative abundance of proteins without chemical labelling (label-free quantification, LFQ). The 
relative abundance of proteins is generally determined either by integrating the area under an 
ion peak from the MS1 spectra, or spectral counting of the MS2 spectra for a given protein, of 
which the former approach is generally more widely utilised due to improved accuracy [57, 59, 
60]. The combination of qualitative and quantitative analytical capabilities renders shotgun 
proteomics an insightful technique to characterise venom composition as well as to supplement 







1.5.4. Q-IM-TOF mass spectrometer  
 
Q-TOF mass analysers are also hybrid mass analysers that are conventionally used for 
protein analysis. The versatility of this configuration also enables Q-TOF MS to be coupled to 
another separation technique known as ion mobility (IM) separation, and the Synapt G1 mass 
spectrometer is a prime example of this type of instrument.  In the Q-IM-TOF configuration 
(Figure 1.5), ions are first selected in the quadrupole based on the analyte ion’s m/z ratios under 
a certain radio frequency (RF) voltage applied between opposing pairs of metal rods; only ions 
possessing a specific m/z ratio under the certain applied voltage will have a stable trajectory 
through the quadrupole, while other ions with unstable trajectories will collide with the parallel 
rods [50, 61].  
 
 
Figure 1.5. Schematic representation of the Synapt G1 HDMS quadrupole-ion mobility-time 
of flight (Q-IM-TOF) mass spectrometer. Samples are introduced into the mass spectrometer 
under soft ionisation conditions by nanoelectrospray ionisation. The ions are transmitted 
through the quadrupole, further separated by travelling wave ion mobility separation, and 
analysed in the time-of-flight sector based on the mass-to-charge (m/z) ratios of the ions.  
 
 
The successfully selected ions can then undergo travelling wave ion mobility separation 
(TWIMS) in the drift cell. Here, the charge and size of an ion influences its mobility through a 
region of neutral buffer gas when under the influence of a weak electric field applied during 
IM separation [49, 62, 63]. Subsequent analysis of the ions is performed by the TOF component 




known strength and distance. The time taken for an ion to travel through this drift region and 
reach the detector can be measured and related back to the velocity of the ion which is 
dependent on its m/z ratio [50, 61]. The Q-IM-TOF configuration offers multi-dimensional 
separation of ions and greatly lends itself to the field of native ion-mobility mass spectrometry 
(IM-MS) in the analysis of quaternary protein structures and interactions.  
 
1.5.5. Native ion-mobility mass spectrometry  
 
Native ion-mobility MS (IM-MS) is a technique that combines the mildness of nanoESI 
and the multi-dimensional separation imparted by the Q-IM-TOF configuration. It has emerged 
as a powerful biophysical technique that contributes to the higher-order protein structural 
knowledge gap as soft ionisation conditions preserve any non-covalent complexes of interest, 
and the addition of IM separation lends another degree of separation and structural 
characterisation to the native MS analysis. Larger, more extended and unfolded protein 
structures are known to take longer to traverse the drift cell as they are hindered by more 
frequent collisions with the neutral gas molecules in the cell; these ions would thus possess a 
longer drift time than a protein ion that is smaller and more compact [49]. Collision cross 
section (CCS) values, which are an inherent physical property of the measured ion that infers 
structural geometry of the molecule, can be calculated from these drift times, which is valuable 
for studying the shape, size, and various conformations proteins can adopt [49, 64].   
 
In previous studies, IM-MS has shown its potential in the successful characterisation of 
various multiprotein assemblies and their topologies [49, 65, 66], but is still in relatively early 
stages in the context of venom protein characterisation where it has only been applied to study 
phospholipase A2s (PLA2s) from the  eastern brown snake (Pseudonaja textilis) and the 
Australian taipans (Oxyuranus spp.)  [66, 67].  The speed and sensitivity of IM-MS data 
acquisition, ability to maintain proteins in native-like states, unrestricted by protein size, and 
capability to capture transient protein interactions are all factors that make native IM-MS an 
appealing technique to help characterise higher-order oligomeric protein species in venoms  








1.6. Characterisation of snake venoms by mass spectrometry  
 
In this project, we aim to apply MS based techniques to structurally characterise 
proteins in medically significant snake venoms that are both exotic and native to Australia. We 
firstly aim to contribute towards venom adaptational curiosities, investigating the differences 
in the venom proteomes of the geographically and morphologically diverse Australian tiger 
snakes (Notechis scutatus). Next, characterisation of higher-order venom protein complexes 
will be conducted for a small, phylogenetically diverse repertoire of venoms from medically 
important yet underexplored snakes, namely the Collett’s snake (Pseudechis colletti), forest 
cobra (Naja melanoleuca), and the puff adder (Bitis arietans). Finally, further structural and 






~ Chapter 2 ~ 
Proteomic Variations Between Venoms of Different Populations of 
Notechis scutatus (Australian Tiger Snake) 
 
2.1. Introduction 
2.1.1. Ecological significance of N. scutatus  
 
There is considerable ecological and adaptational fascination surrounding N. scutatus, 
which stands out as being the most widely distributed species of all Australian elapids and 
inhabits the South-West and South-East regions of mainland Australia as well as a few 
Southern off-shore islands [3, 68]. Prior to approximately 10 000 years ago, a continuous 
stretch of N. scutatus populations was thought to have extended from regions of Western 
Australia all the way to Queensland; however, the inundation of the South Australian coastal 
plains by rising sea levels fragmented this population into isolated pockets [3, 68]. From an 
ecological perspective, N. scutatus became a fascinating model because the resulting mainland 
and insular island populations developed very distinct morphological traits.  
 
N. scutatus is a single polymorphic species, which displays striking differences in body 
size and colour between mainland and island populations. Mainland N. scutatus are relatively 
consistent in body size, ranging in colouration, from tan and olive to brown, with distinct 
crossbands along their backs [68-70]. In contrast, most island N. scutatus are completely black 
and can vary significantly in body size with both dwarves and giants found on different islands 







Figure 2.1. Morphology of (A) mainland N. scutatus and (B) island N. scutatus. Image 
attributions: “Notechis scutatus (Peters, 1861), Tiger Snake” by David Paul is licensed under 
CC BY-NC 4.0.   
 
Previous taxonomical classifications were predominantly based on morphology, hence 
there has been long-standing contention over whether island populations represent a separate 
N. scutatus subspecies [68-70, 72]. This classification was debated until a more recent study 
demonstrated minimal genetic divergence occurred between the different populations and 
therefore concluded that N. scutatus was in fact a single, albeit highly polymorphic, species 
[72]. The genetic similarity contrasted by the very different morphology observed for various 
N. scutatus populations suggests potential adaptation in protein expression, which could arise 
from different prey types and other environmental influences [31].  
 
2.1.2. Geographical variations in N. scutatus venom composition  
  
Given the morphological variability between different populations of N. scutatus, we 
predicted that differences in phenotype could extend to the level of venom composition. 
Understanding intra-species variations in venom proteomes of different N. scutatus populations 
is not only of ecological significance, but may have important clinical implications for the 
treatment of snakebites. Significant variations in N. scutatus venom composition and 
subsequently venom activity could influence antivenom efficacy, which can have serious 
clinical consequences as N. scutatus antivenom is used to neutralise the snakebites of not only 
N. scutatus, but also other species within the Notechis clade including Austrelaps, 
Hoplocephalus, Tropidechis carinatus, and Pseudechis porphyriacus [3]. The aim of this 




populations. In this study, venoms from age-matched male N. scutatus were sourced from 
populations in Melbourne, Mount Gambier, Tasmania, Franklin Island, and Reevesby Island 
(Figure 2.2).   
 
Figure 2.2. Geographical populations from which the venoms of adult male N. scutatus were 
sourced for this study: Franklin Island (purple), Reevesby Island (blue), Mt Gambier (green), 
Melbourne (orange), Tasmania (red). 
  
N. scutatus are generalist predators, being indiscriminate with their prey types and often 
feeding on a combination of ectothermic prey, such as anurans and small reptiles, as well small 
endothermic mammals and occasionally birds [3, 69, 73]. However, the geographically 
fragmented nature of N. scutatus populations restricts prey type availability, and distinctions 
in the prey types consumed by different N. scutatus populations have been noted [68, 69, 73]. 
Of the five populations in this study, Franklin Island and Reevesby Island N. scutatus have 
been observed preying on additional local prey types that are unavailable for mainland 
populations. For example, Franklin Island N. scutatus also feed on large mutton bird chicks 
(Thomson et al., unpublished fieldwork observations, 2018). This may be an important driver 
for diversification of the venom proteome.  
The research presented in this chapter details the investigation of proteomic variations 
of five N. scutatus venoms, for which a shotgun proteomics approach was utilised to analyse 
venom composition. A focussed quantitative analysis was also conducted for two South 





2.2. Results and discussion  
2.2.1. Venom complexity analysis by 2D gel electrophoresis  
 
To first visualise the general complexity of N. scutatus venoms, crude whole venoms 
of two male N. scutatus from each of the five geographical regions were pooled in a 1:1 ratio 
(dry weight). The protein components were separated using 2D sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), and visualised by silver staining (Figure 2.3).  
 
 
Figure 2.3. 2D SDS-PAGE analysis of whole N. scutatus venom from five populations in 
Australia: (A) Franklin Island, (B) Reevesby Island, (C) Melbourne, (D) Mt Gambier, and (E) 
Tasmania, visualised by silver staining. 
 
Proteins were first separated along a pH gradient based on the charge of the protein 
using isoelectric focusing, where the proteins migrate to and are maintained at a position on 
the pH gradient that equates the isoelectric point of the protein. Proteins were then separated 
based on their molecular weight by gel electrophoresis where proteins with a lower molecular 
weight migrate through the gel faster than higher molecular weight proteins. Thus, separation 
patterns of whole venoms by 2D SDS-PAGE afforded an overall preliminary picture of the 
venom complexities and proteomic diversity, where protein groups of varying molecular 
masses are distinguished based on their clustering in the gel, and horizontal trains of spots in 




Consistent with the broad mass range of proteins that is characteristic of N. scutatus venom 
[74, 75], four major protein clusters were generally categorised based on their molecular mass: 
high (>100 kDa), intermediate (50 – 70 kDa), intermediate-low (20 – 30 kDa), and low (9 – 16 
kDa) molecular weight proteins.  
These four protein clusters were identified in all five venoms, albeit at varying 
abundances and displaying various isoforms, which are indicated by the protein spot intensity 
and the horizontal trains of spots in the gels [74], respectively. Basic, high molecular weight 
proteins were present at approximately pH 10 for all five venoms.  A cluster of neutral 
intermediate molecular weight proteins appeared to be abundant across the five venoms, with 
more variety observed for the Tasmanian venom. Neutral, intermediate-low molecular weight 
proteins were also found in the majority of venoms. The gel profile for the Franklin Island 
venom was more distinctly complex within this molecular weight range, in which more basic 
proteins were noted, compared to other venoms. Various isoforms of low molecular weight 
proteins were also observed in all five venoms at varying abundances. An intense cluster of 
protein spots at approximately pH 10 for the Franklin Island venom suggests abundance of 
more basic isoforms in this low molecular weight range. Overall, crude fractionation via 2D 
SDS-PAGE demonstrated that N. scutatus venom proteomes are quite diverse and complex, 
including a range of large to small proteins with various potential isoforms. However, the 
venom proteomes of the five populations appeared to be generally similar, despite some 
variations in protein abundance and isoforms (Figure 2.3).  
 
2.2.2. Qualitative proteomic analysis reveals diversity of N. scutatus venoms  
 
Whole venoms from each of the five populations were digested with trypsin and 
analysed by LC-MS/MS. Duplicate experiments were conducted for each biological replicate 
to afford four replicates per population; restricted physical access to a greater number of 
biological replicates thus limited this study to a relatively modest sample size. Proteins in the 
venom samples were then identified by database searching using the protein identification 
search engine Mascot (Matrixscience), where the experimentally generated peptide sequences 
in the mass spectral data files were matched against existing peptide sequences in the protein 
database. The data was searched against all Chordata entries present in the Swiss-Prot database 
with the significance threshold set as P-value < 0.05 to ensure the exclusive inclusion of the 




during this filtering process, and the protein matches from all four replicates for each N. 
scutatus population were pooled together for further qualitative analysis. As this study was 
focussed on toxin components (TOXINs) of the venoms, cellular (CELL) and uncharacterised 




Within each N. scutatus population, the number of pooled toxin hits were then counted 
and categorised for a given toxin family based on their toxic mode of action in the venom.  It 
should be noted that given the nature of database searching, the same peptide sequence may 
have been matched to very similar proteins but across different snake species during the 
analysis. As this section of the study only presents a very general and qualitative proteomic 
perspective of the whole venoms, these protein hits that share the same peptide sequence but 
possess different homologies were all included in Appendix A. However, recurring protein hits 
(identical protein accession codes) in the four replicates within each N. scutatus population 
were only counted once during the analysis (Appendix A). For qualitative proteomic purposes, 
the protein families identified for each population in Appendix A are summarised in Table 2.1 
as simply being present or absent in the five N. scutatus venoms, denoted by the respective tick 




Table 2.1. Protein families identified in whole venoms from five N. scutatus populations.  









✓ ✓ ✓ ✓ ✓ 
Serine protease 
(SVSP) 
✓ ✓ ✓ ✓ ✓ 
Metalloproteinase 
(SVMP) 
✓ ✓ ✓ ✓ ✓ 
L-amino acid 
oxidase (LAAO) 




✓ ✓ ✓ ✓ ✓ 
Nerve growth factor 
(NGF) 
✓ ✓ ✓ ✓ ✓ 
3-Finger toxin 
(3FTx) 





The total toxin hits for each population are further summarised in Figure 2.4 which 
represents a preliminary and qualitative comparison of venom diversity. The protein hits 
belonging to the same protein group, for instance PLA2, for a given N. scutatus population are 
counted and categorised into one toxin group, shown as one coloured wedge in Figure 2.4.  Of 
note, the size of the protein family proportions represented in Figure 2.4 is not representative 
of relative protein abundance; rather, as mentioned previously they show the number of protein 
hits within protein superfamilies of a specific toxic function (denoted by coloured wedges) that 








✓ ✓ ✓ ✓ ✓ 
Natriuretic peptide 
(NP) 
✓ ✓ ✓ ✓ ✓ 
5ʹnucleotidase 
(5ʹNUC) 
✓ ✓ ✓ ✓ ✓ 
Acetylcholinesterase 
(AChE) 
✓ ✓ ✓ ✓ ✓ 
Vespryn (VESP) ✓ ✓ ✓ ✓ ✓ 
Complement factor 
(Cʹ ) 
✓ ✗ ✗ ✓ ✗ 
Venom factor (VF) ✓ ✗ ✗ ✓ ✗ 
Phosphodiesterase 
(PDE) 
✓ ✗ ✓ ✓ ✗ 




✗ ✗ ✗ ✓ ✗ 
Cystatin (CYS) ✗ ✓ ✓ ✓ ✗ 
Hyaluronidase 
(HYAL) 





Figure 2.4. Toxin protein families identified in the venoms of five N. scutatus populations: (A) 
Franklin Island, (B) Reevesby Island, (C) Melbourne, (D) Mt Gambier, and (E) Tasmania 
(n=2).  
 
Proteomic analysis revealed that all five venom proteomes share similar components, 
which is not unexpected given they are from the same species. The overall venom proteome of 
N. scutatus, disregarding populational variations, is diverse with numerous protein 
superfamilies identified across the five venoms. For reference, the terms “diversity” and 
“complexity” will be used frequently in text here, and in this context will be designated in 
reference to the number of different protein superfamilies present in the venom and to the 
number of individual proteins, respectively.  
 
20 different protein families were identified across the five populations, with the 
majority congruent across all five proteomes. The majority of these families identified by 
shotgun proteomics can be categorised based on their molecular weights which correspond 
closely to the clusters observed in the 2D gels (Figure 2.3). Abbreviations for the venom protein 
families may be referred to in Table 2.1. High molecular weight toxins included PDE, VF, and 
Cʹ while SVSP, SVMP, LAAO, PLB, 5ʹNUC, and AChE were categorised as the intermediate 
molecular weight toxins. Intermediate-low molecular weight toxins included NGF, CRISP, 
VESP, and low molecular weight toxins such as KUN, PLA2, 3FTx, and NP were also 





Despite their overall similarities in major toxin families identified, slight variations in 
venom diversity were noted across the populations. Notably, Mt Gambier and Franklin Island 
venoms were the most diverse with 19 and 17 toxin families identified, respectively. Some of 
the minor toxin families appeared unique to each population: Cʹ and VF were identified in both 
venoms whereas PLA2 INH appeared unique to the venom of the Mt Gambier population and 
CTL was only identified in the Franklin Island venom. The diverse repertoire of toxin families 
identified here, from an ecological perspective, is consistent with N. scutatus’ nature as a 
generalist predator. This species would likely benefit from having various toxic components to 
aid immobilisation and digestion of a wide range of ectothermic and endothermic prey-types 
[3, 73].  
 
Notably, the proteins identified here correspond to the best matches against a protein 
database search using the broad Chordata taxonomy filter, and therefore do not necessarily 
represent the entirety of the proteins in these venoms. It is possible that some of the more 
unique proteins in N. scutatus venom were not identified here, owing to the fact that many 
proteins would not have been sequenced and collated in the database yet, hence assignment 
would not have been made. Transcriptomics of the N. scutatus venoms described here is 
currently being undertaken in parallel with this study; while the results are not yet available, a 
combination of the proteomic analysis with the transcriptomic results will potentially provide 
a more comprehensive understanding of the N. scutatus venom composition and diversity. 
 
2.2.3. Quantitative proteomic analysis of N. scutatus venoms  
 
In order to obtain more quantitative insight on the proteomic variations of these N. 
scutatus venoms, this protein dataset was further processed using the MaxQuant software [76] 
to compare relative toxin protein abundances based on label-free quantification (LFQ) intensity 
values, which  can be regarded as a proxy for relative protein abundance [77]. These intensities 
were used to construct a clearer picture of the relative proportions of toxin families within 
venoms (amount of protein expressed within each protein family, as opposed to numbers of 
different protein hits within families; Figure 2.5). For this analysis, more stringent parameters 
were applied so that a valid protein hit consisted of peptide matches for at least two of the four 
replicates within a population; hence, some previously identified minor toxin families were 




(Figure 2.5) were calculated as ratios of total averaged LFQ intensities for each protein family 
to the overall sum of LFQ intensities of all identified protein hits.  
 
 
Figure 2.5. Relative abundance of venom proteins from each toxin family in the five N. 
scutatus populations: (A) Franklin Island, (B) Reevesby Island, (C) Melbourne, (D) Mt 
Gambier, and (E) Tasmania.  
 
With the application of more stringent identification parameters for valid protein hits, 
a total of 14 toxin families were identified across the five N. scutatus populations (Figure 2.5). 
Venom diversity appeared to be quite variable between populations, with Franklin Island 
venom being the most diverse and containing all 14 toxin families, followed by Melbourne, Mt 
Gambier, Tasmania, and Reevesby Island venoms with 13, 12, 12, and 9 toxin families, 
respectively.  
Out of the 14 toxin families, PLA2 was the predominant component in all five N. 
scutatus venoms, although SVSP and KUN were also major components in all.  VESP, AChE, 
PLB, LAAO, and SVMP toxin families were also identified at lower abundance levels in all 
venoms. The general abundance of PLA2 is in good agreement with proteomic identifications 
for N. scutatus venom in literature [75] and is known to be a characteristic component of many 
Australian elapid venoms [78]. Interestingly, however, parallel transcriptomics analysis of the 




compared to that of PLA2 (Thomson et al., unpublished results, 2018). Thus, the strong 
presence of PLA2 and comparably low, more variable levels of 3FTx in all five venom 
proteomes could reflect differences between the extent of RNA expression of these genes and 
their translation into functional proteins. Given the high abundance of 3FTx proteins in 
Melbourne and Mt Gambier venoms, it is unlikely these proteins were not observed in the other 
populations due to sample preparation or analytical methods. This, nonetheless, forms the 
subject of ongoing analysis. 
Aside from their shared toxin groups, notable variations in venom diversity and 
complexity were observed across the five different populations. The most remarkable 
difference was the variation in 3FTx abundances that distinguished certain N. scutatus venom 
proteomes from others.  Melbourne and Mt Gambier venoms had comparable levels of 3FTx, 
PLA2, and SVSP proteins, which are also the most abundant protein families for these venoms.  
In contrast, Franklin Island, Reevesby Island, and Tasmanian venoms all had a low abundance 
or absence of 3FTxs in their proteomes. These differences are interesting in that they could 
suggest a correlation between venom composition and diet prey types. Melbourne and Mt 
Gambier N. scutatus have a diet that is rich in ectotherms (predominantly frogs) (Thomson et 
al., unpublished fieldwork observations, 2018).  It is plausible that the high-expression of 
paralytic 3FTxs in these venoms provides an advantage for immobilising agile prey types. 
Contrastingly, the endothermic mutton bird-dominant diet observed for Franklin and Reevesby 
Island N. scutatus populations could have a correlation with the minimal or absent 3FTx 
proteins for these venoms.  
This diet hypothesis, however, does not account for the unique composition of 
Tasmanian venoms, which appear to share traits from both island and mainland populations 
groups. Despite the similar diets of Tasmanian, Melbourne, and Mt Gambier N. scutatus, the 
Tasmanian venom proteome more closely resembled those of Franklin and Reevesby Islands 
in that 3FTxs were absent. However, it should be noted that although the N. scutatus venoms 
used in this study were sourced from mainland Tasmania, mutton bird colonies have been 
observed on small islands surrounding mainland Tasmania (Thomson et al., unpublished 
fieldwork observations, 2018).  Thus, there is a possibility that the diets of Tasmanian N. 
scutatus also includes larger birds, which could therefore explain the similarities between 
Tasmanian venoms and those of Franklin and Reevesby Islands. Furthermore, the influence of 




have been extensively discussed in previous studies for other snake venoms [8, 31] and may 
likely have an impact on the venom proteomes of these N. scutatus populations as well.  
 
2.2.4. Quantitative proteomic analysis of Franklin Island and Mt Gambier venom proteomes 
  
Due to the small sample sizes, a comparison between all five N. scutatus populations 
was not statistically feasible; however, two venoms were selected for a quantitative comparison 
of their protein expression levels. Additional biological replicates were sourced for Franklin 
Island and Mt Gambier venoms, which were selected as representative South Australian island 
and mainland venoms, respectively. Experiments were conducted using three different venoms 
from each population (biological triplicates), with three technical replicates performed for each 
individual venom that were relatively consistent with similar protein hits.  
Venom samples were prepared as previously described, except with mass spectrometric 
analysis of tryptic digests performed using a Bruker Impact II Q-TOF mass spectrometer, 
owing to issues with instrument availability. PEAKS (Bioinformatics Solutions Inc.) software 
was used to generate a heatmap of relative protein expression levels for the biological 
triplicates in each population (Figure 2.6). The relative abundance of a given protein is 
represented by the colour intensity on the heatmap, based on log2(ratio) values derived from 
the ratio of peak area of the relevant peptide ions being compared (ie. sample protein abundance) 
to the average abundance of that protein across all samples [79]. Only proteins that met 
statistical requirements of P-value < 0.05 and fold change ≥ 1 were included in Figure 2.6, 
where red in the heatmap represents high protein expression level while low expression is 
shown in green. The dendrogram in Figure 2.6 displays hierarchal clustering of the proteins 
based on their similarity in expression trends across the various samples [79]; proteins 






Figure 2.6. Relative protein expression levels in the Franklin Island and Mt Gambier N. 
scutatus venoms (n = 3). The heatmap (right) displays the relative abundance of a given protein 
identified across the venom samples with red and green representing higher and lower protein 
expression, respectively. The proteins identified are shown in the dendrogram (left) which are 
categorised based on their similarity in expression trends across the samples. Proteins included 
here have a P-value < 0.05 to indicate their statistical significance and a fold change ≥ 1 to 
display only those that showed significant differences in the expression levels across the venom 
samples.  
 
From the six replicates, 21 proteins that passed the significance threshold were 
quantified. Data for CELL and UN proteins was included to identify differences in expression 
at the level of individual proteins. Based on the expression level-based clustering of proteins, 
there are indeed distinctions between the Franklin Island and Mt Gambier venoms. For example, 
some PLA2s are notably more highly expressed in Franklin Island venoms, compared to Mt 
Gambier venoms. In addition, higher expression of a few other proteins from the KUN, CYS, 
SVSP, and 3FTx toxin families were noted for Franklin Island venoms.  
Notably, significant differences in protein expression levels were observed even within 
the same population and indicate intrinsic variability in venom composition between N. 
scutatus individuals. This individual variation, in addition to other ecological factors such as 
diet and environmental conditions, are all likely to contribute to variability in venom 
composition [8]. Although we were able to control the sex and age of our N. scutatus specimens, 
determining the exact factors responsible for these proteomic variations is difficult. Further 




period of time with additional representative populations will provide a more accurate 
representation of the effect of these factors on N. scutatus venom protein composition. 
 
 
2.3. Concluding remarks  
 
In this chapter, we have applied a shotgun proteomic pipeline to investigate the venom 
composition of five different N. scutatus populations. 2D gel electrophoretic and proteomic 
analyses revealed N. scutatus to be a diverse, predominantly PLA2-abundant venom. Variations 
in 3FTx abundance appeared to exist between certain mainland and island populations, which 
may suggest some dietary influence over venom composition. However, focussed quantitative 
comparisons of representative South Australian mainland and island population venoms 
revealed significant intra-population differences consistent with intrinsic variability between 
N. scutatus individuals. Nonetheless, our findings here showcase the impressive variability of 
N. scutatus venom across different populations. While prey types may play a role in proteomic 
variability, our findings infer that other factors are also likely involved. Further 
experimentation with a larger sample size and the integration of our proteomics results with 
transcriptomics data would be crucial for providing a more comprehensive understanding of N. 





2.4. Experimental procedures 
2.4.1. Materials, reagents and buffers used 
 
All reagents were purchased from Sigma Aldrich (NSW, Australia) unless specified otherwise.  
 
Whole lyophilised N. scutatus venoms were kindly supplied by Dr. Vicki Thomson and Venom 
Supplies Pty. Ltd. (Tanunda, Australia). The venoms were stored at -20 oC until required for 
experimentation.  
Rehydration buffer: 7 M urea, 2 M thiourea, 4% (w/v) CHAPs, 10 mM dithiothreitol (DTT), 
0.2% (w/v) SERVALYT carrier ampholytes (SERVA electrophoresis GmbH, Heidelberg, 
Germany)  
Reducing buffer: 0.05 M tris-HCl (pH 8.8), 6 M urea, 2% (w/v) SDS, 20% (v/v) glycerol, and 
10 mM DTT in 100 mM ammonium acetate (NH4OAc).  
Alkylating buffer: 0.05 M tris-HCl (pH 8.8), 6 M urea, 2% (w/v) SDS, 20% (v/v) glycerol, and 
55 mM iodoacetamide (IAA) in 100 mM NH4OAc.  
1x SDS-tris-glycine running buffer: diluted from 10x running buffer (25 mM tris, 192 mM 
glycine, 0.1% SDS, pH 8.5). 
Solvent A: 2% (v/v) acetonitrile (ACN) 0.1% (v/v) formic acid (FA) 
Solvent B: 80% (v/v) ACN 0.1% (v/v) FA 
 
 
2.4.2.  2D-SDS PAGE 
 
The method was adapted from [74]. Crude whole venoms from the biological duplicates 
for each population were combined in a 1:1 (w/w) ratio. Lyophilised whole venom (2 mg) for 
each N. scutatus population was dissolved in 200 µL of 50% glycerol and 50% 1x phosphate 
buffered saline (PBS).  30 µL (i.e. 300 µg of whole venom) of each reconstituted venom was 
then added to rehydration buffer, to a final volume of 185 µL. The mixture was applied onto a 
ReadyStripTM Bio-Rad IPG strip (11 cm, pH 3 - 10) (Bio-Rad, California, US), and rehydrated 
overnight in rehydration buffer. First dimension isoelectric focusing (IEF) was performed in 
an Ettan IPGphor II isoelectric focusing unit (Amersham Biosciences, Amersham, UK) at 20 
oC. A 3-phase program was used: 250 V rapid gradient for 15 min, 8000 V linear gradient for 




The IPG strips were incubated in reducing buffer for 15 min, then subsequently in 
alkylating buffer for 15 min with gentle agitation in both instances. The IPG strips were layered 
onto 4 - 15% Bio-Rad Criterion tris-HCl polyacrylamide gels (11cm, IPG+1 wells) (Bio-Rad, 
California, US). Protein separation by molecular weight in the second dimension was 
performed by electrophoresis at 180 V and 100 mA for 1 h, using 1x SDS tris-glycine running 
buffer. Precision Plus Protein dual colour standards (Bio-Rad, California, US) were used as 
molecular weight markers in the Franklin Island and Reevesby Island venom gels, and Novex 
Sharp unstained protein standards (Invitrogen, California, US) were the protein markers used 
in the Melbourne, Mt Gambier, and Tasmanian venom gels. Gels were then silver-stained 
according to the SilverQuest Kit protocol (Thermo Fisher Scientific, Massachusetts, US) and 
imaged using an Imagescanner densitometer (Amersham Biosciences, Amersham, UK).  
  
 
2.4.3.  Filter-aided, in-solution tryptic digestion 
 
All whole venom tryptic digests were performed as in-solution, filter-aided tryptic 
digests in Amicon Ultra-0.5mL centrifugal filter units (MerckMillipore, Darmstadt, Germany) 
with a 10 kDa molecular weight cut-off. In the case of the quantitative proteomic study, spin 
filters with 3 kDa molecular weight cut-offs were used instead. 
 
Whole venom (0.1 mg) in 200 μL of 7 M urea/100 mM ammonium bicarbonate 
(NH4HCO3) was incubated with 50 mM DTT for 1 h at room temperature, then further 
incubated with 55 mM IAA for 20 min in darkness. Promega MS grade trypsin (Thermo Fisher 
Scientific, Massachusetts, US), resuspended at 100 ng/μL in 10 mM NH4HCO3, was added to 
the sample so that a mass ratio of 1:50 (enzyme:protein) was achieved, and the sample was 
incubated at 37 oC overnight. The digested peptides were eluted through the spin-filter, 
collected, then dried using vacuum centrifugation, before being reconstituted in 100 µL of 2% 
(v/v) ACN 0.1% (v/v) FA. The sample was then purified with a C18 Biospin column (Thermo 
Fisher Scientific, Massachusetts, US) according to the manufacturer’s protocol, and 
concentrations were verified on a NanoDrop 2000/2000c UV-Vis spectrophotometer (Thermo 
Scientific, Massachusetts, US) at a wavelength of 205 nm, ε205 of 31 mL mg
-1cm-1 as per the 






2.4.4.  LC-MS/MS analyses of the multi-populational study  
 
For qualitative and quantitative proteomic analyses of the venoms, digested samples 
were investigated by LC-MS/MS using an Ultimate 3000 nano-flow system (Thermo Fisher 
Scientific, California, US) coupled to a LTQ XL Orbitrap ETD mass spectrometer (Thermo 
Fisher Scientific, California, US). 2 µg of each peptide sample was first concentrated on a C18 
trapping column (Acclaim PepMap 100 C18 75 µm x 20 mm, Thermo-Fisher Scientific) at a 
flow rate of 5 µL/min using 2% (v/v) ACN 0.1% (v/v) trifluoroacetic acid (TFA) for 10 min. 
Peptides were then separated using a 75 µm ID C18 column (Acclaim PepMap100 C18 75 µm 
x 50 cm, Thermo-Fisher Scientific) at a flow rate of 0.3 µL/min, using a linear gradient of 5 to 
45% Solvent B over 60 min. This was followed by a 5 min wash with 90% Solvent B, and then 
a 15 min equilibration process with 5% Solvent B. Samples were acquired in technical 
duplicates.  
LC-MS/MS acquisitions were controlled by Xcalibur (version 2.1, Thermo Fisher 
Scientific). The mass spectrometer was operated in data-dependent acquisition mode. 
Conditions used were as follows: m/z range, 300 – 2000 at a resolution of 60 000 in FT mode; 
polarity, positive. The 10 most intense precursor ions were selected for CID fragmentation with 
a dynamic exclusion of 5 seconds. The dynamic exclusion criteria included: minimum relative 
signal intensity of 1000 and ≥ 2 positive charge state. The isolation width used was 3.0 m/z and 
a normalised collision energy of 35 was applied. 
 
2.4.5. LC-MS/MS analysis for comparison between Franklin Island and Mt Gambier venoms 
 
For quantitative proteomic analysis, the samples were investigated by nano-LC-ESI-
MS/MS using an Ultimate 3000 RSLC system (Thermo Fisher Scientific, Waltham, US) 
coupled to an Impact II HD QTOF mass spectrometer (Bruker Daltonics, Bremen, Germany) 
with an Advance CaptiveSpray nanosource (Bruker Daltonics). 2 µg of each peptide sample 
was first pre-concentrated on a C18 trapping column (Acclaim PepMap 100 C18 75 µm x 20 
mm, Thermo-Fisher Scientific) at a flow rate of 5 µL/min using 2% (v/v) ACN 0.1% (v/v) TFA 
for 10 min. Peptides were then separated using a 75 µm ID C18 column (Acclaim PepMap100 
C18 75 µm x 50 cm, Thermo-Fisher Scientific) at a flow rate of 0.3 µL/min, using a linear 




Solvent B, and then a 15 min equilibration process with 5% Solvent B. Samples were acquired 
in technical triplicates.  
 
LC-MS/MS acquisition were performed in data-dependent acquisition mode. The 
conditions used were as follows: m/z range, 300 – 2200; polarity, positive. Previously chosen 
precursor ions were excluded unless the ion’s chromatographic peak intensity increased by a 
factor of 5. Singly charged precursor ions were also excluded from the acquisition. Collision 
energy used varied from 23% to 65% and was dependent on the precursor ion’s m/z value.  
 
2.4.6. Mascot Protein Identification  
 
Raw MS/MS data were converted to MGF file formats and submitted for qualitative 
protein identification on the in-house Mascot server (version 2.3.01, Matrixscience). The data 
was searched against all Chordata entries present in the Swiss-Prot database. Parameters set 
for the performed search were as follows: tryptic peptides with up to 2 missed cleavages were 
allowed, peptide mass tolerance of 10 ppm, fragment mass tolerance of 0.8 Da, cysteine 
carbamidomethylation set as fixed modification and methionine oxidation as a variable 
modification.  
 
2.4.7.  MaxQuant Analysis  
 
Raw MS/MS data acquired on the Orbitrap mass spectrometer were submitted for 
analysis using MaxQuant (version 1.6.10, Max Planck Institute of Biochemistry). The data was 
searched against all Serpentes entries present in the Swiss-Prot database. Standard Orbitrap 
settings in MaxQuant were used with the parameter settings as follows: tryptic peptides with 
up to 2 missed cleavages were allowed, MS mass error tolerance of 20 ppm, MS/MS mass error 
tolerance of 0.5 Da, cysteine carbamidomethylation set as fixed modification and methionine 
oxidation as a variable modification.  Label-free quantification (LFQ) was performed with 
minimum ratio count of 2 and matches between runs, and unidentified features were enabled. 
LC-MS/MS runs were normalised according to the least overall proteome variation where the 
majority of proteins remain unchanged between the sample runs. False discovery rate (FDR) 






2.4.8. PEAKS Studio X Analysis 
 
The raw MS/MS data acquired on the Bruker mass spectrometer were analysed using 
PEAKS Studio X software package (Bioinformatics Solutions Inc). The data was searched 
against all Serpentes entries present in the Swiss-Prot database. The settings used were as 
follows: tryptic peptides with up to 2 missed cleavages were allowed, parent mass error 
tolerance of 30 ppm, fragment mass error tolerance of 0.6 Da, cysteine carbamidomethylation 
set as fixed modification and methionine oxidation as a variable modification. PEAKS Q 
algorithm was used for LFQ analysis: mass error tolerance was 20 ppm, and retention time 
shift tolerance was 1.0 min. Statistical filters were further applied to the identified proteins: 




~ Chapter 3 ~ 
Proteomic and Structural Investigation of Higher-order Protein 
Assemblies in Pseudechis colletti, Naja melanoleuca and Bitis 
arietans Venoms Using Mass Spectrometry 
 
3.1. Introduction  
3.1.1. Efforts to characterise snake venoms from sequence to structure  
 
Understanding the protein composition of a snake’s venom and exploiting its potency 
for therapeutic uses have been long-standing challenges since ancient times [21, 22]. As 
mentioned in Chapter 1, increasing efforts over the past few decades have been undertaken 
from various fields to characterise protein components of snake venoms; key developments 
include functional studies to understand the activities of certain isolated proteins [5], structural 
analysis by high resolution techniques [6, 45, 80, 81], and high-throughput venomic 
characterisation of various snake venoms [11, 32, 82]. However, amidst these developments, 
dynamic non-covalent protein assemblies remain comparatively underexplored despite the fact 
that these interactions have been speculated to be critical in driving venom potency. It has been 
postulated that protein oligomerisation may be an effective means to increase toxin 
effectiveness and consequently lethality [66]. While certain studies that have celebrated 
successful characterisation of some non-covalent complexes using NMR spectroscopy and x-
ray crystallography, there is still great difficulty in capturing these interactions in a high-
throughput manner, given the heterogeneous nature of many of these complexes and expansive 
catalogue of venom proteins [6, 81, 83].  
Native MS is a powerful technique that can be used to investigate these quaternary 
structures owing to its capability towards interrogating heterogenous protein mixtures in a 
comparatively more high-throughput manner than the aforementioned traditional techniques 
[46, 51, 63, 65, 84]. Abundant examples of native MS capturing structures of a myriad of 
biomolecular assemblies are available in the literature, which includes studies of the DNA 
polymerase III complex [85] and viral capsids [86] to name a few. However, application of 
native MS to snake venom proteins is still in its pioneering stages with only a few venom 
proteins characterised so far, specifically non-covalent phospholipase A2 complexes in 




snake Pseudonaja textilis, and the trimeric complexes Paradoxin from the Inland Taipan 
Oxyuranus microlepidotus and Taipoxin from the Coastal Taipan Oxyuranus scutellatus are 
prominent examples [66, 67]. Another critical aspect that has been a long-standing hurdle to 
overcome in snake venom research is the sheer number of venomous species that require 
characterisation, and furthermore, the complexity of each species’ venom. To establish a 
comprehensive understanding of each species’ venom from primary sequence to higher-order 
structure is a challenging feat, and one which presents an ultimate goal in terms of furthering 
venom-derived therapeutics and applications.  
 
3.1.2. Pseudechis colletti, Naja melanoleuca, and Bitis arietans venoms  
 
Amongst the numerous species of snakes, here we aim to explore the venoms of three 
geographically and phylogenetically variable species that are of medical significance: an 
Australian elapid representative Collett’s snake (Pseudechis colletti), and two venoms exotic 
to Australia from the African elapid forest cobra (Naja melanoleuca), and the African viperid 







Figure 3.1. Appearance and geographical distribution of (A) Pseudechis colletti (Collett’s 
snake) in central Queensland, Australia, (B) Naja melanoleuca (forest cobra) across central, 
western, and southern Africa, and (C) Bitis arietans (puff adder) across sub-Saharan Africa. 
Image attributions: “Pseudechis colletti” by Taipan198 is licensed under CC BY-SA 3.0. “A 
forest cobra with its hood spread” by Warren Klein is licensed under CC BY-SA 3.0. “Young 
Puff Adder (Bitis arietans” by Bernard Dupont is licensed under CC BY-SA 2.0.  
 
P. colletti is an Australian elapid of the Pseudechis genus (black snakes), which is 
considered as one of the most venomous Australian snake genera alongside taipans (Oxyuranus 
spp.), brown snakes (Pseudonaja spp.), and tiger snakes (Notechis spp.) [3, 87]. As a result of 
its considerably isolated habitat in central Queensland shrouded from most human activities 
and its more placid disposition, very few cases of P. colletti envenomation have been reported 
which has led to the misconception of P. colletti being only moderately dangerous [88].  Due 
to this, the P. colletti venom is arguably one of the most underexplored ones in the Pseudechis 
genus compared to some of the more notorious Pseudechis members. However, recent studies 
involving rare but severe P. colletti snakebites have overthrown previous misconceptions and 
revealed that its venom is in fact highly toxic [88]; systemic envenomation characterised by 
anticoagulant coagulopathy and rhabdomyolysis have been reported [88]. To our knowledge, 




characterisation of the most abundant or toxic protein components such as phospholipase A2 
(PLA2), which form a major toxin family known to participate in various pathophysiological 
effects that lead to many of the aforementioned symptoms [89]. While P. colletti’s rather 
simple but PLA2-dominant venom has only been revealed in recent proteomic studies [90], any 
dynamic protein structural interactions still remain largely unexplored.  
N. melanoleuca is the largest species out of the African cobras, and is found to inhabit 
a diverse range of habitats from river areas, forests to suburban regions in Central, Western, 
and Southern Africa [91, 92]. The extensive diversity of N. melanoleuca’s habitat along with 
its enormous venom yields and severe envenomation symptoms render N. melanoleuca as a 
category 1 snake of highest medical significance as categorised by the World Health 
Organisation [91]. Envenomation by N. melanoleuca is predominantly characterised by 
neurotoxicity which results in progressive paralysis of respiratory muscles and leads to death; 
this neurotoxicity has been attributed to the abundance of long and short neurotoxins known as 
3 finger toxins (3FTx) and various PLA2 proteins in N. melanoleuca venom [91]. 
Native to widespread regions of sub-Saharan Africa, B. arietans has also been regarded 
as an extremely venomous species belonging to the viperid family [93]. Notoriety of B. arietans 
venom arises from its remarkably extensive habitat, inclination to bite and venom potency [93-
95]; B. arietans envenomation is known to be responsible for the majority of snakebite fatalities 
in Africa, with coagulopathy and tissue necrosis observed upon envenomation resulting in 
morbidity and eventually death [93]. Much of envenomation severity is due to the abundance 
of both enzymatic and non-enzymatic toxins. These include snake venom metalloproteinase 
(SVMP) and serine proteases (SVSP) that target tissues and toxins such as disintegrins (DIS) 
that disrupt haemostasis [93]. The pathophysiological effects described are starkly different to 
the two elapids P. colletti and N. melanoleuca but are commonly observed in many viper 
envenomation.  
The severity and frequency of N. melanoleuca and B. arietans envenomation have 
spurred on research efforts to catalogue the entire venom proteomes [91, 94, 96],  characterise 
activities of individual venom proteins by biochemical and immunological analyses, and 
slowly accumulate three-dimensional structures corresponding to a few of these proteins in a 





Despite these efforts to characterise venoms, however, as aforementioned a distinct 
knowledge gap in our understanding of the various higher-order, non-covalent interactions 
between protein constituents that elicit such severe pathophysiological effects remains. From 
a therapeutic perspective, understanding the protein composition of snake venom and how 
proteins therein interact to elicit toxicity are critical steps towards improving treatment as well 
as the long-standing goal of utilising venoms for therapeutics. In this chapter, the venoms of P. 
colletti, N. melanoleuca, and B. arietans were explored for critical quaternary, non-covalent 
protein complexes that may be involved in driving venom toxicity, using an integrated MS 
based approach of shotgun proteomics and native MS.  
 
3.2. Results and discussion 
3.2.1. Separation of P. colletti, N. melanoleuca, and B. arietans whole venoms by size 
exclusion chromatography 
 
Fractionation of crude whole venom from P. colletti, N. melanoleuca, and B. arietans 
by size-exclusion chromatography (SEC) was performed in order to obtain a broad view of the 
respective venom complexities (Figure 3.2). The proteins were eluted in ammonium acetate 
buffer which is known to maintain the proteins and any potential non-covalent complexes in 






Figure 3.2. (A) Normalised SEC elution profiles of whole venoms from P. colletti, N. 
melanoleuca, and B. arietans. (B) SDS-PAGE of P. colletti (top gel), N. melanoleuca, and B. 
arietans (bottom gel) venom SEC fractions. The following gel lanes correspond to SEC peak 
from which the sample fraction was taken: lanes 1 (PC1), 2 (PC2a), 3 (PC2b), 4 (PC3), 5 
(NM1a), 6 (NM1b), 7 (NM2a), 8 (NM2b), 9 (NM3), 10 (BA1), 11 (BA2a), 12 (BA2b), 13 
(BA3), 14 (BA4), 15 (BA5), and 16 (BA6).  
  
As shown in Figure 3.2.A, the SEC elution profiles revealed variations in the different 
protein species present in the three venoms. Based on separation by size, P. colletti venom 
appeared to be the simplest venom with only three main peaks corresponding to proteins that 
were eluted in the high, intermediate, and low mass ranges. The prominent intensity of peak 
PC2b in the elution profile of P. colletti venom, however, suggested an abundance of 
intermediate-sized proteins. Similar to P. colletti venom, the SEC profile for N. melanoleuca 
venom also consisted of three main peaks with the intense peak NM2b inferring an abundance 




colletti venom by the significantly broader peaks NM1b and NM2b, corresponding to larger 
and smaller protein species, respectively.   
In contrast to both elapid venoms, the SEC trace from B. arietans venom was 
significantly more complex with numerous peaks eluting across the entire elution range, 
inferring a diverse suite of proteins of various sizes. Of note, peaks BA2b and BA6 were most 
intense which correspond to large and very small (potentially peptidic) species, respectively. 
This distinguishes B. arietans venom from P. colletti and N. melanoleuca venoms, and the 
complexity of the B. arietans venom SEC profile may be a reflection of the phylogenetic 
differences between viperid and elapid venoms. Of note, the high mass range fractions may not 
be solely composed of large proteins; the presence of non-covalent complexes constituted from 
smaller proteins may also be present in these larger fractions given the native-like buffer 
environment that enables these weakly held complexes to remain intact.  
 
3.2.2. Analysis of the venom SEC fractions by reducing SDS-PAGE 
 
In order to further separate the protein components in the venom fractions as well as 
begin probing potential non-covalent complexes that are present, reducing SDS-PAGE was 
conducted for the various SEC fractions across the entire elution range for all three venoms, 
where each lane in Figure 3.2.B corresponds numerically to the SEC peak from which the 
venom fraction was taken from. From the simplicity of the protein bands observed in Figure 
3.2.B, P. colletti venom appeared to be the least complex of the three venoms. Apart from 
larger and smaller proteins around 50 – 70 kDa and 15 kDa respectively, the multiple protein 
bands between 20 – 60 kDa that are apparent in N. melanoleuca and B. arietans venoms are 
not observed in P. colletti venom. This is not, however, unexpected for P. colletti venom given 
the simplicity of its SEC elution profile from which these fractions were derived.  
Comparison of the gel migration patterns for fractions corresponding to similar elution 
volumes suggested that P. colletti and N. melanoleuca venoms may be composed of quite 
similar proteins based on molecular weight. Fractions PC1 (P. colletti) and NM1b (N. 
melanoleuca) that eluted in the high molecular mass range are shown to contain 50 – 70 kDa 
protein species. A similar trend was also noted for venom fractions PC2b (P. colletti) and 
NM2b (N. melanoleuca) that eluted in the intermediate mass range as protein bands at 10 – 15 




While the two elapid venoms appear to have similar protein compositions in general by 
molecular mass, the SDS-PAGE results for B. arietans venom fractions were comparatively 
distinct. High mass range fractions such as fractions BA1 and BA2a were found to be 
composed of smaller protein species around 15 kDa which is interesting. Non-covalent protein 
complexes that were maintained in a native-like state during separation by SEC would be 
disrupted by the reducing conditions of the SDS-PAGE analysis, affording protein bands that 
correspond to monomeric masses. Thus, identification of small proteins in a high mass range 
fraction as observed in B. arietans venom fractions BA1 and BA2a suggested the presence of 
potential non-covalent complexes.  
Notably, mass shifts in certain protein bands were observed which may be due to post 
translational modifications (PTMs). A key example is the B. arietans venom fraction BA4 
where the protein at 25 kDa is considerably higher than what is anticipated for a low molecular 
weight range fraction. The mass shift may be indicative of PTMs which are likely to be 
glycosylation, a modification known to be common for certain snake venom proteins [66]. As 
the focus of this study was primarily on non-covalent protein complexes, only the higher and 
intermediate mass range venom fractions were considered for further analysis; fractions beyond 
25 mL which correspond to peptidic species were not included.  
 
3.2.3. Shotgun proteomics of the three whole venoms  
 
While distinctions between the three venoms were observed through simple 
fractionation analyses, gaining insight on the venom diversities at a proteomic level is essential. 
To first catalogue the proteomic composition of the three snake venoms of interest, whole 
venoms of P. colletti, N. melanoleuca, and B. arietans were digested with trypsin and analysed 
by LC-MS/MS in a shotgun bottom-up workflow. Proteins were identified by database 
searching using the protein identification search engine Mascot (Matrixscience) with Chordata 
applied as the taxonomy filter. The significance threshold was set as P-value < 0.05 and false 
positives, contaminants, and proteins that did not possess a toxic function were eliminated from 
further analysis as only toxin families are of interest in this study (Appendix B). Relative 
abundance of the different toxin groups within a whole venom mixture was determined from 
the Exponentially Modified Protein Abundance Index (emPAI) scores generated by Mascot, 
which is a label-free quantitative estimation for relative protein abundance within the sample 




same family, for instance the PLA2 superfamily, were then used to construct the relative 
proportions shown in Figure 3.3 below. The coloured wedges depict the relative abundance of 
a given toxin family identified in each of the three venom proteomes. 
 
 
Figure 3.3. Proteomic composition of whole venoms from (A) P. colletti, (B) N. melanoleuca, 
and (C) B. arietans based on the estimated relative abundances of the toxin families within 
each venom.  Abbreviations for the toxin families are given in Table 1.1 (n=1).  
 
As shown in Figure 3.3, significant proteomic diversity was observed across the three 
different venoms, based on the distribution of distinct toxin superfamilies. P. colletti venom 
appeared to be the least diverse with only four protein families identified, whereas N. 
melanoleuca and B. arietans venoms possessed substantially more varied proteomes being 
constituted of 14 and 12 distinct protein families, respectively. Each venom proteome appeared 
to afford intrinsic profiles; despite the lack of diversity in P. colletti venom, the proteome 
demonstrated a strikingly high proportion of PLA2 which distinguished P. colletti venom from 
the other two venoms. This abundance of PLA2 corresponded to what was reported in literature 
for P. colletti venom where PLA2 was the main component identified in the venom [90]. The 
most notable elements of the N. melanoleuca venom proteome were the dominant proportions 
of PLA2 and 3FTx. This appeared to be in agreement with the venom proteome reported for N. 
melanoleuca [91], however 3FTxs were reported to be the most abundant component rather 
than PLA2. B. arietans venom was set apart from the other two venoms by a broader range of 
highly abundant protein families such as DIS, CTL, 3FTx, and VEGF. The abundance of CTL 
corresponded to the reports of another study on B. arietans venom proteome [94], and while 
the presence of DIS and 3FTx were also described in the study, they were not reported as major 




These variations in the relative abundance of different protein groups may be attributed 
to intraspecies venom variation, but the overall proteomic profiles of these venoms are in 
agreement with what is known in literature [90, 91, 94]. 
Distinctions between the two elapid venoms and the viperid venom were also apparent. 
The predominance of smaller enzymes such as PLA2 and the presence of 3FTx in both P. 
colletti and N. melanoleuca venom proteomes are in line with what is known for elapid venoms 
which is generally a higher abundance of PLA2 and 3FTx [90, 91]. PLA2 is known to participate 
in a myriad of pathways that elicit pre- and post-synaptic neurotoxicity, cardiotoxicity, 
myotoxicity, and anti- and pro-coagulation to name a few [47, 98] while 3FTx predominantly 
acts to elicit neurotoxicity and cardiotoxicity in the case of cobra venoms [99]. The tremendous 
abundance of PLA2 in P. colletti venom appeared to be in good agreement with what is 
symptomatically known for its envenomation [88]. Similarly, the high composition of PLA2 
and 3FTx in N. melanoleuca venom may be attributed to the severe symptoms of paralysis 
reported for envenomation by this species.  
As the viperid venom in the study, B. arietans venom proteome was distinct compared 
to the other two elapid venoms as shown in Figure 3.3.C, being rich in DIS, CTL, 3FTx, and 
VEGF. These proteins are known to participate in disrupting haemostasis and preventing 
platelet aggregation, resulting in envenomation symptoms such as strong haemorrhage, which 
is quite characteristic of viperid envenomation [45, 93]. The relatively strong presence of 3FTx 
is interesting as previous studies on B. arietans venom have not observed this, but rather higher 
abundance of SVMPs and SVSPs [93, 100].  
It is also noteworthy that while proteomic studies have been performed for these 
venoms in the past [90, 91, 94], to our knowledge the feasibility of a high throughput approach 
by shotgun proteomics is reported here for the first time for these venoms. As noted perhaps 
more prominently for the B. arietans venom, intrinsic variations in the venom proteomes tend 
to occur, thus, being able to apply shotgun proteomics as a tool to accurately help characterise 







3.2.4. Shotgun proteomic analysis of venom high and intermediate sized protein fractions 
from SEC 
 
In order to begin interrogating the higher-order structures and potential non-covalent 
interactions in these venoms, SEC fractions corresponding to the 14 mL and 18 mL elution 
volumes were selected from each of the three venoms, since any larger protein assemblies 
would most likely be found in these higher mass range fractions. Prior to higher-order structural 
interrogation by native MS, however, it is necessary to have more confidence in the protein 
identities found specifically in these fractions. Therefore, these high and intermediate 
molecular weight fractions were selectively analysed by shotgun proteomics (Appendix C), 
and proteins were identified and their relative abundances determined by Mascot-generated 
emPAI scores in the same manner as those in the proteomic analysis of the whole venoms 
(Figure 3.4).  
 
Figure 3.4. Proteomic composition of selected SEC venom fractions: (A) Fraction PC1 (P. 
colletti), (B) Fraction NM1b (N. melanoleuca), (C) Fraction BA2a (B. arietans), (D) Fraction 
PC2b (P. colletti), (E) Fraction NM2b (N. melanoleuca), and (F) Fraction BA3 (B. arietans).  
 
From Figure 3.4, a variety of protein families was identified across the six venom 
fractions. Proteomic analysis of the P. colletti venom fractions revealed LAAO as the 
predominant protein family in the fraction PC1, and PLA2 is the most abundant family in 




was revealed in fraction NM1b where LAAO, SVMP, DIS, and VF appear to be abundant 
protein families; PLA2 and 3FTx were the dominant families in fraction NM2b. In terms of B. 
arietans venom, CTL and DIS were most abundant in fraction BA2a whereas DIS appeared to 
be the predominant species in fraction BA3.  
The proteins families identified in the six venom fractions are predominantly in good 
agreement with those identified in the whole venoms, in particular the two B. arietans venom 
fractions where the most dominant protein families identified were also very abundant in the 
whole venom analysis (Figure 3.3.C). While some protein families of low abundance were 
noted here and not observed in the whole venoms, this is most likely due to the fact that 
fractionation and further separation of the whole venoms have depleted the more abundant 
protein families, mitigating the suppression of the lower abundance signals, and hence allowing 
identification of more protein families in these fractions. This does indicate some limitations 
in the shotgun proteomics approach and suggests limited fractionation may be necessary for 
future studies where wide proteome coverage is required. Importantly, the results from the 
proteomic analysis of these SEC fractions will supplement the assignment of protein identities 
for a higher-order structural analysis.  
 
3.2.5. Native MS analysis of SEC fractions 
 
To interrogate the potential higher-order structural interactions present in the six venom 
fractions, the fractions were further analysed by native MS whereby the protein samples were 
infused directly into the mass spectrometer under gentle ionisation conditions known to 
preserve intact protein assemblies. Figure 3.5 shows the resulting native mass spectra for the 
six fractions analysed in which spectral peak assignment has been performed by selecting m/z 
values from the left-hand side of a given peak distribution to avoid the inclusion of adducts 






Figure 3.5. Native mass spectra of P. colletti, N. melanoleuca, and B. arietans venom fractions 
(10 µM). The selected SEC fractions (A) Fraction PC1 (P. colletti), (B) Fraction NM1b (N. 
melanoleuca), and (C) Fraction BA2a (B. arietans) were obtained at 14 mL elution volume. 
SEC fractions (D) Fraction PC2b (P. colletti), (E) Fraction NM2b (N. melanoleuca), and (F) 
Fraction BA3 (B. arietans) were obtained at 18 mL elution volume. Proteins were maintained 
in 200 mM NH4OAc (pH 7.0) for nanoESI-MS analysis. Different protein species identified 
with their various charge states and oligomeric states are labelled with coloured circles. 
 
The mass spectral results for the three high mass range fractions (Figure 3.5.A – C) 
revealed very different protein populations, all of which appeared to display some form of PTM, 
most likely glycosylation, as suggested by the broadness of the spectral peaks [66, 67]. Fraction 
PC1 from P. colletti venom seemed to be composed of two main protein species, 64 kDa and 
117 kDa, which were assigned as monomeric and dimeric LAAO, respectively based on the 
natively observed molecular weights (Figure 3.5.A). While there is a mass discrepancy between 




this discrepancy is most likely due to the broadness and lower resolution of the spectral peaks 
limiting accurate peak assignment. Nonetheless, these species can be confirmed to be 
monomeric and dimer LAAOs given the additional information supplemented by the lack of a 
protein band corresponding to 117 kDa in the SDS-PAGE analysis (Figure 3.1.B), and the 
predominance of LAAO identified in this fraction by shotgun proteomics (Figure 3.4.A).  
Further investigation of the interaction between the dimer will be discussed in Section 3.2.6.  
Protein species at 28.1 kDa and 49.9 kDa were identified in fraction NM1b from N. 
melanoleuca venom (Figure 3.5.B), which are rather different to what was observed in P. 
colletti venom at the same elution volume, despite the similar SDS-PAGE results noted earlier 
between the two venoms. While these protein species could correspond to CRISPs, SVSPs, 
and LAAOs to name a few, based on molecular weight correlation to the proteomic analysis of 
the fraction (Figure 3.4.B), the complexity and limited resolution of the native mass spectrum 
implies that confident assignment of protein identities is difficult at this stage and further 
separation of this fraction will be required.  
A 60 kDa protein species was observed in the B. arietans venom fraction BA2a (Figure 
3.5.C). This is interesting as the SDS-PAGE results showed a single 15 kDa protein band 
(Figure 3.1.B). Based on this information and the corresponding proteomic analysis (Figure 
3.4.C), this 60 kDa protein species is most likely a tetramer of 15 kDa monomeric CTL.  
Moreover, CTLs are found abundantly in B. arietans venom as shown in the proteomic analysis 
as well as in literature and are known to be capable of oligomerisation [6, 100, 101]. Again, 
the higher-order interactions of this assigned tetramer will be further explored in Section 3.2.6.  
Native MS analysis of the venom fractions that eluted in the intermediate mass range 
showed that the proteins being identified in all three venoms were largely monomeric (Figure 
3.5.D – F), which is in agreement with the previous SDS-PAGE results that showed protein 
bands corresponding to 15 kDa or lower (Figure 3.1.B). The native mass spectrum of the P. 
colletti venom fraction PC2b showed a predominant protein species at 13.1 kDa (Figure 3.5.D), 
correlating well to a PLA2 enzyme based on the proteomic analysis of the fraction (Figure 
3.4.D).  In Figure 3.5.E, the native mass spectrum of the N. melanoleuca venom fraction NM2b 
was substantially more complex, showing a variety of small protein species ranging from 6.7 
– 7.8 kDa, which the proteomic analysis of the fraction suggested to be 3FTxs (Figure 3.4.E). 
Interestingly, a 14.2 kDa species was also noted in this N. melanoleuca venom fraction which 




cobra venoms such as Naja kaouthia [6, 102]. Alternatively, this protein species may also be a 
PLA2; both 3FTx and PLA2 are reported to be abundant in the complementary proteomic 
analysis (Figure 3.4.E). The predominant 9.0 kDa protein species identified in the B. arietans 
venom fraction BA3 (Figure 3.5.F) corresponded to monomeric DIS which is in line with the 
proteomic results for this fraction where DIS was the most abundant constituent (Figure 3.4.F).  
Importantly, while the native MS spectra appeared simpler in terms of the number of 
protein species observed in comparison to the various protein constituents identified in the 
proteomic analysis of the corresponding venom fractions, it should be noted that the various 
protein assignments in the native MS analysis highlights only the most prominent protein 
species observed. Signal suppression of lower abundant protein ions may be contributing to the 
absence of certain protein families that were noted in the proteomic analyses. In addition, the 
intrinsic ionisation efficiency of different proteins is also a considerable factor determining 
which proteins ions can be observed.   
It should be reiterated that the purpose of this study is a preliminary overview of the 
higher-order structures by native MS of venom fractions that have only undergone one 
dimension of protein separation. At this point, it can be said that the study would benefit from 
further purification of certain fractions to reduce the protein complexity and reveal new protein 
complexes, but due to time constraints, such endeavours for a more rigorous structural 
interrogation will be considered in future investigations. In addition, top-down protein 
sequencing will be another useful approach to confirm the identities of proteins in the 
aforementioned complexes.  
 
 
3.2.3. Denatured MS analysis offers insight into the nature of higher-order protein structures  
 
Having identified protein assemblies in the high molecular weight venom fractions, 
denatured MS analysis was performed for the three venom fractions in order to further probe 





Figure 3.6. Denatured MS analysis of the high mass range SEC venom fractions: (A) Fraction 
PC1 (P. colletti), (B) Fraction NM1b (N. melanoleuca), (C) Fraction BA2a (B. arietans), and 
(D) Fraction BA2a (B. arietans) treated with 1 mM dithiothreitol. Proteins were diluted with 
50% ACN and 0.1% FA prior to ESI-MS analysis, and the different protein species identified 
with their various charge states and oligomeric states are labelled with coloured circles.  
 
The results in Figure 3.6 revealed interesting interactions between protein subunits of 
the three venom fractions in study. A heavily modified 57.6 kDa protein species, as shown by 
the broad spectral peaks, was identified in the P. colletti venom fraction (Figure 3.6.A), which 




LAAO monomer (Figure 3.5.A). While there is a 6.4 kDa mass difference between the 
monomeric species identified by native and denatured mass spectra, this mass discrepancy may 
likely arise from the loss of labile PTMs such as complex glycosylation moieties which have 
been noted for certain venom proteins isolated from Ophiophagus hannah [103]. Further 
structural characterisation targeting PTMs would be required; nevertheless, the LAAO 
monomer can be confirmed in Figure 3.6.A. Doubling the mass of the 57.6 kDa monomer 
affords a dimeric mass of 115.2 kDa which corresponds closely to the 117.4 kDa LAAO dimer 
that was observed natively, with the 2.2 kDa mass difference potentially accounted for by 
PTMs. Importantly, the absence of the larger dimeric LAAO species in the denatured MS 
spectrum is a good indication that the species being observed is a non-covalent complex. 
Furthermore, homodimeric LAAOs are known to exist around the 110 – 150 kDa mass range, 
and that both covalent and non-covalent interactions between the subunits are possible [6]. 
Thus, it is exciting to report these dimers in P. colletti venom for the first time by MS.  
The denatured MS of the N. melanoleuca venom fraction (Figure 3.6.B) revealed a 49.6 
kDa protein species that corresponded very closely to the 49.9 kDa species observed natively 
(Figure 3.5.B). This may imply that the 49.6 kDa species is the intact mass of the protein, or 
alternatively a covalently bound dimeric species, whereas the 28.1 kDa species previously 
assigned in the native MS analysis was not identified in the denatured MS. In the interest of 
time, this complex fraction was not further explored; however, further fraction purification, 
investigation and deconvolution of the corresponding native MS spectrum will be useful in 
future experiments to better characterise these protein species.   
Denatured MS of the B. arietans venom fraction showed interesting results; despite the 
low ion intensities, 60 kDa and 30 kDa species were observed (Figure 3.6.C), which 
corresponded to covalently-linked CTL tetramer and dissociated dimer, respectively. This is 
considering the 60 kDa CTL tetramer assigned in the corresponding native MS spectrum and 
the 15 kDa monomeric subunits noted in the reducing SDS-PAGE analysis. Further treatment 
of the 60 kDa tetramer with reducing agent dithiothreitol and subsequent denatured MS 
analysis confirmed disulphide interactions between the protein subunits as only 30 kDa CTL 
dimers were observed, indicating dissociation of the tetramer (Figure 3.6.D). As monomeric 
CTL masses were not noted, stronger reducing agents such as TCEP (tris(2-
carboxyethyl)phosphine) may be considered in future experiments. The finer mechanisms that 




specific PTMs or structural moieties that facilitate oligomerisation are interesting aspects to 
explore in future experiments.   
 
 
3.3. Concluding remarks 
 
In this chapter, we have used an integrated MS-based approach to explore the higher-
order structures of various venom proteins from a repertoire of phylogenetically diverse 
venoms of P. colletti, N. melanoleuca, and B. arietans. Shotgun proteomics revealed the 
diversity in the three venom proteomes where P. colletti venom is simple yet highly abundant 
in PLA2. N. melanoleuca venom is significantly more complex with a pronounced abundance 
of PLA2 and 3FTx, whereas B. arietans venom reflects the proteomic characteristics of viperid 
venom where DIS and CTL are some of the more abundant constituents. Importantly, 
supplemented by the proteomic findings, new higher-order protein complexes were identified 
by native MS analysis in various venom fractions from the three venoms. Denatured MS 
analysis further confirmed a non-covalent LAAO dimer present in the P. colletti venom and a 
CTL tetramer in the B. arietans venom. Further separation and purification of these venom 
fractions will be beneficial for mass spectral deconvolution and more accurate peak assignment. 
Future studies will also include the investigation of the finer structural moieties and PTMs that 
potentially enable protein oligomerisation. While this study only captures protein species from 
very selective venom fractions, the established workflow is nonetheless a good foundation to 





3.4. Experimental procedures 
3.4.1. Materials, reagents, and buffers used 
 
All reagents were purchased from Sigma Aldrich (NSW, Australia) unless specified otherwise. 
Whole lyophilised P. colletti, N. melanoleuca, and B. arietans venoms were purchased from 
Venom Supplies Pty. Ltd. (Tanunda, Australia), and were stored at -20 oC until required for 
experimentation.   
200 mM NH4OAc buffer (pH 7.0) was filtered using a Nalgene Rapid-Flow bottle top filter 
(Thermo Fisher Scientific, Massachusetts, US) and de-aerated with an ultrasonic cleaner 
(Soniclean, SA, Australia) prior to its use in SEC and MS analyses.  
3x SDS-PAGE loading buffer: 150 mM tris-HCl (pH 6.8), 300 mM DTT, 6% SDS, 30% 
glycerol, 0.3% bromophenol blue. 
1x SDS-tris-glycine running buffer: diluted from 10x running buffer (25 mM tris, 192 mM 
glycine, 0.1% SDS, pH 8.5). 
Coomassie Brilliant Blue staining solution: Coomassie Brilliant Blue R250 dye, 10% (v/v) 
glacial acetic acid, 40% (v/v) methanol in distilled water.  
Destain solution: 40% (v/v) methanol, 10% (v/v) acetic acid in distilled water.  
Solvent A: 2% (v/v) ACN 0.1% (v/v) FA 
Solvent B: 80% (v/v) ACN 0.1% (v/v) FA 
   
3.4.2. Separation of whole venom by SEC 
 
Lyophilised whole venom was reconstituted to a concentration of 10 mg/mL in 200 
mM NH4OAc (pH 7.0) and loaded onto a Superdex200 10/300 size exclusion column (GE 
Healthcare, Illinois, USA) coupled to an ÄKTA Prime FPLC system (Amersham Biosciences, 
Amersham, UK). The column was equilibrated with 200 mM NH4OAc (pH-adjusted to 7.0 
with ammonium hydroxide) prior to sample loading. 400 µL fractions were collected at a flow 
rate of 0.4 mL/min with 200 mM NH4OAc as the eluent over a volume of 36 mL. UV 




process was performed for P. colletti, N. melanoleuca, and B. arietans whole venoms. Fractions 
were then stored at -20oC until required for further analysis.  
 
3.4.3. 1D SDS-PAGE analysis 
 
The venom fractions of interest were added to 3x reducing sample buffer in a 1:1 (v/v) 
ratio and denatured at 95 oC for 15 min. The samples were then loaded onto 4 – 15% Mini-
Protean TGX tris-HCl polyacrylamide gels (Bio-Rad, California, US). Protein separation by 
molecular weight was performed by gel electrophoresis at 140 V and 400 mA for 1 h, using 1x 
SDS tris-glycine running buffer. Precision Plus Protein dual colour standards (Bio-Rad, 
California, US) were used as molecular weight markers. The gels were then developed with 
Coomassie Brilliant blue staining solution for 30 min, and destained with destaining solution 
for 3 h before being imaged using an Imagescanner densitometer (Amersham Biosciences, 
Amersham, UK).  
 
3.4.4. Filter-aided, in-solution tryptic digestion 
 
Venoms were digested using an in-solution, filter-aided tryptic digest protocol in 
Amicon Ultra-0.5mL centrifugal filter units (MerckMillipore, Darmstadt, Germany) with a 10 
kDa molecular weight cut-off. Venom (approximately 0.1 mg) in 200 μL of 7 M urea/100 mM 
NH4HCO3 was incubated with 50 mM DTT for 1 h at room temperature, and further incubated 
with 55 mM IAA for 20 min in darkness. Promega MS grade trypsin (Thermo Fisher Scientific, 
Massachusetts, USA), resuspended at 100 ng/μL in 10 mM NH4HCO3, was added to the sample 
so that a mass ratio of 1:50 (enzyme:protein) was achieved, and the sample was incubated at 
37 oC overnight. The digested peptides were then eluted through the spin-filter, collected, and 
dried using vacuum centrifugation, before being reconstituted in 100 µL of 2% (v/v) ACN 0.1% 
(v/v) FA. The sample was then purified with a C18 Biospin column (Thermo Fisher Scientific, 
Massachusetts, US) according to the manufacturer’s protocol, and concentrations were verified 
on a NanoDrop 2000/2000c UV-Vis spectrophotometer (Thermo Scientific, Massachusetts, US) 
at a wavelength of 205 nm, ε205 of 31 mL mg
-1cm-1 as per the manufacturer’s instructions. All 
samples were stored at -20 oC until required for LC-MS/MS. Acquisition and analysis of the 




3.4.5. LC-MS/MS analysis of venom samples   
 
The digested venom samples were analysed by LC-MS/MS using an Ultimate 3000 
nano-flow system (Thermo Fisher Scientific, California, US) coupled to a LTQ XL Orbitrap 
ETD mass spectrometer (Thermo Fisher Scientific, California, US). 2 µg of each peptide 
sample was pre-concentrated on a C18 trapping column (Acclaim PepMap 100 C18 75 µm x 20 
mm, Thermo-Fisher Scientific); a flow rate of 5 µL/min with 2% (v/v) ACN 0.1% (v/v) TFA 
was applied over 10 min. Peptides were then separated using a 75 µm ID C18 column (Acclaim 
PepMap100 C18 75 µm x 50 cm, Thermo-Fisher Scientific) at a flow rate of 0.3 µL/min, where 
a linear gradient of 5% to 45% Solvent B was applied over 60 min. This was followed by a 5 
min wash with 90% Solvent B, and then a 15 min equilibration process with 5% Solvent B.  
LC-MS/MS acquisitions were controlled by Xcalibur (version 2.1, Thermo Fisher 
Scientific), and the mass spectrometer was operated in data-dependent acquisition mode. 
Spectra were acquired in positive mode in the mass range of 300 – 2000 m/z at a resolution of 
60 000 in FT mode. The 10 most intense precursor ions were selected for CID fragmentation 
using a dynamic exclusion of 5 seconds where the dynamic exclusion criteria included:  
minimum relative signal intensity of 1000 and ≥ 2 positive charge state. The isolation width 
used was 3.0 m/z and a normalised collision energy of 35 was applied. 
 
3.4.6. MASCOT analysis 
  
MS/MS data was converted to MGF file format and submitted for qualitative protein 
identification on the in-house Mascot server (version 2.3.01, Matrixscience). The data was 
searched against all Chordata entries present in the Swiss-Prot database. Parameters for the 
performed search were as follows: tryptic peptides with a maximum of 2 missed cleavages 
were allowed, peptide mass tolerance of 30 ppm, fragment mass tolerance of 0.8 Da, cysteine 
carbamidomethylation set as fixed modification and methionine oxidation, acetylation of the 
protein N-terminus, and deamidation of glutamine and asparagine set as variable modifications. 
Relative abundance values of the toxin groups in a given venom mixture were calculated from 






3.4.7. Native MS analysis of the venom samples  
 
All native MS spectra were obtained using a Synapt G1 HDMS quadrupole ion mobility 
time-of-flight mass spectrometer (Waters, Manchester, UK). 4 µL of sample was introduced 
into the instrument by nano-electrospray from platinum-coated borosilicate capillaries, 
prepared in-house. Mass spectra were acquired under the control of MassLynx software 
(version 4.1, Waters). Instrument conditions were set to optimise maintenance of non-covalent 
interactions as follows: scan range, 500 – 6000 m/z; polarity, positive; capillary voltage, 1.7 
kV; sampling cone voltage, 50 kV; extraction cone, 3 kV; source temperature, 50 oC; 
desolvation temperature; 180 oC; trap collision energy, 30 V; transfer collision energy, 30 V; 
IMS wave velocity, 300 m/s; backing pressure, 4.07 mbar. The protein samples were 
maintained in 200 mM NH4OAc buffer, pH 7.0 prior to analysis.  
 
3.4.8. Denatured MS analysis of the venom samples  
 
All denatured mass spectra were obtained using an Agilent 1260 LC system coupled to 
an Agilent 6230 TOF mass spectrometer (Agilent Technologies, California, US) tuned in the 
3200 m/z mass range. 2 µL of sample was directly injected into the instrument via the LC auto 
sampler and eluted at a flow rate of 0.2 mL/min without chromatographic separation. An 
isocratic elution of 50% Solvent B was used; Solvent A (0.1 % (v/v) FA in water) and Solvent 
B (99.9% (v/v) ACN 0.1% (v/v) FA). The instrument conditions were set as follows: m/z range, 
500 – 3200; polarity, positive; capillary voltage, 3.5 kV; nozzle voltage, 2 kV; gas temperature; 
325 oC. Mass spectra were acquired under the control of MassHunter Workstation software 
(version B.08.00, Agilent Technologies). MS data analysis was performed using MassHunter 
Workstation software (version B.07.00, Agilent Technologies) where spectra were summed 
over the time period of sample elution. For MS experiments under both reducing and denatured 
conditions, the sample was first incubated with 1 mM DTT in 200 mM NH4OAc for 1 h prior 







~ Chapter 4 ~ 
Structural and Functional Insights into Phospholipase A2 Enzymes Isolated from 
P. colletti Venom 
 
4.1.  Introduction  
4.1.1. Significance and structure of phospholipase A2     
 
Of the various protein families that constitute snake venoms, phospholipase A2 (PLA2, 
Figure 4.1.A) is of significant interest owing to its abundance in elapid venoms and various 
viperid venoms. Aside from its abundance and critical role in envenomation, PLA2 is an 
extensive superfamily of enzymes highly expressed in insect venoms and are also expressed in 
plants, bacteria, invertebrates and vertebrates [104]. PLA2 activity is characterised by the 
hydrolysis of phospholipids at the sn-2 position on the glycerol backbone, liberating a lyso-
phospholipid and fatty acid (Figure 4.1.B) [104]. PLA2s are broadly classified into two forms: 
an extracellular form known as secreted PLA2s (sPLA2s) and an intracellular form termed 
cytosolic PLA2s (cPLA2s); this study focuses on the former class of PLA2s in the context of 
snake venoms.   
While human PLA2s are not known to have any toxic effects, but rather participate in 
regulating phospholipid turnover and cell maturation, venom-derived PLA2s are extremely 
potent [104]. They are known to elicit neuro- and myotoxic effects by hydrolysing cell 
membrane phospholipids, resulting in the destruction of neuromuscular junctions and skeletal 
muscles [104]. Downstream cellular pathways mediated by hydrolysed products of cell 
membranes are also thought to contribute to the indirect toxicity of PLA2, leading to increased 
neuro-, myo- and cardiotoxicity, disruption of haemostasis and platelet aggregation [2, 105]. 
Together, the role of PLA2 in envenomation and toxicity is highly complex, despite its straight-
forward function as a phospholipase. Therefore, it is increasingly vital to extensively 









 Figure 4.1. (A) Crystal structure of PLA2 notexin from Notechis scutatus (PDB 1ae7) with 
the Ca2+ binding loop highlighted in red and the interacting sulphate ions shown. (B) Schematic 
representation of PLA2-catalysed hydrolysis of phospholipid at the sn-2 position on the 
glycerol backbone to liberate lyso-phospholipid and a fatty acid on the cell membrane.  
 
Structurally, snake venom PLA2s are relatively small proteins ranging from 13 – 16 
kDa, 118 – 133 amino acids in length, comprised of three α-helices and two antiparallel β-
sheets, and a Ca2+ binding loop as a part of the catalytic core (Figure 4.1.A) [47, 106]. PLA2 
monomers are relatively cysteine-rich, forming 6 – 8 highly conserved disulphide bonds [47, 
106, 107]. Despite the robust scaffold imparted by these disulphide bonds, significant 
variations in the amino acid residues near the PLA2 active site are apparent, contributing to 
isoform diversity and varied functionality across the PLA2 superfamily [104, 105]. Such multi-
functional variability of PLA2s further arises from higher-order oligomerisation of PLA2 
subunits, which are quaternary interactions that are in the pioneering stages of characterisation 
as mentioned in Chapter 1.  
 
4.1.2. Higher-order structures of snake venom phospholipase A2 
 
Monomeric PLA2 in snake venoms possess a great deal of biological activity on their 
own. The potency in catalytic activity of monomeric PLA2, however, is thought to be 
augmented further by the diversity of oligomeric states and interactions that PLA2 subunits can 
adopt [2, 6, 106]. For example, covalently-linked crotoxin dimers have been reported, as well 
as non-covalent assemblies including heterotrimeric taipoxin and paradoxin, and pentameric 




of PLA2 is speculated to finely regulate the degree of toxicity when compared to monomeric 
PLA2. While the mechanisms responsible for enhanced potency in multimeric PLA2s are not 
well understood, it is thought that binding affinity at the target site, which is at the phospholipid 
bilayer of cell membranes, is increased by oligomerisation [6, 106]. PLA2s have also been 
observed to oligomerise with other venom toxins such as 3-Finger toxins (3FTxs) and snake 
venom metalloproteinases (SVMPs) to exert toxicity [6, 106]. Together, the promiscuous 
nature of PLA2 oligomerisation contributes greatly to the myriad of complex downstream 
pathophysiological effects that result in the diverse range of envenomation symptoms.  
Despite the speculated importance of these higher-order structures in venom, only a 
few of these complexes have been successfully characterised. There remains many other PLA2 
complexes in medically significant snake species that are yet to be explored. As revealed in 
Chapter 3, the venom of P. colletti is relatively simple in composition yet highly PLA2-
abundant. This renders it an ideal model venom to investigate PLA2 oligomerisation, in 
addition to gaining further insight on PLA2 structure and function by IM-MS. The fact that P. 
colletti envenomation results in potent systemic symptoms despite the lack of diversity in 
venom composition raises interesting questions as to whether higher-order structural 
interactions between PLA2s are potentially responsible for enhanced activity. In this chapter, 
we interrogate the venom of P. colletti for higher-order PLA2 complexes by native IM-MS, 
and gain insight on the effect of these interactions on PLA2 function.  
 
 
4.2. Results and discussion 
4.2.1. Purification of PLA2 oligomers from crude P. colletti venom 
 
As described in Chapter 3, P. colletti venom was shown to be highly abundant in PLA2, 
which predominantly eluted at approximately 18 mL during SEC fractionation (fraction P2, 
Figure 4.2.A), corresponding to intermediate-sized protein species; the focus will thus be on 
further purification and interrogation of PLA2 proteins in this chapter. As only P. colletti 
venom will be explored, the SEC peaks labels are simplified to peak numbers for ease of 
reference (Figure 4.2.A). Fractions corresponding to the P2 peak from SEC separation of P. 
colletti whole venom (Figure 4.2.A, shaded box) were pooled for further separation by ion-




in the elution of four peaks (labelled 1 - 4), corresponding to potentially distinct PLA2 
isoforms (Figure 4.2.B). Given the positively-charged stationary phase used during IEX 
separation, proteins in peaks 1-4 are expected to elute in the order of most basic through to 
neutral and most acidic PLA2 isoforms. Combined, this data demonstrates the structural 
complexity of PLA2s in this seemingly simple venom mixture.  
 
 
Figure 4.2. Purification of PLA2 proteins from crude P. colletti venom. (A) SEC elution profile 
of P. colletti whole venom (10 mg/mL) in 200 mM NH4OAc (pH 7.0) with PLA2 highly 
abundant in the P2 peak (shaded box).  (B) IEX elution profile of the P2 peak containing PLA2 
in 10 mM tris-HCl, 2 mM EDTA and 0.05% NaN3 (pH 8.5). Proteins were eluted using a 50% 
1 M NaCl gradient (purple line).  
 
4.2.2. Analysing the quaternary structure of P. colletti PLA2 by native IM-MS  
 
The quaternary structures of isolated PLA2 proteins from IEX chromatography were 
interrogated by native IM-MS. The majority of the PLA2 species across the fractions examined 
are monomeric at approximately 13 kDa (Figure 4.3), consistent with the native MS data 
described in Chapter 3. The observed molecular masses of these monomeric PLA2 are very 
similar, ranging from 12.9 – 14 kDa with mass differences ranging from 0.1 – 1 kDa. The 
observed variations in mass may be indicative of numerous PLA2 isoforms which differ by a 
single amino acid or additionally due to post-translational modifications (PTMs), particularly 
glycosylation. Previous studies have indicated glycosylation to be a common modification in 




67], with highly variable and often atypical glycosylation patterns, including sialic acid-
containing glycans that fall within the previously reported mass range [41, 42].  
Interestingly, a 27.7 kDa species was also observed which is potentially indicative of 
dimeric PLA2 based on its charge state distribution and molecular mass (Figure 4.3.C). The 
presence of this dimeric species is novel as there is no structural data reporting the existence 
of PLA2 dimers in P. colletti venom, although the presence of such dimers has been briefly 
speculated in a previous study based on SDS-PAGE analysis of whole P. colletti venom [90]. 
To date therefore, this is the first observation of dimeric PLA2 in a venom thought to contain 
monomeric PLA2, and indicates that quaternary structure and dynamics may be at play in 






Figure 4.3. Native IM-MS reveals monomeric and dimeric P. colletti PLA2. (A-D) Native mass 
spectra of PLA2 isoforms (10 µM) from IEX chromatography fractions (insets, shaded box). 
Dimeric PLA2 was observed in fraction 3 with a molecular mass of 27.7 kDa (C). The various 
monomeric and dimeric PLA2 species and their corresponding charge states are indicated. (E 
and F) IM heat maps of PLA2 spectra acquired in C and D respectively. Proteins were prepared 
in 200 mM NH4OAc (pH 7.0) prior to native IM-MS analysis.  
 
4.2.3.  Structural investigation of dimeric PLA2 by native IM-MS 
 
In order to further interrogate the 27.7 kDa species, the initial SEC elution profile was 
revisited (Figure 4.4.A), which revealed a shoulder on the P2 peak, potentially corresponding 
to larger protein species that were incorporated into the pooled SEC P2 fractions analysed by 
native IM-MS (Figure 4.3.C). To determine whether the previously observed dimeric PLA2 
species was a result of insufficient resolution during initial SEC separation, smaller volume 
fractions were collected in order to enhance separation. SEC fractions corresponding to the 




respectively (Figure 4.4.A), were chosen for SDS-PAGE and direct native IM-MS analysis 
(Figure 4.4.C-F).   
 
Figure 4.4. Separation and analysis of monomeric and dimeric P. colletti PLA2 by native IM-
MS. (A) SEC of P. colletti whole venom (10 mg/mL) containing PLA2 in peaks S2 and P2 
(shaded boxes). (B) SDS-PAGE analysis of eluted SEC fractions. Lanes 1 to 4 correspond to 
SEC fractions P1, S2, P2, and P3, respectively. (C and D) Native mass spectra of peaks P2 (C) 
and S2 (D) containing PLA2 isoforms (10 µM) from SEC fractions (insets, shaded box). 
Dimeric PLA2 was observed in peak S2 with a molecular mass of approximately 27.7 kDa (C). 
The various monomeric and dimeric PLA2 species and their corresponding charge states are 
indicated. (E and F) Corresponding IM heat maps of PLA2 spectra acquired in B and C 






Under the denaturing and reducing conditions of SDS-PAGE, both S2 and P2 fractions 
showed a single protein band at approximately 15 kDa (Figure 4.4.B). Native IM-MS of P2 in 
this SEC separation is consistent with what was observed in the previous analysis of the main 
P2 fraction, where monomeric PLA2 species at 13.1 kDa and 12.9 kDa were observed (Figure 
4.4.C). In addition, the complex and broader spectral peaks of the monomeric PLA2 species 
that were observed previously were also noted (Figure 4.4.C-D) which may be attributed to 
additional PTMs. However, native MS analysis of the S2 fraction revealed a mixed population 
of a 12.9 kDa monomer, 13.1 kDa monomer, and notably an enriched 27.7 kDa dimeric PLA2 
species (Figure 4.4.D). A large 1.5 kDa mass discrepancy between a theoretical 26.2 kDa PLA2 
dimer formed from the 13.1 kDa monomers and the experimentally observed 27.7 kDa species 
suggests that the 27.7 kDa dimer is potentially a separate PLA2 species [41, 42]. The 
accompanying IM heatmaps further highlight the populations of monomeric and dimeric PLA2 
across various charge states (Figure 4.4.E-F), confirming that the 27.7 kDa species are present 
in the S2 fraction corresponds to the shoulder of the SEC P2 peak.  
As to the nature of the interaction, the S2 fraction containing the 27.7 kDa dimer was 
analysed by MS under denaturing conditions to investigate the whether the dimer was 
covalently or non-covalently linked (Figure 4.5.A). The 27.7 kDa species was still observed in 
a mixed distribution with 12.9 kDa monomeric PLA2, albeit at a lower relative abundance to 
the monomer with monomeric PLA2 species displaying complex and broad spectral peaks 
compared to dimeric PLA2, which as previously mentioned infers PTMs on the monomers. The 
low abundance of the 27.7 kDa species further implies that the dimeric PLA2 species is being 
held by very strong interactions capable of persisting under denaturing conditions, and is 
possibly the result of a covalent interaction, such as a disulphide bond, holding the two subunits 
together. This is plausible as such covalently-linked PLA2s have been observed in other studies, 








Figure 4.5. Denatured mass spectrum of eluted PLA2 fraction S2 (5 µM), purified from P. 
colletti venom. (A) Fraction S2 following SEC separation was mixed with 50% (v/v) ACN and 
0.1% (v/v) FA prior to ESI-MS analysis. (B) Fraction S2 was incubated with 1 mM DTT prior 
to denatured MS analysis as described in (A). Charge state distributions of PLA2 monomers 
and dimers are illustrated with their corresponding charge state.   
 
Further treatment of the 27.7 kDa dimer with a reducing agent DTT prior to denatured 
MS analysis showed dissociation of the dimer into 13.8 kDa monomers (Figure 4.5.B). This 
further confirmed the covalent nature of the PLA2 dimer and is in good agreement with the 
single protein band corresponding to monomeric masses previously observed by reducing 
SDS-PAGE (Figure 4.4.B); in addition, this affirmed the large mass discrepancy noted earlier 
in the native MS analysis (Figure 4.4.B).  Certain PTMs or structural moieties of these specific 
PLA2s may be involved for dimerization; however, due to the fact that a comprehensive protein 
sequence library has yet to be curated for P. colletti venom, as well as many other venoms, 
confident identification of the PLA2 isoforms and speculated PTMs is difficult to achieve at 






4.2.4. CCS determinations reveal compactness and sphericity of P. colletti PLA2 
 
While the previous native IM-MS analysis show the various populations of PLA2 
isoforms, further structural insight on the overall shape and conformation of these protein 
species can be probed by performing travelling wave ion-mobility separation (TWIMS) derived 
collision cross-sectional area (CCS) measurements. CCS measurements were performed by 
calibrating the analyte drift time, across a range of charge states, against the known CCS values 
of various protein standards (cytochrome c and myoglobin) (Table 4.1).  CCS values obtained 




Table 4.1. CCS values of PLA2 ions isolated from P. colletti venom. The four major peaks 
isolated from IEX separation (P2-1, P2-2, P2-3, and P2-4) were analysed for protein CCS 
determination for all observed charge states acquired.  
Protein ID (Da) m/z (charge) Collision cross-section (Å2) 
P2-1 PLA2 monomer (12,910) 2582 (5) 1017 
2152 (6) 1170 
1845 (7) 1276 
1614 (8) 1421 
P2-1 PLA2 monomer (13,112) 2628 (5) 982 
2186 (6) 1162 
1874 (7) 1280 
1640 (8) 1411 
P2-2 PLA2 monomer (14,097) 2821 (5) 987 
2350 (6) 1154 
1874 (7) 1280 
1763 (8) 1350 
P2-2 PLA2 monomer (13,093) 3274 (4) 783 
2620 (5) 976 
2169 (6) 1136 
1871 (7) 1228 
1637 (8) 1395 




2582 (5) 982 
2152 (6) 1120 
1844 (7) 1249 
1614 (8) 1387 
P2-3 PLA2 dimer (27,741) 3078 (9) 1629 
2771 (10) 1605 
2521 (11) 1859 
2310 (12) 2294 
P2-3 PLA2 monomer (12,910) 2153 (6) 1120 
1845 (7) 1249 
1617 (8) 1420 
P2-4 PLA2 monomer (13,024) 2610 (5) 1137 
2171 (6) 1175 
1861 (7) 1271 
1629 (8) 1398 
P2-4 PLA2 monomer (13,267) 2659 (5) 1159 
2216 (6) 1174 
1896 (7) 1274 
1662 (8) 1403 
 
Measured CCS values were subsequently used to determine the effective density for 
each of the protein species which infers preliminary structural geometry and the degree of 
sphericity these protein species adopt. CCS values in helium were approximated using the 
measured CCS values for the PLA2 proteins (Table 4.1) to determine the effective density of 
PLA2 species using the method in [109].  
The effective protein radius (reff) from the averaged CCS values (?̅?) for all the observed charge 




− 𝑟𝐻𝑒 (reff = 1)   (1) 









The effective density (Deff) is then calculated using the Veff, molecular weight (MW) of the 







    (3) 
 
Table 4.2. Effective density (Deff) of the various PLA2 species from P. colletti venom.  
Protein ID (Da) Effective protein 
density (Deff) (g cm-1) 
P2-1 PLA2 monomer (12,910) 0.76 
P2-1 PLA2 monomer (13,112) 0.78 
P2-2 PLA2 monomer (14,097) 0.88 
P2-2 PLA2 monomer (13,093) 0.90 
P2-2 PLA2 monomer (12,907) 0.89 
P2-3 PLA2 dimer (27,741) 0.85 
P2-3 PLA2 monomer (12,910) 0.72 
P2-4 PLA2 monomer (13,024) 0.74 
P2-4 PLA2 monomer (13,267) 0.75 
 
The calculated Deff for the various PLA2 species were relatively consistent (Table 4.2). 
For the monomeric PLA2 species, the Deff ranged from 0.72 to 0.90 g cm
-3, whereas the 
calculated Deff for the dimeric PLA2 species is 0.85 g cm
-3. These density values correspond 
well to previously reported native-like proteins [109] and also implies that these proteins adopt 
a spherical geometry based on preliminary coarse-grain sphere fitting [109]. The general 
sphericity of these PLA2s demonstrate the lack of significant extended or unfolded structural 
components and further implies that the degree of compactness observed in these P. colletti 
PLA2 ions may be correlated to the cysteine-rich structure known for PLA2 [110]. As 
previously mentioned, snake venom PLA2s are relatively small proteins ranging from 118 – 
133 amino acid in length with 6 – 8 conserved disulphide bonds [47]. This number of disulphide 
bonds is considered unusually high for the corresponding protein size; a study correlating the 
frequency of disulphide bonds to the size of a protein has shown that eukaryotic proteins of 
this size (100 – 300 amino acids) generally possessed the smallest average number of cysteines 




Thus, the high number of disulphide bonds in PLA2s may be critical in ensuring that 
the protein’s structural integrity is maintained. The determined Deff values and corresponding 
implied compact spherical structures for these PLA2s is an interesting prelude to more refined 
structural characterisation and modelling, and demonstrates the power of IM-MS analysis in 
high-throughput structural characterisation.    
 
4.2.5. Functional characterisation of dimeric and monomeric P. colletti PLA2  
 
Another aim of this study was focussed on if and how the differences in PLA2 
oligomeric state affect biological activity. To probe the functional effects of oligomerisation 
on PLA2 from P. colletti venom, a MS-based PLA2 enzyme assay was used to monitor the 
catalytic efficiencies of monomeric and dimeric PLA2. While conventional assessment of PLA2 
enzymatic activity is usually performed using fluorescence-based colorimetric assays, MS 
characterisation allows for multiple analytes to be studied simultaneously, which is exploited 
here whereby substrate depletion and product formation are monitored simultaneously [112]  
PLA2s hydrolyse phospholipids specifically at the sn-2 position on the glycerol 
backbone to liberate a fatty acid from the lyso-phosphatidylcholine (LPC). Here, 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphocholine (POPC) was selected as the phospholipid substrate and 
the asymmetry of the phospholipid in its fatty acid chains enables discrimination of substrate 
hydrolysis by PLA2, as opposed to PLA1 activity which hydrolyses at the sn-1 position. In this 
instance, POPC exists as a pair of regioisomers, POPC 16:0/18:1 and POPC 18:1/16:0 (number 
of carbons:number of unsaturated bonds along the fatty acid chain), which produce different 
LPC major products (LPC 16:0 and LPC 18:1) from the specific hydrolysis by PLA2 at the sn-
2 position (Figure 4.6). In addition, POPC was chosen as it is known to mimic the composition 
of numerous cell membranes [113, 114] along with the fact that PLA2s are known to interact 
directly with the cell membrane [47, 115]. Given this, POPC is an ideal phospholipid substrate 





Figure 4.6. PLA2-mediated hydrolysis of a pair of regioisomeric phosphatidylcholines (POPC) 
16:0/18:1 and POPC 18:1/16:0. The liberated lyso-phosphatidylcholine (LPC) products (A) 
LPC 16:0 and (B) LPC 18:1 are cleavage products produced by PLA2 which are detectable by 
MS.  
 
Here, the MS-based PLA2 enzyme assay enables simultaneous depletion of the POPC 
substrate and the evolution of the LPC products to be monitored by MS. PLA2 enzyme and 
POPC substrate were mixed in a 1:1 molar ratio and incubated prior to direct infusion through  
ESI-MS. Enzymatic activity was monitored by the identification and extraction of the parent 
ion (as well as sodium adducted ions) correlating to intact substrate (POPC) and product (LPC) 
at various time points, whereby the ion intensity was taken as a measure of relative abundance 
of the species present (Figure 4.7). The PLA2 monomer from honeybee venom (Apis mellifera, 
BV-PLA2) was used as a proof of principle to verify the feasibility of this approach. This assay 
was conducted for SEC fraction P2 containing only monomeric PLA2 and the fraction S2 
containing the 27.7 kDa dimeric PLA2 from P. colletti (with BV-PLA2 as the positive control). 
It should be noted that while there is a mixed population of monomeric and dimeric PLA2s in 
the dimer fraction, the same concentration of total monomeric PLA2 was used for these assays.  
The temporal depletion of POPC and subsequent increased abundance of products 
(LPC 16:0 and LPC 18:1) show the enzymatic activity of BV-PLA2 that is consistent with 
previously reported activities of PLA2s (Figure 4.7.A) [112].  The enzymatic activities of 
monomeric and dimeric PLA2 (PC-PLA2) obtained from P. colletti venom (Figure 4.4.A) were 
also tested on POPC using this MS-based assay.  Both P. colletti PLA2s exhibited similar 
activities compared to BV-PLA2, whereby the depletion of POPC and the evolution of LPC 
products were observed during the assay (Figure 4.7). Fluctuations in the various trendlines 




far apart, being every three minutes as opposed to monitoring on the scale of seconds. Thus, 
the variations in the activity traces may be mitigated with shorter time intervals.  Nevertheless, 
the differences in enzymatic activities of the PLA2 monomer and dimer fractions from P. 
colletti venom first become apparent upon examining the point at which the rate of POPC 
consumption equates that of LPC formation. For dimeric PLA2, this occurs substantially earlier 
in the reaction (four min) compared to monomeric PLA2 (seven min) (Figure 4.7.B and C)). 
 
 
Figure 4.7. MS-based PLA2 enzymatic assays of monomeric and dimeric PLA2 from P. colletti 
venom. The enzymatic activity of (A) monomeric bee venom PLA2 (BV-PLA2), (B) 
monomeric P. colletti PLA2 (PC-PLA2) and (C) dimeric P. colletti PLA2 (PC-PLA2). The 
increased abundance of major products LPC 16:0 (green), LPC 18:1 (orange), and the depletion 
of substrate POPC (blue) were monitored by ESI-MS (n=3).  
 
  The relative abundance of POPC at the completion of the enzymatic assays was also 
measured in order to confirm the enhanced enzymatic activity afforded by the enriched dimeric 
PC-PLA2 (Figure 4.8). As shown in Figure 4.8, the abundance of POPC substrate was observed 
to be significantly lower for dimeric PC-PLA2 than it was for both monomeric PC-PLA2 and 
BV-PLA2, which the latter has been shown to have good substrate specificity to POPC and 
substantial activity that is comparable to other monomeric snake venom PLA2s [116]. This data 
further suggested the enhanced enzymatic activity of the enriched dimeric PC-PLA2 compared 
to purely monomeric PC-PLA2. Despite being a preliminary approach to exploring PLA2 
enzyme activity of crude venom fractions, together, this difference in enzymatic activity further 
accentuates the importance of recognising higher-order protein interactions in the scheme of 
characterising venom protein function and activity. Further endeavours to purify the PLA2 





Figure 4.8. Relative abundance of POPC remaining at the conclusion of the MS-based 
enzymatic assay upon respective treatment of monomeric BV-PLA2, monomeric PC-PLA2, and 
enriched dimeric PC-PLA2. The relative abundance of POPC substrate was measured as 
averaged ion abundance at the endpoint (15 min) of the assay (**** P-value < 0.0001, n=3).  
 
It should be noted that neat methanol was used to maintain the lipid substrate solubility, 
which is not ideal in the context of performing enzymatic assays pertaining to physiologically 
relevant systems. It is interesting to note that the enzymatic activity of the PLA2s were not 
completely compromised, which is consistent with results reported in a previous study [112]. 
The highly disulphide-bonded state of venom PLA2s may contribute to the ability of PLA2 to 
resist chemical denaturation, thereby preserving some of its activity. Although the unique 
structural features of PLA2s permit such treatment under the current experimental conditions 
presented, further assay optimisation is required, particularly augmenting buffer composition, 
temperature, pH, redox state, and stoichiometries (substrate:enzyme ratios) that are more 
physiologically relevant in the future, especially as reduced enzymatic activity could be the 
result of certain solvent conditions.  
 
 
4.3. Concluding remarks  
 
Here, the higher-order structures of various PLA2s in the venom of P. colletti were 
investigated using native IM-MS. Our findings show that different PLA2 proteoforms are 
present in the venom, most of which are extensively modified and adopt a compact spherical 




presence of PLA2 dimers in the venom of P. colletti for the first time. Further analysis and 
avenues of investigation are therefore necessary to answer finer mechanistic questions 
regarding the formation of PLA2 dimers. Moreover, the development and use of a MS-based 
PLA2 enzymatic assay to investigate enzymatic activity of dimeric and monomeric PLA2 in 
SEC venom fractions on a phospholipid substrate, revealed a positive correlation between 
higher-order states and activity. While further experimental optimisation is required to gain 
accurate and more quantitative measurements, the data demonstrates not only the feasibility of 
this MS-based approach, but importantly, showcases the changes in activity as a result of PLA2 
dimerisation. In summation, this study further emphasises and establishes the importance of 
understanding the formation of higher-order structures for snake venom proteins in order to 





4.4. Experimental procedures  
4.4.1. Materials, reagents, and buffers used 
 
All reagents were purchased from Sigma Aldrich (NSW, Australia) unless specified otherwise.  
Whole lyophilised P. colletti venom was purchased from Venom Supplies Pty. Ltd. (Tanunda, 
Australia), and were stored at -20 oC until required for experimentation.   
200 mM NH4OAc buffer (pH 7.0) was filtered using a Nalgene Rapid-Flow bottle top filter 
(Thermo Fisher Scientific, Massachusetts, US) and de-aerated with an ultrasonic cleaner 
(Soniclean, SA, Australia) prior to its use in SEC and MS analyses.  
3x SDS-PAGE loading buffer: 150 mM tris-HCl (pH 6.8), 300 mM DTT, 6% SDS, 30% 
glycerol, 0.3% bromophenol blue. 
1x SDS-tris-glycine running buffer: diluted from 10x running buffer (25 mM tris, 192 mM 
glycine, 0.1% SDS, pH 8.5). 
Coomassie Brilliant Blue staining solution: Coomassie Brilliant Blue R250 dye, 10% (v/v) 
glacial acetic acid, 40% (v/v) methanol in distilled water.  
Destain solution: 40% (v/v) methanol, 10% (v/v) acetic acid in distilled water.  
 
4.4.2. Separation of whole P. colletti venom by SEC  
 
Lyophilised whole P. colletti venom was reconstituted in 200 mM NH4OAc (pH 7.0) 
at a concentration of 10 mg/mL and loaded onto a Superdex200 10/300 size-exclusion column 
(GE Healthcare, Illinois, US) coupled to an ÄKTA Pure FPLC system (GE Healthcare, Illinois, 
US). The column was equilibrated with 200 mM NH4OAc (pH 7.0) prior to sample loading 
(400 µL). Fractions (400 µL) were collected at a flow rate of 0.4 mL/min. 
 
4.4.3. Separation of P. colletti PLA2 fractions by IEX  
 
SEC fractions of interest were pooled, freeze-dried and reconstituted in Buffer A (20 
mM tris-HCl, 1 mM EDTA, 0.02% NaN3 in water). The sample was loaded onto a MonoQ 
5/50 GL anion-exchange column (GE Healthcare, Illinois, US) coupled to an ÄKTA Pure 




flow rate of 1 mL/min and a linear gradient to 50% Buffer B (Buffer A containing 2 M NaCl) 
was applied over 20 mL, followed by a 15 mL elution with Buffer B. Fractions (2 mL) were 
collected and buffer-exchanged into 200 mM NH4OAc (pH 7.0) using Vivaspin 2 
centrifugation units (GE Healthcare, Illinois, US) with a molecular weight cut-off of 3 kDa. 
Samples were stored at -20 oC until required for use. 
 
4.4.4. 1D SDS-PAGE 
 
Venom fractions of interest were added to 3x reducing sample buffer (1:1 v/v) and 
denatured at 95 oC for 15 min prior to loading onto a 4 – 15% Mini-Protean TGX tris-HCl 
polyacrylamide gel (Bio-Rad, California, US). Gel electrophoresis was performed at 140 V and 
400 mA for 1 h in 1x SDS tris-glycine running buffer. Precision Plus Protein Dual Colour 
standards (Bio-Rad, California, US) were used as molecular weight markers. SDS-PAGE gels 
were stained with Coomassie Brilliant blue staining solution for 30 min and destained with 
Coomassie Brilliant blue destain solution for 3 h prior to imaging using an Imagescanner 
densitometer (Amersham Biosciences, Amersham, UK).  
 
4.4.5. IM-MS analysis of venom subunits   
 
All mass spectra were obtained using a Synapt G1 HDMS quadrupole ion mobility 
time-of-flight mass spectrometer (Waters, Manchester, UK). Protein samples were buffer-
exchanged into 200 mM NH4OAc prior to MS analysis. 4 µL of sample (10 µM) was 
introduced into the instrument by nano-ESI using platinum-coated borosilicate capillaries that 
were prepared in-house. The instrument conditions were set to preserve non-covalent 
interactions as follows: m/z range, 500 – 6000; polarity, positive; capillary voltage, 1.5 kV; 
sample cone voltage, 50 kV; extraction cone, 3 kV; source temperature, 50 oC; desolvation 
temperature; 180 oC; trap collision energy, 30 V; transfer collision energy, 30 V; IMS wave 
velocity, 300 m/s; IMS wave height, 7 V; IMS gas flow, 28 mL/min; backing pressure, 4.07 
mbar. All native mass spectra were analysed using MassLynx software (version 4.1, Waters) 
and IM data was analysed using Driftscope software (version 2.1, Waters). Drift times which 
correspond to the identified charge states of interest were extracted from IM heatmaps and 
further analysed in MassLynx. CCS calculations for proteins of interest were determined as 




4.4.6. Denatured MS analysis  
 
All denatured mass spectra were obtained using an Agilent 1260 LC system coupled to 
an Agilent 6230 TOF mass spectrometer (Agilent Technologies, California, US) tuned over a 
3200 m/z mass range. 2 µL of sample (5 µM) was directly injected into the instrument via the 
LC auto sampler and eluted at a flow rate of 0.2 mL/min without chromatographic separation. 
An isocratic elution of 50% Solvent B was used; Solvent A (0.1 % (v/v) FA in water) and 
Solvent B (99.9% (v/v) ACN 0.1% (v/v) FA). The instrument conditions were set as follows: 
m/z range, 500 – 3200; polarity, positive; capillary voltage, 3.5 kV; nozzle voltage, 2 kV; gas 
temperature; 325 oC. Mass spectra were acquired under the control of MassHunter Workstation 
software (version B.08.00, Agilent Technologies). MS data analysis was performed using 
MassHunter Workstation software (version B.07.00, Agilent Technologies) where spectra were 
summed over the time period of sample elution. For MS experiments under both reducing and 
denatured conditions, the sample was first incubated with 1 mM DTT in 200 mM NH4OAc for 
1 h prior to MS analysis by the workflow described above.  
 
4.4.7. MS-based PLA2 enzymatic assay 
 
This assay was adapted from [112] with minor modifications. Essentially, P. colletti 
dimeric and monomeric PLA2 samples were concentrated using Vivaspin 2 centrifugation units 
(GE Healthcare, Illinois, US) with a molecular weight cut-off of 3 kDa, and protein 
concentration was determined using a bicinchoninic (BCA) assay (Thermo Fisher Scientific, 
SA, Australia) according to the manufacturer’s protocol. PLA2 from honeybee venom (Apis 
mellifera) (Sigma Aldrich, NSW, Australia) was used as a positive control.  PLA2 samples 
were prepared to 0.84 µM (i.e. 0.016 mg/mL, corresponding to 20 units/mL for the positive 
control) in 200 mM NH4OAc (pH 7.0). 9 µM of lipid substrate (POPC 16:0/18:1) (Avanti Polar 
Lipids, Alabama, US) was prepared in 5 mM NH4OAc (pH 7.0) dissolved in neat methanol. 
PLA2 (30 µL) was added to the lipid substrate (30 µL), followed by mixing by pipetting and a 
3 min incubation at room temperature. All samples were analysed using an Agilent 1260 LC 
system coupled to an Agilent 6230 TOF mass spectrometer (Agilent Technologies, California, 
US) tuned over a 1700 m/z mass range. 5 µL of sample was directly injected into the instrument 
via the LC auto sampler and eluted at a flow rate of 1 mL/min without chromatographic 




for 2 min to ensure elution of both POPC substrate and LPC products; Solvent A (0.1% (v/v) 
FA in water) and Solvent B (99.9% (v/v) ACN 0.1% (v/v) FA). The reaction was monitored 
every 3 min for a 15 min duration.  
MS instrument conditions were set as follows: m/z range, 100 – 2000; polarity, positive; 
capillary voltage, 1.2 kV; nozzle voltage, 1 kV; gas temperature; 325 oC. Mass spectra were 
acquired under the control of MassHunter Workstation software (version B.08.00, Agilent 
Technologies). MS data analysis was performed using MassHunter Workstation software 
(version B.07.00, Agilent Technologies) where spectra were summed over the time period of 
sample elution and the error tolerance was set to 60 ppm. The extracted ion count intensities of 
intact POPC substrate (760.6 m/z), LPC 18:1 (522.3 m/z), and LPC 16:0 (496.3 m/z) product 
ions along with the corresponding adducted ions were summed at a given timepoint and the 







~ Chapter 5 ~ 
Summary 
 
5.1. Investigation of proteomic variations in the venoms of different N. scutatus 
populations  
 
A study on the proteomic variations in the venom compositions of various N. scutatus 
from different geographical regions was conducted using a shotgun proteomics pipeline, where 
age-matched male N. scutatus were selected from five locations: Franklin Island, Reevesby 
Island, Melbourne, Mt Gambier, and Tasmania.  2D SDS-PAGE and a qualitative proteomic 
analysis revealed N. scutatus venom to be generally diverse and abundant in PLA2 toxins. A 
more quantitative analysis of the five venom proteomes further established the high degree of 
proteomic diversity in the venoms across various populations. Significant variation in the 
relative abundance of 3FTxs was the greatest distinction identified across the five venoms; 
Melbourne and Mt Gambier N. scutatus venoms were noted to possess the highest proportions 
of 3FTxs while very little to none were observed in the Franklin Island, Reevesby Island, and 
Tasmanian venoms. The possibility of a diet prey-type influence was considered for the stark 
distinction in 3FTx abundance as the N. scutatus on the two island populations (Franklin and 
Reevesby Islands) were noted to consume a more bird-specialised diet. The similarity of the 
Tasmanian venom proteome to that of the two island populations despite having different diets, 
however, suggested other ecological factors are likely to contribute to the observed variations.  
Considerable intra-population proteomic variations at an individual protein level were 
observed in a more focussed quantitative proteomic comparison of Franklin Island and Mt 
Gambier N. scutatus venoms. Despite certain distinctions in protein expression levels across 
populations, these variations inferred intrinsic venom variabilities between N. scutatus 
individuals. A distinct variability in the venom compositions of different N. scutatus 
populations was captured in this study. The complexity implies the contribution of multiple 
factors aside from the diet prey-types consumed by different N. scutatus populations, including 
climate, seasonal, or intrinsic individual variabilities. This further emphasises the importance 
of characterising proteomic variations in venoms in an ecological context. To establish a more 
comprehensive picture, further experimentation with a larger sample size as well as integration 




5.2. Higher-order structural characterisation of venom proteins from P. 
colletti, N. melanoleuca, and B. arietans venoms  
 
An integrated MS-based approach was used to explore the higher-order structures of 
venom proteins from a repertoire of phylogenetically diverse yet medically significant venoms 
from P. colletti, N. melanoleuca, and B. arietans. Emerging differences between the two elapid 
venoms (P. colletti and N. melanoleuca) and the viperid venom (B. arietans) were captured 
during separation of the whole venoms by SEC and SDS-PAGE; these differences which are a 
good reflection of the phylogenetic distinctions between the venoms were further enhanced by 
shotgun proteomics, revealing significant diversities in the three venom proteomes. The simple 
and extremely PLA2-abundant proteomic profile of the P. colletti venom was revealed; the 
more diverse, PLA2 and 3FTx-rich venom of N. melanoleuca as well as the significantly 
different B. arietans venom proteome abundant in DIS, CTL, 3FTx and VEGF were also 
catalogued.  
A combination of proteomic and native MS analysis of high and intermediate mass 
range venom fractions revealed a 117 kDa dimeric LAAO species in the P. colletti venom and 
a 60 kDa CTL tetramer in the B. arietans venom for the first time by MS. Denatured MS studies 
further confirmed the nature of the dimeric LAAO and the CTL tetramer to be non-covalent 
and covalent, respectively.  This study offered preliminary insight into the structures of protein 
complexes by MS. Further structural studies can be built on the foundation that this MS-based 
workflow has established; these may include further separation of the venom fractions to 
explore other venom proteins of interest as well as a more detailed analysis of the structural 
moieties that facilitate the protein oligomerisations observed here.   
 
5.3. Structural and functional insight on PLA2s from P. colletti venom  
 
Investigation of the higher-order structure and function of PLA2s as an important toxin 
family was conducted using P. colletti venom as a model venom. Native IM-MS analysis of 
purified P. colletti venom fractions revealed a variety of PLA2 isoforms, the majority of which 
were found to be structurally monomeric ranging from 12.9 – 14.0 kDa and likely highly 
modified with various PTMs. A 27.7 kDa PLA2 dimer was reported in P. colletti venom for 
the first time by MS, and while further investigation is necessary to give finer, mechanistic 




native MS analysis confirmed the PLA2 dimer to be a covalently-linked species. These PLA2 
species were also found to adopt a highly compact and relatively spherical geometry based on 
CCS-derived calculations, which may be attributed to the highly disulphide-bonded structure 
of these proteins.  
The difference in the catalytic efficiencies of monomeric and dimeric PLA2 was further 
explored using a MS-based PLA2 enzyme assay using a phospholipid substrate. Dimeric PLA2 
demonstrated substantially greater bioactivity than the monomeric PLA2; the difference in 
activity infers the importance of understanding oligomeric protein species, PLA2 in the case of 
this study, in augmenting venom protein bioactivity. Further experimental optimisation to 




5.4. Concluding remarks  
 
The work presented in this thesis demonstrates the implementation of MS-based 
techniques, namely shotgun proteomics and native IM-MS, to investigate various structural 
biological and ecological questions surrounding snake venoms from a fundamental protein 
structure perspective. The findings here provide a good foundation for further MS-based 
investigation of venom proteins and can hopefully contribute towards the combined 
interdisciplinary effort to bridge the knowledge gap in our current proteomic and structural 
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4299 14382 784.8369 4 K.RPTWHYMDYGCYCGAGGSGTPVDELDR.
C      





3238 14465 1011.3857 2 K.MSAYDYYCGENGPYCR.N 
     





1354 15050 1436.2387 3 K.LPACNYMMSGPYYNTYSYECNEGELTCK
DNNDECK.A      
1098.4379 4 R.HYMDYGCYCGKGGSGTPVDELDRCCQTH
DDCYGEAEK.L      











532 17223 1011.3857 2 K.MSAYDYYCGENGPYCR.N 
     





482 17735 646.9674 3 R.APYNDANWNIDTKTRC.- 
     




















































































44 17206 601.7905 2 K.GGSGTPVDELDR.C 


















181 64404 1004.4536 2 R.QDLYYMTPVPAGCYDSK.V 
     










3762 52265 855.4426 3 R.MKTPIQFSENVVPACLPTADFAK.E 
     





736 52799 967.9246 2 K.DGIGSYTCTCLPNYEGK.N 
     
828.9322 2 K.LGECPWQAVLINEK.G 































126 54066 829.4231 2 K.LGECPWQAVLIDEK.G 
     























453 52173 967.9253 2 K.DGIGSYTCTCLPNYEGK.N 
     





255 70323 1261.2118 3 K.MCGKLLCQEGNATCICFPTTDDPDYGMV
EPGTK.C      
982.4123 3 R.AAKDDCDLPESCTGQSAECPTDSFQR.N      





546 59363 1073.3095 4 R.NGLNETSNPKHVVVVGAGMAGLSAAYVL
AGAGHNVTLLEASER.V      
1043.5139 2 K.LNEFLQENENAWYFIR.N      






268 59374 791.0354 3 K.YAMGSITSFAPYQFQDFIER.V 
     
659.7104 3 K.TSADIVINDLSLIHQLPK.K      














m/z  z Peptide sequence 
LAAO 
    





34 59049 900.7701 3 R.RRPLEECFREADYEEFLEIAK.N 
     
552.2522 2 K.SDDIFSYEK.R  
OXLA_NAJ
AT 

















365 27222 1190.8076 3 K.SGPTCGDCPSACVNGLCTNPCKYEDDFSN
CK.A      











102 27364 744.7122 3 R.RSVKPPARNMLQMEWNSR.A 
     






















260 9472 709.9859 3 R.TCLEFIYGGCYGNANNFK.T 
     



















m/z  z Peptide sequence 
KUN 
    







1028.0602 2 K.ISVLGDPVAQIIENSIDGSK.L 
     












149 28209 535.4525 5 R.ENHPVHNQGEHSVCDSVSDWVIK.T 
     





93 28215 690.9954 3 K.GNMVTVMVDVNLNNEVYK.Q 
     
















142 68601 755.3616 3 K.QLGCHFNNDSELVSCLRSK.N 
     
590.2761 4 R.MMRYWANFARTGNPTDPADK.S      
















117 9489 894.3792 3 R.GCGCPNVKPGVQINCCKTDECNN.- 
     
























22 8700 645.2595 2 R.TWCDAFCSSR.G 
Cʹ  CO3_NAJN
A 
Naja naja  95 18635
0 
1028.0602 2 R.ISVLGDPVAQIIENSIDGSK.L 

















88 21220 749.3661 2 R.FSSSPCVLGSPGFR.S 
     










67 65077 725.3684 2 R.VVSLNVLCTECR.V 
     





























7128 14465 1074.464 3 R.RPTRHYMDYGCYCGWGGSGTPVD
ELDR.C      















Tropidechis carinatus  3210 17735 1431.57 3 K.LPACNYMMSGPYYNTYSYECNDGE
LTCKDNNDECK.A      

























Hydrophis hardwickii  63 17787 1133.123 3 R.MTLDYMDYGCYCGTGGSGTPVDEL
DRCCK.I 














m/z  z Peptide sequence 
PLA2 PA2BE_PSE
AU 




Naja sagittifera  17 14757 586.2276 3 R.SWQDFADYGCYCGK.G 
     
1157.568 2 R.LAAICFAGAPYNDANYNIDLK.A  
PA2B2_AUS
SU 










Pseudechis australis  42 13816 481.2444 2 K.ANWNIDTK.T 



































Austrelaps superbus  233 17234 735.2731 2 K.HYMDYGCYCGK.G 














m/z  z Peptide sequence 
PLA2 PA2AG_AU
SSU 














272 52173 967.9261 2 K.DGIGSYTCTCLPNYEGK.N 
     























Pseudonaja textilis 32 55249 531.3077 2 K.VVTLPYVDR.H 
     
632.9872 3 K.RANSLFEEFKSGNIER.E  
FAXC_PSET
E 











310 9630 803.3673 2 K.FIYGGCQGNSNNFK.T 
CRISP CRVP_DRY
CN 
Drysdalia coronoides  247 27283 1206.49 2 K.SGPTCGDCPSACVNGLCTNPCK.Y 
















m/z  z Peptide sequence 
CRISP 





















Demansia vestigiata  53 27364 654.7989 2 R.NMLQMEWNSR.A 
     
475.2187 2 K.GLCTNPCK.R  
CRVP_LATS
E 
Laticauda semifasciata  18 27311 1276.133 2 K.YLYVCQYCPAGNIIGSIATPYK.S 
     

















Tropidechis carinatus  71 3764 660.3297 2 K.IGDGCFGLPIDR.I 
ACHE ACES_BUN
FA 

































Austrelaps superbus  160 10416 813.3584 2 K.SEPCAPGENLCYTK.T 
VESP VESP_DRY
CN 
Drysdalia coronoides  51 21220 749.3661 2 R.FSSSPCVLGSPGFR.S 
PLB PLB_CROA
D 
Crotalus adamanteus  48 64350 945.4456 2 K.QNSGTYNNQYMILDTK.K 
     
786.3518 4 K.EIYNMSGYGEYVQRHGLEFSYEMA
PR.A      
649.965 3 R.DQGKVTDMESMKFIMR.Y  
PLB_DRYC
N 
Drysdalia coronoides  163 64404 1004.455 2 R.QDLYYMTPVPAGCYDSK.V 
HYAL HYAL_ECH
OC 
Echis ocellatus  52 53137 724.0485 4 R.ENFMCQCYQGWQGLYCEEYSIK.D 
     
635.3126 3 K.HSDSNAFLHLFPESFR.I  
HYAL_ECH
PL 





38 16170 492.2739 3 R.FQVWSRPWLQK.I 
5ʹNUC V5NTD_GL
OBR 
















































627 15050 1144.4647 3 K.LPACNYMMSGPYYNTYSYECNEGELT
CK.D      
646.9672 3 -.NLYQFGNMIQCANHGR.R  
PA2A4_AU
SSU 




















Austrelaps superbus  2227 17223 1011.386 2 K.MSAYDYYCGENGPYCR.N 























































Austrelaps superbus  74 16741 606.257 2 R.TVCDCDATAAK.C 




































Austrelaps superbus  62 17599 928.748 3 K.LPACKAMLSEPYNDTYSYSCIER.Q 
























2805 10909 727.0696 4 K.SYEDVTCCSTDNCNPFPVRPRPHP.- 
     













Naja kaouthia  31 8396 696.3379 2 R.VDLGCAATCPTVK.T 
     
658.2871 2 K.TWCDAFCSIR.G  
3L21_AUSS
U 



























Pseudonaja textilis  77 53606 912.3826 3 K.TETFWNVYVDGDQCSSNPCHYR.G 
     









Demansia vestigiata  41 54015 964.8144 3 R.TPIQFSENVVPACLPTADFADEVLMK.Q 



















28 55292 640.6576 3 K.FVPSTYDYDIALIQMK.T 
     
531.308 2 K.VVTLPYVDR.H  
FAXD1_DE
MVE 
Demansia vestigiata  28 54066 829.4182 2 K.LGECPWQAVLIDEK.G 
     











789 52173 967.926 2 K.DGIGSYTCTCLPNYEGK.N 
     





495 52265 855.4375 3 R.MKTPIQFSENVVPACLPTADFAK.E 
     











731 59363 885.7203 4 K.TSADIVINDLSLIHQLPKEEIQALCYPSM
IK.K      






566 59374 1471.7007 2 R.NPLEECFREADYEEFLEIARNGLK.K 
     
659.7117 3 K.TSADIVINDLSLIHQLPK.K  
OXLA_DE
MVE 
























m/z  z Peptide sequence 
LAAO 
    































202 64404 1009.486 2 K.KQNSGTYNNQYMILDTK.K 
     
1004.4539 2 R.QDLYYMTPVPAGCYDSK.V      
503.5865 3 K.GYWPSYNIPFHK.V  
PLB_CROA
D 
Crotalus adamanteus  26 64350 649.9741 3 R.DQGKVTDMESMKFIMR.Y 
     














































m/z  z Peptide sequence 
NGF NGFV2_NA
JSP 

































54 65077 807.7214 3 R.FHECNLGNLICDAVIYNNVR.H 




























47 70323 1102.4817 3 K.LLCQEGNATCICFPTTDDPDYGMVEPG
TK.C      
1342.2318 3 K.DKMCGKLLCQEGNATCICFPTTDDPDY
GMVEPGTK.C      
982.4066 3 R.AAKDDCDLPESCTGQSAECPTDSFQR.N 















m/z  z Peptide sequence 
CYS CYT_AUSS
U 






96 27311 1276.1327 2 K.YLYVCQYCPAGNIIGSIATPYK.S 
HL HYAL_ECH
OC 
Echis ocellatus  29 53137 635.3092 3 K.HSDSNAFLHLFPESFR.I 
     
622.3345 2 R.NDQLLWLWR.E 
AChE ACES_BUN
FA 
Bungarus fasciatus  116 68601 958.8021 3 R.FPFVPVIDGDFFPDTPEAMLSSGNFK.E 
     
896.9459 2 K.DEGSYFLIYGLPGFSK.D      
566.7737 4 K.QLGCHFNNDSELVSCLRSK.N 
PDE PDE1_CRO
AD 






































5889 17223 1011.39 2 K.MSAYDYYCGENGPYCR.N 
     





2691 15050 1139.14 3 K.LPACNYMMSGPYYNTYSYECNEGELTCK.
D      























426 14112 1186.53 2 K.SYSCTPYWTLYSWQCIEK.T 

















30 16900 363.415 4 K.IHDDCYGDAEKK.G 



















































46 16741 606.257 2 R.TVCDCDATAAK.C 
     










































1476 52265 1189.17 3 R.VQSETQCSCAESYLLGVDGHSCVAEGDFS
CGR.N 















m/z  z Peptide sequence 
SVSP 
    
1241.2 3 K.RVQSETQCSCAESYLLGVDGHSCVAEGDF
SCGR.N      





219 52173 967.926 2 K.DGIGSYTCTCLPNYEGK.N 
     



























Pseudonaja textilis  45 53606 932.382 4 R.EVFEDDEKTETFWNVYVDGDQCSSNPCH
YR.G      






















111 9489 495.732 4 K.TTTTCAESSCYKKTWR.D 
     














































316 59363 900.77 3 R.RRPLEECFQEADYEEFLEIAR.N 
     






497 59374 791.033 3 K.YAMGSITSFAPYQFQDFIER.V 
     











231 59069 1141.53 4 K.EGNLSRGAVDMIGDLLNEDSSYYLSFIESL
KNDDLFSYEK.R      





62 59049 900.766 3 R.RRPLEECFREADYEEFLEIAK.N 
     





































m/z  z Peptide sequence 
SVMP 
    





150 68601 1437.7 2 R.FPFVPVIDGDFFPDTPEAMLSSGNFK.E 
     







149 28032 962.439 2 R.DEQSVEFLDNEDTLNR.N 
     





103 28209 669.064 4 R.ENHPVHNQGEHSVCDSVSDWVIK.T 
     






































77 64404 546.284 3 R.KGYWPSYNIPFHK.V 
     
1004.45 2 R.QDLYYMTPVPAGCYDSK.V      




















84 64350 945.443 2 K.QNSGTYNNQYMILDTK.K 
     





91 27283 1206.49 2 K.SGPTCGDCPSACVNGLCTNPCK.Y 
     























46 23558 569.305 2 R.FPGDIAYNIK.G 
     





39 98192 678.339 2 K.AATYFWPGSEVK.I 
     





32 186149 830.333 3 K.CCEDGMHENPMGYTCEKRAK.Y 
     
















80 65077 725.366 2 R.VVSLNVLCTECR.V 






















50 65268 669.039 3 R.GAQGCPRSSPSPPLLLLVR.A 
Cʹ  CO3_NAJN
A 
Naja naja  149 186350 685.71 3 R.ISVLGDPVAQIIENSIDGSK.L 




























z Peptide sequence 
PLA2 PA2B_NOT
SC 
























Austrelaps superbus  942 527
3 




Notechis scutatus scutatus  886 167
48 
974.442 3 R.RPTLAYADYGCYCGAGGSGTPVDELDR.C 










































































m/z  z Peptide sequence 
PLA2 

















































































Austrelaps superbus  1597 17124 1355.
55 
2 K.KGCYPKMLAYDYYCGGDGPYCR.N 
















































































Demansia vestigiata  442 54066 829.4
24 
2 K.LGECPWQAVLIDEK.G 






































Homology  Mascot 
score 
MW (Da) m/z  z Peptide sequence 
SVMP VM3_NAJK
A 

































261 59363 696.013 3 K.LNEFLQENENAWYFIR.N 








123 59374 659.712 3 K.TSADIVINDLSLIHQLPK.K 
     
745.747 3 K.HVVVVGAGMAGLSAAYVLAGAGHK.V  
OXLA_NAJ
AT 
Naja atra  111 51805 652.969 3 R.TNCSYILNKYDSYSTK.E 
     



























m/z  z Peptide sequence 
ACHE ACES_BUNF
A 
Bungarus fasciatus  201 68601 964.13
5 
3 R.FPFVPVIDGDFFPDTPEAMLSSGNFK.E 























Drysdalia coronoides  129 27283 1206.4
9 
2 K.SGPTCGDCPSACVNGLCTNPCK.Y 









91 27196 1211.5 2 K.SGPPCADCPSACVNGLCTNPCK.H 











Demansia vestigiata 25 27364 654.8 2 R.NMLQMEWNSR.A 
PLB PLB_DRYCN Drysdalia coronoides  116 64404 945.44
5 
2 K.QNSGTYNNQYMILDTK.K 





PLB_CROAD Crotalus adamanteus  84 64350 649.96
5 
3 R.DQGKVTDMESMKFIMR.Y 










Protein family  Accession code Homology  Mascot score MW (Da) m/z  z Peptide sequence 
3FTX 3L21_ACAAN Acanthophis antarcticus  52 8700 645.26 2 R.TWCDAFCSSR.G  
3S11_NOTSC Notechis scutatus scutatus  29 9489 894.38 3 R.GCGCPNVKPGVQINCCKT
DECNN.-  
3L21_TROCA Tropidechis carinatus  26 10757 812.864 2 K.SEPCAPGQNLCYTK.T  
3S11_AUSSU Austrelaps superbus  28 9513 894.042 3 R.GCGCPNVKPGIQLVCCETN
ECNN.-      
704.794 2 K.TTTTCAESSCYK.K  
3L22E_ACAAN Acanthophis antarcticus  25 9325 1068.03 2 R.VEMGCATTCPKVNRGVDI
K.C      
404.677 2 K.TWCDAR.C  
3L2A2_ACAAN Acanthophis antarcticus  28 4331 1051.46 2 R.GYNYAQPCPPGENVCFTK.
T 
VESP VESP_DRYCN Drysdalia coronoides  54 21220 749.367 2 R.FSSSPCVLGSPGFR.S 
NGF NGFV1_NOTSC Notechis scutatus scutatus  48 28209 669.064 4 R.ENHPVHNQGEHSVCDSVS
DWVIK.T 
HYAL  HYAL_ECHOC Echis ocellatus  66 53137 723.849 2 K.AEYEKAAKSFMR.D      
622.338 2 R.NDQLLWLWR.E  
HYAL_ECHPL Echis pyramidum leakeyi  66 53224 1266.67 2 R.GHFFHGIIPQNESLTKHLN
KSK.S 
VF VCO31_AUSSU Austrelaps superbus  43 186149 830.334 3 K.CCEDGMHENPMGYTCEK
RAK.Y 
5ʹNUC V5NTD_GLOBR Gloydius brevicaudus  38 65077 807.726 3 R.FHECNLGNLICDAVIYNNV
R.H      








Table B1.  All toxin hits identified for P. colletti whole venom by Mascot search. 
Protein 
family 




 m/z z Peptide sequence 




PA2A3_PSEAU Pseudechis australis  7307 13941 904.358 3 R.HYMDYGCYCGWGGSGTPVDELDR.C  
PA2BA_PSEA
U 




PA2BF_PSEAU Pseudechis australis  3249 13758 993.2057 5 K.GSRPSLNYADYGCYCGWGGSGTPVDELDRCC
QVHDNCYEQAGK.K  
PA2BB_PSEAU Pseudechis australis  3234 13755 993.2057 5 K.GSRPSLDYADYGCYCGWGGSGTPVDELDRCC
QVHDNCYEQAGK.K  












Pseudechis australis  665 14002 668.2822 3 R.AAWHYLDYGCYCGPGGR.G 
 




PA2SC_AUSSU Austrelaps superbus  156 5273 608.8386 2 -.NLIQLSNMIK.C  
PA2H_LATSE Laticauda 
semifasciata  




Hydrophis hardwickii  94 17787 1063.183 4 K.NMIQCANHGSRMTLDYMDYGCYCGTGGSGT
PVDELDR.C  
























 m/z z Peptide sequence 
PLA2 PA2A1_TROC
A 




PA2A2_PSETE Pseudonaja textilis  53 17983 904.3574 3 R.CCQAHDYCYDDAEKLPACNYR.F  
PA21_OXYSC Oxyuranus scutellatus 
scutellatus  










PA2B_GLOHA Gloydius halys  34 3789 395.7322 2 -.NLLQFR.K  
PA2BA_BUNF
A 
Bungarus fasciatus  34 15683 601.7869 2 K.GGSGTPVDQLDR.C 
 
PA2A5_AUSSU Austrelaps superbus  33 17234 590.8932 3 R.CCKVHDDCYGEAEK.S  
PA2B_BUNCE Bungarus caeruleus  33 16609 909.6903 3 R.TAAICFASAPYNSNNVMISSSTNCQ.-  
PA2A1_AUSSU Austrelaps superbus  33 16898 950.9161 2 K.APYNKENYNIETRCQ.-  
PA2B8_AUSSU Austrelaps superbus  29 16741 779.3463 2 K.APYNNKNYNIDTK.K 
LAAO OXLA_PSEAU Pseudechis australis 70 59049 853.3861 3 -.MNVFFMFSLLFLAALGSCADDR.R  
OXLA_NOTSC Notechis scutatus 
scutatus  
132 59363 967.9802 2 K.TLSYVTADYVIVCSTSR.A 
NGF NGFV_PSEPO Pseudechis 
porphyriacus  




Pseudechis australis  80 27595 874.9193 2 R.LWNSYCTTTQTFVK.A 






















m/z z Peptide sequence  
PLA2 PA2A2_N
AJME 














































































Naja sputatrix  58 17034 622.24
8 
3 R.SWWHFADYGCYCGR.G 















m/z z Peptide sequence  
PLA2 PA2NB_
NAJSP 


































































































m/z z Peptide sequence  
Cʹ   CO3_NAJ
NA 








































Drysdalia coronoides  173 64404 1079.9 3 R.SIEDGTLYIIEQVPNLVEYSDQTTILRK.G 
5ʹNUC V5NTD_
CROAD 




















































m/z z Peptide sequence  
VESP VESP_N
AJKA 






































































m/z  z Peptide sequence 
DIS VM2_BITA
R 







































































































































37 29589 848.92 2 K.NYTLWDKDIMLIR.L 
LAAO OXLA_DA
BRR 





















































31 64350 946.913 2 K.QNSGTYNNQYMILDTK.K 
VEGF TXVE_BIT
AR 
















220 65268 868.431 3 R.YDAMALGNHEFDNGLAGLLDPLLK.H 
CYS CYT_BITA
R 
























14005 59049 326.6741 2 R.VNTYR.N 
          338.1819 2 R.SIHYR.S 
          338.1927 2 K.SGLTAAR.D 
          354.7054 2 R.EYIRK.F 
          412.7162 2 K.SASQLYR.E 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          443.7708 2 K.VIEELKR.T 
          498.7622 2 K.IFLTCSQK.F 
          512.2642 2 R.VNTYRNEK.D 
          364.2288 3 R.IIREYIRK.F 
          552.2472 2 K.SDDIFSYEK.R 
          567.2946 2 K.YPVKPSEEGK.S 
          587.8343 2 R.IHFEPPLPPK.K 
          607.8276 2 R.DVNLASQKPSR.I 
          406.1961 3 K.FWEADGIHGGK.S 
          630.2978 2 K.SDDIFSYEKR.F 
          631.8236 2 R.RRPLEECFR.E 
          434.9233 3 R.IHFEPPLPPKK.A 
          662.3113 2 K.DGWYVNLGPMR.L 
          444.2587 3 R.RIHFEPPLPPK.K 
          668.8317 2 K.EQIQALCYPSK.I 

























m/z z Peptide sequence  
 LAAO         746.873 2 R.FDEIVGGFDQLPR.S 
          762.3847 2 K.YDTYSTKEYLIK.E 
          824.9236 2 K.RFDEIVGGFDQLPR.S 
          840.3939 2 R.NEKDGWYVNLGPMR.L 
          853.931 2 K.EQIQALCYPSKIQK.W 
          607.3026 3 K.DGWYVNLGPMRLPER.H 
          1013.4926 2 R.EADYEEFLEIAKNGLQR.T 
          682.6876 3 R.SMYQAIAEKVHLNAQVIK.I 
          699.3577 3 K.DGWYVNLGPMRLPERHR.I 
          548.2736 4 R.NEKDGWYVNLGPMRLPER.H 
          732.027 3 K.IFLTCSQKFWEADGIHGGK.S 
          753.3773 3 R.IYFAGEYTASVHGWLDSTIK.S 
          771.3782 3 R.VNTYRNEKDGWYVNLGPMR.L 
          636.805 4 R.RPLEECFREADYEEFLEIAK.N 
          650.0748 4 R.SSTKIFLTCSQKFWEADGIHGGK.S 
          675.8335 4 R.RRPLEECFREADYEEFLEIAK.N 
          1032.8893 3 R.VVVVGAGMAGLSAAYVLAGAGHQVTLLE
ASER.V 
          778.8829 4 R.RPLEECFREADYEEFLEIAKNGLQR.T 
          813.9446 4 K.RVVVVGAGMAGLSAAYVLAGAGHQVTLL
EASER.V 







4919 59363 326.6741 2 R.VNTYR.N 
          338.1819 2 R.SIHYR.S 















m/z z Peptide sequence  
LAAO          354.7054 2 R.EYIRK.F 
          412.7165 2 K.SASQLYR.E 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          439.2422 2 R.VAYQTPAK.T 
          443.7708 2 K.VIEELKR.T 
          455.7419 2 K.IFLTCTR.K 
          364.2288 3 R.IIREYIRK.F 
          552.2472 2 K.SDDLFSYEK.R 
          406.1957 3 K.FWEADGIHGGK.S 
          420.5346 3 K.SDDLFSYEKR.F 
          508.592 3 K.YDTYSTKEYLIK.E 
          967.9819 2 K.TLSYVTADYVIVCSTSR.A 
          990.0589 2 K.TSADIVINDLSLIHQLPK.E 
          931.8072 3 R.VAYQTPAKTLSYVTADYVIVCSTSR.A 





1831 56887 338.1927 2 K.SGLTAAR.D 
          354.7054 2 R.EYIRK.F 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          728.847 2 R.EADYEEFLEIAK.N 
          762.3847 2 K.YDTYSTKEYLIK.E 





















m/z z Peptide sequence  
 LAAO         354.7054 2 R.EYIRK.F 
          412.7163 2 K.SASQLYR.E 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          439.2422 2 R.VAYQTPAK.T 
          443.7708 2 K.VIEELKR.T 
          364.2288 3 R.IIREYIRK.F 
          552.2472 2 K.SDDLFSYEK.R 
          378.5329 3 K.YPVKPSEEGK.S 
          406.196 3 K.FWEADGIHGGK.S 
          420.5346 3 K.SDDLFSYEKR.F 
          661.3209 2 K.EGWYVNLGPMR.L 
          726.863 2 K.EIQALCYPSMIK.K 
          960.9711 2 K.TLSYVTADYVIVCSSSR.A 
          990.0589 2 K.TSADIVINDLSLIHQLPK.K 
          732.027 3 K.IFLTCSKKFWEADGIHGGK.S 





438 59069 326.6741 2 R.VNTYR.D 
          338.1927 2 K.SGLTAAR.N 
          412.7165 2 K.SASQLYR.E 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          439.2422 2 R.VAYQTPAK.T 
          443.7708 2 K.VIEELKR.T 
          455.7419 2 K.IFLTCTR.K 















m/z z Peptide sequence  
LAAO          406.1957 3 K.FWEADGIHGGK.S 
          670.3077 2 K.EGWYVNMGPMR.L 
          508.592 3 K.YDTYSTKEYLIK.E 
          612.3005 3 K.EGWYVNMGPMRLPER.H 
          990.0589 2 K.TSADIVINDLSLIHQLPK.N 
          1013.4926 2 R.EADYEEFLEIARNGLKK.T 
  OXLA_NAJ
AT 
Naja atra 390 51805 338.1819 2 R.SIHYR.S 
          354.7054 2 R.EYIRK.F 
          438.7243 2 K.STTDLPSR.F 
          443.7708 2 K.VIEELKR.T 
          378.5329 3 K.YPVKPSEEGK.S 
          406.1961 3 K.FWEADGIHGGK.S 
          670.3077 2 R.EGWYVNMGPMR.L 
          612.3005 3 R.EGWYVNMGPMRLPER.H 
          732.0317 3 K.IFLTCSKKFWEADGIHGGK.S 





161 58963 338.1927 2 K.SGLTAAR.D 
          354.7054 2 R.EYIRK.F 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          567.2946 2 K.YPVKPSEEGK.S 
          762.3847 2 K.YDTYSTKEYLIK.E 




















m/z z Peptide sequence  
 LAAO         438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          378.5329 3 K.YPVKPSEEGK.S 
          464.2992 3 K.VHLNAQVIKIQK.N 
          762.3847 2 K.YDTYSTKEYLLK.E 





107 57251 338.1923 2 K.SGLTAAR.D 
          354.7054 2 R.EYIRK.F 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          364.2288 3 R.IIREYIRK.F 
          762.3847 2 K.YDTYSTKEYLIK.E 





106 57163 338.1923 2 K.SGLTAAR.D 
          354.7054 2 R.EYIRK.F 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 





106 56740 338.1923 2 K.SGLTAAR.D 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          762.3847 2 K.YDTYSTKEYLIK.E 















m/z z Peptide sequence  






106 59025 338.1923 2 K.SGLTAAR.D 
          438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          762.3847 2 K.YDTYSTKEYLLK.E 











78 56712 438.7243 2 K.STTDLPSR.F 
          439.1999 2 K.YDTYSTK.E 
          762.3847 2 K.YDTYSTKEYLLK.E 





36 59225 326.6741 2 R.VNTYR.N 
          439.1999 2 K.YDTYSTK.D 
          730.0361 3 R.NEQEGWYVNLGPMRLPER.H 
          946.1482 3 R.VTYQTPAKNLSYVTADYVIVCSTSR.A 





1139 14149 622.2502 3 R.SWWHFANYGCYCGR.G 
          1093.7548 3 K.TYTYDSCQGTLTSCGAANNCAASVCDCDR.
V 
















m/z z Peptide sequence  






574 14216 622.2473 3 R.SWWHFANYGCYCGR.G 
          1021.4813 2 -.NLYQFKNMIQCTVPNR.S 











139 13941 847.4111 2 -.NLIQFGNMIQCANK.G 
          1055.9995 2 K.LTLYSWDCTGNVPICSPK.A 





135 13914 1069.5048 2 K.LTLYSWDCTGNVPICNPK.T 






125 13798 304.6464 2 K.GCFPK.L 
          847.4111 2 -.NLIQFGNMIQCANK.G 
          1070.788 3 K.GSRPSLDYADYGCYCGWGGSGTPVDELDR.
C 






117 13755 304.6464 2 K.GCFPK.L 
          847.4111 2 -.NLIQFGNMIQCANK.G 
















m/z z Peptide sequence  






117 13758 304.6464 2 K.GCFPK.L 
          847.4111 2 -.NLIQFGNMIQCANK.G 
          1070.788 3 K.GSRPSLNYADYGCYCGWGGSGTPVDELDR.
C 






74 13816 304.6464 2 K.GCFPK.L 










764 7133 474.7176 2 R.GCIDVCPK.S 
          681.2545 2 K.YVCCNTDRCN.- 





316 8337 1237.059 2 R.CFITPDVTSQICADGHVCYTK.T 















646 70323 325.697 2 R.YLQVK.K 
          331.176 2 K.VCINR.Q 















m/z z Peptide sequence  
 SVMP         724.8559 2 K.CPIMTNQCIALK.G 
          637.9197 3 R.NGHPCQNNQGYCYNGK.C 
          892.3465 3 K.DDCDLPESCTGQSAECPTDSFQR.N 
          982.4038 3 R.AAKDDCDLPESCTGQSAECPTDSFQR.N 
          840.1132 4 R.NGHPCQNNQGYCYNGKCPIMTNQCIALK.G 






340 70663 325.697 2 R.YLQVK.K 
          331.176 2 K.VCINR.Q 
          393.5176 3 K.CGDGKVCINR.Q 
          956.8701 2 R.NGHPCQNNQGYCYNGK.C 
          713.6043 3 K.LQHEAQCDSGECCEQCK.F 
          1338.0165 2 K.DDCDLPESCTGQSAKCPTDSFQR.N 
          982.4038 3 R.AAKDDCDLPESCTGQSAKCPTDSFQR.N 





205 70476 325.697 2 R.YLQVK.K 
          331.1756 2 K.VCINR.Q 
          393.5176 3 K.CGDGKVCINR.Q 
          956.8701 2 R.NGHPCQNNEGYCYNGK.C 
          1338.0165 2 K.DDCDLPESCTGQSAKCPTDSFQR.N 
          982.4038 3 R.AAKDDCDLPESCTGQSAKCPTDSFQR.N 
          982.4038 3 R.AAKDDCDLPESCTGQSAKCPTDSFQR.N 
  VM3A_NAJ
AT 
Naja atra 162 70376 325.697 2 R.YLQVK.K 















m/z z Peptide sequence  
 SVMP         956.8701 2 R.NGHPCQNNQGYCYNGK.C 
          901.6962 3 K.DDCDLPEFCTGQSAECPTDSLQR.N 





158 46174 413.772 2 R.QTVLLPR.K 










61 71224 313.7208 2 K.KLLPR.K 





52 69841 313.7208 2 K.KLLPR.K 
          394.2281 2 R.KIPCAAK.D 






32 19510 325.697 2 R.YLQVK.K 





571 64404 407.7367 2 R.IIDPQTK.T 
          416.2315 2 K.NVITEQK.V 
          417.6905 2 K.QDEWTR.Q 
          448.2387 2 K.VKDFMQK.Q 
          474.744 2 K.VADINMAAK.F 
          666.2732 2 K.HNPCNTICCR.Q 
          704.3605 2 K.FTAYAINGPPVEK.G 















m/z z Peptide sequence  
 PLB         732.8251 2 K.YGLDFSYEMAPR.A 
          754.8682 2 K.GYWPSYNIPFHK.V 
          546.2792 3 R.KGYWPSYNIPFHK.V 
          945.9286 2 K.QNSGTYNNQYMILDTK.K 
          633.9735 3 R.IANMMADSGKTWAQTFK.K 
          1004.4425 2 R.QDLYYMTPVPAGCYDSK.V 
          673.3261 3 K.QNSGTYNNQYMILDTKK.I 





172 64350 417.6905 2 K.QDEWTR.Q 
          666.7758 2 K.HNPCNTICCR.Q 
          704.3605 2 K.FTAYAINGPPVEK.G 
          945.9286 2 K.QNSGTYNNQYMILDTK.K 






162 65268 476.2788 2 K.VGIIGYTTK.E 
          1089.5182 2 K.GDSSNHSSGNLDISIVGDYIK.R 
          778.7161 3 K.GDSSNHSSGNLDISIVGDYIKR.M 
          602.5209 4 R.HPDDNEWNHVSMCIVNGGGIR.S 





162 65077 476.2788 2 K.VGIIGYTTK.E 
          648.3929 2 K.HANKLTTLGVNK.I 
          1089.5182 2 K.GDSSNHSSGNLDISIVGDYIK.R 
          584.2877 4 K.GDSSNHSSGNLDISIVGDYIKR.M 






















802.8973 2 K.GDNLIQMPGAAMKIK.L 
          1024.8575 3 K.QKTLFQTRVDMNPAGGMLVTPTIEIPAK.E 




Naja naja 54 18635
0 
786.4183 3 R.ASSSWLTAYVVKVLAMASNMVK.D 
          636.8068 4 K.ATMTILTVYNAQLREDANVCNK.F 























 m/z z Peptide sequence 
VF VCO3_NAJ
KA 
Naja kaouthia 3736 185940 351.7109 2 K.GTGLLNK.I 
          527.8096 2 R.IDVPLQIEK.A 
          552.2976 2 R.KCQEALNLK.V 
          661.8578 2 K.GIYTPGSPVLYR.V 
          669.8301 2 K.VNDDYLIWGSR.S 
          462.9101 3 K.QLDIFVHDFPR.K 
          482.2567 3 K.HFEVGFIQPGSVK.V 
          843.4523 2 K.VFFIDLQMPYSVVK.N 
          568.3281 3 R.VGLVAVDKAVYVLNDK.Y 
          857.9644 2 R.QNQYVVVQVTGPQVR.L 
          600.3441 3 K.ILKHFEVGFIQPGSVK.V 
          622.3287 3 R.DSITTWVVLAVSFTPTK.G 
          936.4805 2 K.ATMTILTFYNAQLQEK.A 
          665.3809 3 R.VGLVAVDKAVYVLNDKYK.I 
          1035.534 2 R.VDMNPAGGMLVTPTIEIPAK.E 
          702.0682 3 R.AVPFVIVPLEQGLHDVEIK.A 
          1055.574 2 K.IIIQGDPVAQIIENSIDGSK.L 
          1112.05 2 R.IEEQDGNDIYVMDVLEVIK.Q 
          1121.531 3 K.SDFGCTAGSGQNNLGVFEDAGLALTTS
TNLNTK.Q 
          1121.537 3 K.SDFGCTAGSGQNNLGVFEDAGLALTTS
TNLNTK.Q 













m/z z Peptide sequence  
 VF VCO32_AUSSU Austrelaps 
superbus  
1081 185942 351.7109 2 K.GTGLLNK.I 
          632.8683 2 K.VEGVAFVLFGVK.I 
          813.3993 2 K.GICVAEPYEITVMK.D 
          568.3281 3 R.VGLVAVDKAVYVLNDK.Y 
          665.3809 3 R.VGLVAVDKAVYVLNDKYK.I 
          1035.534 2 R.VDMNPAGGMLVTPTIKIPAK.E 
          1112.048 2 R.IEEKDGNDIYVMDVLEVIK.G 
          1112.05 2 R.IEEKDGNDIYVMDVLEVIK.G 
  VCO31_AUSSU Austrelaps 
superbus 
250 186149 351.7109 2 K.GTGLLNK.I 
          552.2976 2 R.KCQEALNLK.L 
          632.8683 2 K.VEGVAFVLFGVK.I 
          482.2567 3 K.HFEVGFIQPGSVK.V 
          813.3993 2 K.GICVAEPYEITVMK.D 
          545.2828 3 K.ANKAAQFQDQNLRK.C 
          568.3281 3 R.VGLVAVDKAVYVLNDK.Y 
          665.3809 3 R.VGLVAVDKAVYVLNDKYK.I 
          1035.534 2 R.VDMNPAGGMLVTPTIKIPAK.E 
          602.3137 4 K.TLFQTRVDMNPAGGMLVTPTIK.I 
  VCO3_OPHHA Ophiopha
gus 
hannah  
221 185408 351.7109 2 K.GTGLLNK.I 
          661.8578 2 K.GIYTPGSPVLYR.V 
          693.8602 2 K.QLDIFVHDFPR.K 
          482.2567 3 K.HFEVGFIQPGSVK.V 













m/z z Peptide sequence  
 VF         857.9644 2 R.QNQYVVVQVTGPQVR.L 
          600.3441 3 K.ILKHFEVGFIQPGSVK.V 
          666.32 3 R.TDTEEQILVEAHGDNTPK.Q 
          1000.518 2 K.GASLTDNQIHMPGAAMKIK.L 
          831.7595 3 K.VAVIIYLDKVSHSEDECLQFK.I 
  VCO3_CROAD Crotalus 
adamante
us 
208 186346 351.7109 2 K.GTGLLNK.I 
          552.2976 2 R.KCQEALNLK.V 
          606.28 2 K.FEIDNNMAQK.G 
          632.8683 2 R.VEGVAFVLFGVK.I 
          482.2567 3 K.HFEVGFIQPGSVK.V 
          813.3993 2 K.GICVAEPYEITVMK.D 
          833.106 3 R.VDMNPAGGMLVTPTITIPAKDLNK.D 
          952.492 3 R.VDMNPAGGMLVTPTITIPAKDLNKDSR.
Q 
Cʹ  CO3_NAJNA Naja naja 378 186350 552.2976 2 R.KCQEALNLK.L 
          606.28 2 K.FEIDNNMAQK.G 
          473.9279 3 K.ASKAAQFQDQGLR.K 
          482.2567 3 K.HFEVGFIQPGSVK.V 
          813.3993 2 K.GICVAEPYEITVMK.D 
          568.3281 3 R.VGLVAVDKAVYVLNDK.Y 
          665.3809 3 R.VGLVAVDKAVYVLNDKYK.I 
          717.3785 3 R.VDMNQAGSMFVTPTIKVPAK.E 
          815.7325 3 R.LSNGVDRYISKFEIDNNMAQK.G 














m/z z Peptide sequence  
LAAO OXLA_NAJAT Naja atra 1225 51805 400.7473 2 K.KDPSLLK.Y 
          438.7247 2 K.STTDLPSR.F 
          454.2477 2 R.VTYQTPAK.T 
          378.5325 3 K.YPVKPSEEGK.S 
          680.0286 3 K.TCADIVINDLSLIHDLPK.R 
          826.7206 3 K.LNEFFQENENAWYYINNIR.K 
          869.4139 3 K.LNEFFQENENAWYYINNIRK.R 
  OXLA_PSEAU Pseudechi
s australis  
74 59049 412.7164 2 K.SASQLYR.E 
          438.7247 2 K.STTDLPSR.F 
          454.2477 2 R.VTYQTPAK.T 
          567.2955 2 K.YPVKPSEEGK.S 
  OXLA_MACLB Macrovipe
ra lebetina 
57 12541 378.5325 3 R.YPVKPSEEGK.H 
          849.7205 3 K.NPLEECFREDDYEEFLEIAK.N 
  OXLA_DEMVE Demansia 
vestigiata 
47 59225 454.2477 2 R.VTYQTPAK.N 
          634.6462 3 R.DLCYVSMIKKWSLDK.Y 
  OXLA_DABRR Daboia 
russelii 
44 57251 438.7247 2 K.STTDLPSR.F 
          849.7205 3 K.NPLEECFREDDYEEFLEIAK.N 




37 58583 438.7247 2 K.STTDLPSR.F 
          998.9758 2 K.IQQNDQKVTVVYETLSK.E 
SVMP VM3K_NAJKA Naja 
kaouthia  













m/z z Peptide sequence  
 SVMP         414.2525 2 R.QTVLLPR.K 
          480.7231 2 -.TNTPEQDR.Y 
          507.1963 2 K.CGDGMVCSK.G 
          550.2739 2 R.DYQEYLLR.D 
          641.3283 2 R.VYEMINAVNTK.F 
          645.358 2 K.FEVKPAASVTLK.S 
          736.3528 2 R.TAPAFQFSSCSIR.D 
          517.944 3 K.IRVYEMINAVNTK.F 
          560.6425 3 K.FEVKPAASVTLKSFR.E 
          851.4109 3 R.TAPAFQFSSCSIRDYQEYLLR.D 
  VM3B_NAJAT Naja atra 323 68141 330.1809 2 K.IPCAAK.D 
          414.2525 2 R.ETVLLPR.K 
          507.1963 2 K.CGDGMVCSK.G 
          641.3283 2 R.VYEMINAVNTK.F 
          645.358 2 K.FEVKPAASVTLK.S 
          736.3528 2 R.TAPAFQFSSCSIR.E 
          517.944 3 K.IRVYEMINAVNTK.F 
  VM3A_NAJAT Naja atra 175 70376 330.1809 2 K.IPCAAK.D 
          360.6893 2 K.SQCVKV.- 
          516.2633 2 K.IPCAAKDEK.C 
          358.4978 3 R.KGDDVSHCR.K 
          363.1891 3 R.EHQEYLLR.E 
          549.2553 2 K.FKGAETECR.A 
          499.9363 3 R.ERPQCILNKPSR.K 
          630.9185 3 K.LQPHAQCDSEECCEK.C 













m/z z Peptide sequence  
 SVMP         901.0314 3 K.DDCDLPEFCTGQSAECPTDSLQR.N 
          991.0897 3 R.AAKDDCDLPEFCTGQSAECPTDSLQR.N 
  VM3H_NAJAT Naja atra 55 71416 311.6816 2 R.YLQAK.K 
          330.1809 2 K.IPCAAK.D 
          394.2281 2 R.KIPCAAK.D 
          578.2208 2 K.CGDGMVCSNR.Q 
          848.3716 2 K.VYEMINTMNMIYR.R 
          641.5815 3 K.LQHEAQCDSEECCEK.C 
          641.5829 3 K.LQHEAQCDSEECCEK.C 
  VM3_NAJKA Naja 
kaouthia 
55 69841 330.1809 2 K.IPCAAK.D 
          394.2281 2 R.KIPCAAK.D 
          332.4956 3 K.FKGAGAECR.A 
          578.2208 2 K.CGDGMVCSNR.Q 
          848.3716 2 K.VYEMINTMNMIYR.R 
          641.5829 3 K.LQHEAQCDSEECCEK.C 






39 70832 839.0411 3 K.NPCQIYYTPSDENKGMVDPGTK.C 
  VM3_MICIK Micropech
is ikaheca 
77 19510 480.7231 2 -.TNTPEQDR.Y 
          725.8001 2 K.DDCDLPEICTGR.S 
DIS VM2D3_BITAR Bitis 
Arietans  
566 9856 1027.75 3 -.SPPVCGNELLEEGEECDCGSPANCQDR.C 
AChE ACES_BUNFA Bungarus 
fasciatus  
509 68601 544.9437 3 R.AQICAFWNHFLPK.L 













m/z z Peptide sequence  
 AChE         1024.966 2 K.QLGCHFNNDSELVSCLR.S 
          708.7076 3 R.AILQSGGPNAPWATVTPAESR.G 
          839.7665 3 R.VGAFGFLGLPGSPEAPGNMGLLDQR.L 
5ʹNUC V5NTD_GLOBR Gloydius 
brevicaud
us 
262 65077 653.8601 2 R.QVPVVQAYAFGK.Y 
          725.3622 2 R.VVSLNVLCTECR.V 
          859.9398 2 K.ETPVLSNPGPYLEFR.D 
          897.9264 2 K.MKIQLHNYSSQEIGK.T 
          727.009 3 K.GDSSNHSSGNLDISIVGDYIK.R 
          779.3652 3 K.GDSSNHSSGNLDISIVGDYIKR.M 
          1211.074 2 R.FHECNLGNLICDAVIYNNVR.H 
          897.4564 3 K.ETPVLSNPGPYLEFRDEVEELQK.H 
  V5NTD_CROAD Crotalus 
adamante
us 
251 65268 653.8601 2 R.QVPVVQAYAFGK.Y 
          859.9398 2 K.ETPVLSNPGPYLEFR.D 
          897.9264 2 K.MKIQLHNYSSQEIGK.T 
          727.009 3 K.GDSSNHSSGNLDISIVGDYIK.R 
          779.3652 3 K.GDSSNHSSGNLDISIVGDYIKR.M 
          803.0258 3 R.HPDDNEWNHVSMCIVNGGGIR.S 
          1211.074 2 R.FHECNLGNLICDAVIYNNVR.H 
PDE PDE1_CROAD Crotalus 
adamante
us 
235 98192 339.6947 2 R.AVYPTK.T 
          546.7937 2 R.TLGMLMEGLK.Q 
          678.3342 2 K.AATYFWPGSEVK.I 













m/z z Peptide sequence  
PLA2 PA2A2_NAJME Naja 
melanoleu
ca 
117 14216 607.2227 2 K.CAASVCDCDR.V 
          595.2322 3 R.CCQIHDNCYGEAEK.I 
          722.8099 4 R.CCQIHDNCYGEAEKISGCWPYIK.T 
          1117.77 3 K.TYTYESCQGTLTSCGANNKCAASVCDC
DR.V 
PLB PLB_CROAD Crotalus 
adamante
us 
71 64350 730.8801 2 K.KVVPESLFAWER.V 
          1449.627 2 K.TWAETFEKQNSGTYNNQYMILDTK.K 
  PLB_DRYCN Drysdalia 
coronoide
s 
56 64404 724.829 2 K.YGLDFSYEMAPR.A 
          768.3829 2 R.RDQGKVIDIESMK.R 
SVSP VSP1_BUNMU Bungarus 
multicinct
us 
96 31731 811.9147 2 R.FPCAQLLEPGVYTK.V 
          841.885 2 K.NCTQWSQDIMLIR.L 
3FTx 3L22_NAJME Naja 
melanoleu
ca 
94 8337 667.3476 3 R.VDLGCAATCPTVKPGVNIK.C 
VEGF TXVE_BITAR Bitis 
Arietans  
36 17126 768.395 2 R.ETLVSILEEYPDK.I 






















 m/z z Peptide sequence 
CTL SL5_BITAR Bitis arietans  154 17642 410.695 2 K.SWAEAEK.F 
          469.247 2 K.VTYVNWR.E 
          698.329 3 K.FCMEQANDGHLVSIQSIK.E 
          952.448 3 K.FCMEQANDGHLVSIQSIKEANFVAK.L 
  SL3_BITGA Bitis 
gabonica  
148 18483 439.697 2 K.TWEDAEK.F 
          699.305 2 R.EGESQMCQALTK.W 
          777.81 2 K.EQQCSSEWNDGSK.V 
          561.574 3 R.KEQQCSSEWNDGSK.V 
          460.457 4 R.RKEQQCSSEWNDGSK.V 
  SLA_BITAR Bitis arietans  144 15324 305.177 2 K.SRLPH.- 
          431.255 2 K.LASQTLTK.F 
          890.951 2 K.EEADFVTKLASQTLTK.F 
  SL2_BITGA Bitis 
gabonica  
71 18602 353.674 2 R.AFDEPK.R 
          431.724 2 R.AFDEPKR.S 
          846.931 2 K.EEADFVAQLISDNIK.S 
  SLB_BITAR Bitis arietans  70 15188 353.169 2 R.WTDGAR.L 
          375.231 2 K.VFKVEK.T 
          410.695 2 K.TWADAEK.F 





54 18226 439.697 2 K.TWEDAEK.F 

























43 18171 410.695 2 K.TWADAEK.F 
          474.743 2 K.KTWADAEK.F 
  SL5_ECHPL Echis 
pyramidum 
leakeyi  
37 17121 410.695 2 K.TWADAEK.F 
          342.483 3 R.NYGHFVCK.S 



































63 26108 314.496 3 K.TYTKWNK.D 





63 29370 552.788 2 R.TLCAGVLEGGK.D 
          842.413 2 K.TYTQWNKDIMLIR.L 















m/z z Peptide sequence  
SVSP  VSP_BOTBA Bothrops 
barnetti 





51 28694 552.788 2 R.TLCAGIVEGGK.D 
  VSP_ECHOC Echis 
ocellatus  










81 55745 680.802 2 K.ASQSNLTPEQQR.F 
          835.432 2 K.IYEIVNILNEMFR.Y 
          557.291 3 K.IYEIVNILNEMFR.Y 
  VM3_NAJK
A 
Naja atra 71 69841 578.22 2 K.CGDGMVCSNR.Q 
          644.638 3 K.CPIMTNQCIALRGPGVK.V 
          1351.07 2 R.NSMICNCSISPRDPSYGMVEPGTK.C 
  VM3H_NAJ
AT 
Naja atra 65 71416 578.22 2 K.CGDGMVCSNR.Q 
          644.638 3 K.CPIMTNQCIALRGPGVK.V 




Naja atra 59 70376 398.192 2 K.SFAEWR.A 










39 70954 419.581 3 K.VTSLPKGAVQQK.Y 




















38 48693 900.884 2 K.VCNSNRECVDVNTAY.- 
          797.331 3 K.CEDGKVCNSNRECVDVNTAY.- 












214 57251 385.742 2 K.KDPGLLK.Y 
          359.197 3 K.YPVKPSEAGK.S 
          979.952 2 R.FDEIVGGMDQLPTSMYR.A 
          1008.99 2 K.LNEFVQETENGWYFIK.N 





64 57488 979.952 2 R.FDEIVGGMDKLPTSMYR.A 
          705.671 3 K.RFDEIVGGMDKLPTSMYR.A 
          1205.61 2 M.NVFFMFSLLFLAALGSCANDR.N 
          648.801 4 R.KFGLQLNEFSQENDNAWYFIK.N 





64 57455 979.951 2 R.FDEIVGGMDKLPTSMYR.A 
          705.671 3 K.RFDEIVGGMDKLPTSMYR.A 
          1205.61 2 M.NVFFMFSLLFLAALGSCADDR.N 





45 58583 385.742 2 K.KDPGLLK.Y 















m/z z Peptide sequence  
LAAO          1009.48 2 R.LNEFSQENDNAWYFIK.N 





43 59069 742.848 2 R.EADYEEFLEIAR.N 
          506.517 4 K.SMHQAIAEMVHLNAQVIK.I 






43 59116 742.848 2 R.EADYEEFLEIAR.N 
          787.399 4 K.SMHQDIAEMVHLNAQVTKIQHDAEKVR.V 






100 7584 590.929 3 -.NSAHPCCDPVTCKPK.R 





100 7707 590.929 3 -.NSAHPCCDPVTCQPK.K 
  VM2_BITAR Bitis arietans  88 9796 492.688 2 R.CCNAATCK.L 
          1112.44 2 K.ILEQGEDCDCGSPANCQDR.C 
  VM2D3_BIT
AR 
Bitis arietans  32 9856 492.688 2 R.CCNAATCK.L 
          684.266 3 K.LTPGSQCSYGECCDQCK.F 
VEGF TXVE_BITA
R 
Bitis arietans  138 17126 686.879 2 R.TVELQVMQVTPK.T 
          768.396 2 R.ETLVSILEEYPDK.I 




























10026 59049 338.1829 2 K.SGLTAAR.D 
          412.7174 2 K.SASQLYR.E 
          378.5335 3 K.YPVKPSEEGK.S 
          587.8355 2 R.IHFEPPLPPK.K 
          421.5524 3 R.RRPLEECFR.E 
          662.3113 2 K.DGWYVNLGPMR.L 
          444.259 3 R.RIHFEPPLPPK.K 
          668.8376 2 K.EQIQALCYPSK.I 
          728.8478 2 R.EADYEEFLEIAK.N 
          491.2866 3 R.ESLQKVIEELKR.T 
          746.8723 2 R.FDEIVGGFDQLPR.S 
          550.6213 3 K.RFDEIVGGFDQLPR.S 
          565.6021 3 R.NEKDGWYVNLGPMR.L 
          607.3045 3 K.DGWYVNLGPMRLPER.H 
          676.335 3 R.EADYEEFLEIAKNGLQR.T 
          682.6876 3 R.SMYQAIAEKVHLNAQVIK.I 
          519.2543 4 K.FWEADGIHGGKSTTDLPSR.F 
          699.3575 3 K.DGWYVNLGPMRLPERHR.I 
          544.2749 4 R.NEKDGWYVNLGPMRLPER.H 
          732.3638 3 K.IFLTCSQKFWEADGIHGGK.S 
          753.374 3 R.IYFAGEYTASVHGWLDSTIK.S 
          771.3777 3 R.VNTYRNEKDGWYVNLGPMR.L 
          848.741 3 R.RPLEECFREADYEEFLEIAK.N 















m/z z Peptide sequence  
 LAAO         650.0746 4 R.SSTKIFLTCSQKFWEADGIHGGK.S 
          675.8318 4 R.RRPLEECFREADYEEFLEIAK.N 
          1032.8906 3 R.VVVVGAGMAGLSAAYVLAGAGHQVTL
LEASER.V 
          779.1301 4 R.RPLEECFREADYEEFLEIAKNGLQR.T 
          813.9437 4 K.RVVVVGAGMAGLSAAYVLAGAGHQVT
LLEASER.V 







4151 59363 338.1829 2 K.SGLTAAR.D 
          412.7174 2 K.SASQLYR.E 
          439.2431 2 R.VAYQTPAK.T 
          455.7553 2 K.IFLTCTR.K 
          967.9838 2 K.TLSYVTADYVIVCSTSR.A 
          659.7053 3 K.TSADIVINDLSLIHQLPK.E 
          692.0039 3 K.FWEADGIHGGKSTTDLPSR.F 
  OXLA_ECHO
C 
Echis ocellatus  1721 56887 338.1829 2 K.SGLTAAR.D 
          728.8444 2 R.EADYEEFLEIAK.N 






181 59374 338.1829 2 K.SGLTAAR.D 
          412.717 2 K.SASQLYR.E 
          439.2431 2 R.VAYQTPAK.T 
          378.5334 3 K.YPVKPSEEGK.S 















m/z z Peptide sequence  
 LAAO         960.9717 2 K.TLSYVTADYVIVCSSSR.A 
          659.7053 3 K.TSADIVINDLSLIHQLPK.K 
          675.9966 3 R.EADYEEFLEIARNGLKK.T 
          692.0039 3 K.FWEADGIHGGKSTTDLPSR.F 
          732.0306 3 K.IFLTCSKKFWEADGIHGGK.S 
  OXLA_NAJA
T 
Naja atra 134 51805 378.5335 3 K.YPVKPSEEGK.S 
          678.306 2 R.EGWYVNMGPMR.L 
          519.2543 4 K.FWEADGIHGGKSTTDLPSR.F 





35 59116 338.1829 2 K.SGLTAAR.D 
          412.717 2 K.SASQLYR.E 
          439.2431 2 R.VAYQTPAK.T 
          378.5335 3 K.YPVKPSEEGK.S 
          678.306 2 K.EGWYVNMGPMR.L 
          659.7053 3 K.TSADIVINDLSLIHQLPK.N 
          675.9966 3 R.EADYEEFLEIARNGLKK.T 
          692.0039 3 K.FWEADGIHGGKSTTDLPSR.F 





35 59069 338.1829 2 K.SGLTAAR.N 
          412.7174 2 K.SASQLYR.E 
          439.2431 2 R.VAYQTPAK.T 
          455.7553 2 K.IFLTCTR.K 
          378.5335 3 K.YPVKPSEEGK.S 
          678.306 2 K.EGWYVNMGPMR.L 















m/z z Peptide sequence  
 LAAO         675.9976 3 R.EADYEEFLEIARNGLKK.T 





2422 13798 368.6946 2 K.KGCFPK.L 
          455.7545 2 K.LTLYSWK.C 
          825.9052 2 -.NLIQFGNMIQCANK.G 
          590.8919 3 R.CCQTHDNCYEQAGK.K 
          1070.7892 3 K.GSRPSLDYADYGCYCGWGGSGTPVDEL
DR.C 
          993.8044 5 K.GSRPSLDYADYGCYCGWGGSGTPVDEL
DRCCQTHDNCYEQAGK.K 
  PA2A_PSEAU Pseudechis 
australis  
2396 13815 763.84 2 K.ATYNDANWNIDTK.T 
          825.9052 2 -.NLIQFGNMIQCANK.G 
          1055.9863 2 K.LTLYSWDCTGNVPICSPK.A 
          577.0459 4 -.NLIQFGNMIQCANKGSRPTR.H 
          784.3358 3 K.AECKDFVCACDAEAAKCFAK.A 
          899.0272 3 R.HYMDYGCYCGWGGSGTPVDELDR.C 






2365 13755 368.6948 2 K.KGCFPK.L 
          455.7545 2 K.LTLYSWK.C 
          825.9052 2 -.NLIQFGNMIQCANK.G 
          590.8919 3 R.CCQVHDNCYEQAGK.K 
          592.9332 3 K.SFVCACDAAAAKCFAK.A 
          857.7364 3 K.LTLYSWKCTGNVPTCNSKPGCK.S 
















m/z z Peptide sequence  






2365 13758 368.6946 2 K.KGCFPK.L 
          455.7554 2 K.LTLYSWK.C 
          847.4113 2 -.NLIQFGNMIQCANK.G 
          590.8919 3 R.CCQVHDNCYEQAGK.K 
          592.9332 3 K.SFVCACDAAAAKCFAK.A 
          1070.4624 3 K.GSRPSLNYADYGCYCGWGGSGTPVDEL
DR.C 
          993.2065 5 K.GSRPSLNYADYGCYCGWGGSGTPVDEL
DRCCQVHDNCYEQAGK.K 
  PA2B_PSEAU Pseudechis 
australis  
2065 13914 840.9121 2 -.NLIQFSNMIQCANK.G 
          1069.5042 2 K.LTLYSWDCTGNVPICNPK.T 
          915.0941 3 K.GCYPKLTLYSWDCTGNVPICNPK.T 






1875 13816 368.6946 2 K.KGCFPK.L 
          840.9117 2 -.NLIQFSNMIQCANK.G 
          1069.5042 2 K.LTLYSWDCTGNVPICNPK.S 





84 14216 622.2501 3 R.SWWHFANYGCYCGR.G 
  PA2NA_NAJS
P 




















m/z z Peptide sequence  
 PLA2 PA2C_PSEPO Pseudechis 
porphyriacus  





41 13899 368.6948 2 K.KGCFPK.L 
          455.7554 2 K.LTLYSWK.C 










5295 70323 331.1765 2 K.VCINR.Q 
          725.3661 2 K.CPIMTNQCIALK.G 
          638.2568 3 R.NGHPCQNNQGYCYNGK.C 
          1338.0183 2 K.DDCDLPESCTGQSAECPTDSFQR.N 
          983.0798 3 R.AAKDDCDLPESCTGQSAECPTDSFQR.N 
          836.3613 4 R.NGHPCQNNQGYCYNGKCPIMTNQCIALK
.G 






3809 70663 331.1765 2 K.VCINR.Q 
          638.2568 3 R.NGHPCQNNQGYCYNGK.C 
          714.2752 3 K.LQHEAQCDSGECCEQCK.F 
          604.2468 4 K.LQHEAQCDSGECCEQCKFK.K 
          1338.0183 2 K.DDCDLPESCTGQSAKCPTDSFQR.N 





3805 70476 331.1765 2 K.VCINR.Q 
          638.2568 3 R.NGHPCQNNEGYCYNGK.C 















m/z z Peptide sequence  
 SVMP         982.7449 3 R.AAKDDCDLPESCTGQSAKCPTDSFQR.N 
  VM3A_NAJA
T 
Naja atra 28 70376 638.2568 3 R.NGHPCQNNQGYCYNGK.C 
          901.6956 3 K.DDCDLPEFCTGQSAECPTDSLQR.N 





22 70412 604.2468 4 K.LQHEAQCDSGECCEKCKFK.G 
          853.387 3 K.MSPGLCFMLNWNARSCGLCRK.E 
3FTx 3SA1_NAJME Naja 
melanoleuca  
1996 7133 726.8196 2 K.NLCYQMYMVSK.S 
  3L22_NAJME Naja 
melanoleuca 
43 8337 825.0401 3 R.CFITPDVTSQICADGHVCYTK.T 




Naja haje haje  26 7484 954.0709 3 -.FTCFTTPSDTSETCPDGQNICYEK.R 
PLB PLB_DRYCN Drysdalia 
coronoides  
509 64404 704.3614 2 K.FTAYAINGPPVEK.G 
          732.8271 2 K.YGLDFSYEMAPR.A 
          503.5822 3 K.GYWPSYNIPFHK.V 
          546.2799 3 R.KGYWPSYNIPFHK.V 
          575.2984 3 K.NVITEQKVKDFMQK.Q 
          945.9301 2 K.QNSGTYNNQYMILDTK.K 
          633.9729 3 R.IANMMADSGKTWAQTFK.K 
          1004.4435 2 R.QDLYYMTPVPAGCYDSK.V 
          676.6726 3 R.IANMMADSGKTWAQTFKK.Q 
          1037.2015 3 R.SIEDGTLYIIEQVPNLVEYSDQTTILR.K 
          1079.9027 3 R.SIEDGTLYIIEQVPNLVEYSDQTTILRK.G 




















96 68601 1062.0481 2 R.AILQSGGPNAPWATVTPAESR.G 
          834.093 3 R.VGAFGFLGLPGSPEAPGNMGLLDQR.L 
          934.7877 3 R.EALDDIVGDHNVICPVVQFANDYAK.R 






75 27595 874.9186 2 R.LWNSYCTTTQTFVK.A 
VF VCO3_NAJK
A 
Naja kaouthia 62 18594
0 
802.3958 2 K.GDNLIQMPGAAMKIK.L 
























4364 8337 658.7599 2 K.TWCDNFCASR.G 
          1000.5186 2 R.VDLGCAATCPTVKPGVNIK.C 
          719.3811 3 K.RVDLGCAATCPTVKPGVNIK.C 
          1236.5363 2 R.CFITPDVTSQICADGHVCYTK.T 
          686.0652 4 -.IRCFITPDVTSQICADGHVCYTK.T 
          1257.2058 3 R.CFITPDVTSQICADGHVCYTKTWCDNFCA
SR.G 




Naja haje haje  3289 7484 1430.5972 2 -.FTCFTTPSDTSETCPDGQNICYEK.R 





3207 7133 317.1548 2 K.TCPAGK.N 
          322.7024 2 K.STIPVK.R 
          323.7101 2 K.SSLLVK.Y 
          332.1595 2 -.LECNK.L 
          389.2528 2 K.LVPIAHK.T 
          400.753 2 K.STIPVKR.G 
          474.7175 2 R.GCIDVCPK.S 
          544.2174 2 K.YVCCNTDR.C 
          552.7678 2 K.RGCIDVCPK.S 















m/z z Peptide sequence  
 3FTx         726.8194 2 K.NLCYQMYMVSK.S 
  3L27_NAJS
P 





444 7255 344.7026 2 R.GTIIER.G 
          414.6903 2 K.QWSDHR.G 
          432.6888 2 R.GCGCPSVK.K 
          319.4944 3 K.KQWSDHR.G 
          520.2183 2 K.INCCTTDR.C 
          615.2497 2 K.TCPGETNCYK.K 
          453.2005 3 K.TCPGETNCYKK.Q 
          714.2749 2 K.INCCTTDRCNN.- 
          499.9218 3 K.QWSDHRGTIIER.G 
          542.6204 3 K.KQWSDHRGTIIER.G 





295 7995 520.7737 2 R.FYEGNLLGK.R 
          620.7621 2 R.EIVECCSTDK.C 
          659.3053 2 R.GCAATCPEAKPR.E 
          826.3291 2 R.EIVECCSTDKCNH.- 
          871.4073 2 -.LTCLICPEKYCNK.V 
          448.7146 4 K.VHTCRNGENICFKR.F 
  3SAT_NAJ
AT 
Naja atra 273 7262 317.1548 2 K.TCPAGK.N 
          323.7101 2 K.SSLLVK.Y 
          474.7175 2 R.GCIDVCPK.S 















m/z z Peptide sequence  
 3FTx         552.7678 2 K.RGCIDVCPK.S 
          681.7461 2 K.YVCCNTDRCN.- 
          1053.0149 2 K.NLCYKMFMVSNKMVPVK.R 
  3S11_NAJS
A 
Naja samarensis  213 7269 344.7025 2 R.GTIIER.G 
          520.2183 2 K.LNCCTTDR.C 
          714.2764 2 K.LNCCTTDRCNN.- 
  3SA2_NAJN
A 
Naja naja 195 7215 317.1548 2 K.TCPAGK.N 
          323.7095 2 K.SSLVLK.Y 
          474.7175 2 R.GCIDVCPK.S 
          544.2174 2 K.YVCCNTDR.C 
          552.767 2 K.RGCIDVCPK.S 
          681.7461 2 K.YVCCNTDRCN.- 
  3SA6_NAJA
T 
Naja atra 195 9708 323.7095 2 K.SSLLVK.Y 
          474.7175 2 R.GCIDVCPK.S 
          544.2183 2 K.YVCCNTDR.C 
          552.767 2 K.RGCIDVCPK.S 
          707.0175 3 K.NLCYKMFMVAAQRFPVK.R 
  3SAFD_NAJ
AT 
Naja atra 176 7104 323.7095 2 K.SSLLVK.Y 
          474.7175 2 R.GCINVCPK.S 
          552.7678 2 K.RGCINVCPK.S 
  3SA1A_NAJ
AT 
Naja atra  169 9483 317.1548 2 K.TCPAGK.N 
          474.7162 2 R.GCIDVCPK.N 















m/z z Peptide sequence  
 3FTx         681.7461 2 K.YVCCNTDRCN.- 
          1062.5083 2 K.NLCYKMFMMSDLTIPVK.R 
  3SA7_NAJS
P 
Naja sputatrix  169 7513 317.1548 2 K.TCPAGK.N 
          474.7175 2 R.GCIDVCPK.N 
          544.2183 2 K.YVCCNTDR.C 
          552.7678 2 K.RGCIDVCPK.N 
          681.7461 2 K.YVCCNTDRCN.- 
          1062.5083 2 K.NLCYKMFMMSNKTVPVK.R 
  3NO27_NAJ
NA 
Naja naja 156 8202 620.7621 2 R.EIVQCCSTDK.C 
          439.8727 3 R.GCAATCPEAKPR.E 
  3SUC1_NAJ
KA 
Naja kaouthia 143 7817 432.6886 2 R.GCAATCPK.L 
          1091.8374 3 K.FLFSETTETCPDGQNVCFNQAHLIYPGK.Y 






133 7302 323.7101 2 K.SSLLVK.Y 
          395.7439 2 K.GTLKFPK.K 
          432.6888 2 R.GCAATCPK.S 
  3NO26_NAJ
NA 
Naja naja 105 8133 620.7621 2 R.EIVQCCSTDK.C 
          826.3291 2 R.EIVQCCSTDKCNH.- 
          871.4073 2 -.LTCLICPEKYCNK.V 
  3SA2A_NAJ
NA 
Naja naja 66 7162 332.1595 2 -.LQCNK.L 















m/z z Peptide sequence  
3FTx          552.7678 2 K.RGCIDVCPK.N 
  3S12_NAJN
I 
Naja nivea 57 7427 344.7025 2 R.GTIIER.G 
          432.6888 2 R.GCGCPSVK.K 
          615.2482 2 K.TCPGETNCYK.K 
          453.2005 3 K.TCPGETNCYKK.R 
          775.0864 4 -.MICHNQQSSQRPTIKTCPGETNCYK.K 
  3S12_NAJH
A 
Naja annulifera 57 7366 344.7025 2 R.GTIIER.G 
          432.6888 2 R.GCGCPSVK.K 
          615.2497 2 K.TCPGETNCYK.K 
          453.2005 3 K.TCPGETNCYKK.R 
          1014.4067 3 -.MICHNQQSSQPPTIKTCPGETNCYK.K 
  3S11_NAJH
A 
Naja annulifera 57 7295 432.6888 2 R.GCGCPSVK.K 
          615.2497 2 K.TCPGETNCYK.K 
          453.2005 3 K.TCPGETNCYKK.R 
          900.8849 2 -.LECHNQQSSQPPTTK.T 
  3S1A1_NAJ
SP 
Naja sputatrix  56 9727 432.6888 2 R.GCGCPSVK.K 
          863.8488 2 K.GIEINCCTTDRCNN.- 
  3S11_NAJP
A 
Naja pallida 56 7246 344.7025 2 R.GTIIER.G 
          615.2497 2 K.TCPGETNCYK.K 
          453.2005 3 K.TCPGETNCYKK.V 




















m/z z Peptide sequence  





36 6985 900.8849 2 -.MICYNQQSSQPPTTK.T 
          972.3972 3 -.MICYNQQSSQPPTTKTCSEGQCYK.K 
  3S13_NAJS
P 
Naja sputatrix 30 7409 432.6888 2 R.GCGCPSVK.N 















10597 14149 353.6906 2 R.APYIDK.N 
          454.7229 2 R.VAANCFAR.A 
          419.8653 3 K.NMIHCTVPNR.S 
          595.2321 3 R.CCQIHDNCYGEAEK.I 
          605.2994 3 R.APYIDKNYNIDFNAR.C 
          622.2495 3 R.SWWHFANYGCYCGR.G 
          723.0563 4 R.CCQIHDNCYGEAEKISGCWPYIK.T 
          1029.7709 3 K.NMIHCTVPNRSWWHFANYGCYCGR.G 
          1094.0862 3 K.TYTYDSCQGTLTSCGAANNCAASVCDCD
R.V 
          970.9336 4 -.NLYQFKNMIHCTVPNRSWWHFANYGCYC
GR.G 
          1015.7131 4 R.GGSGTPVDDLDRCCQIHDNCYGEAEKISG
CWPYIK.T 
          1043.6749 4 K.TYTYDSCQGTLTSCGAANNCAASVCDCD
RVAANCFAR.A 




















3504 14216 454.7229 2 R.VAANCFAR.A 
          607.2232 2 K.CAASVCDCDR.V 
          595.2321 3 R.CCQIHDNCYGEAEK.I 
          622.2495 3 R.SWWHFANYGCYCGR.G 
          701.6238 3 K.CAASVCDCDRVAANCFAR.A 
          1078.4476 2 K.TYTYESCQGTLTSCGANNK.C 
          723.0563 4 R.CCQIHDNCYGEAEKISGCWPYIK.T 
          775.0879 4 K.NMIQCTVPNRSWWHFANYGCYCGR.G 
          1117.4486 3 K.TYTYESCQGTLTSCGANNKCAASVCDCDR
.V 
          973.4381 4 -.NLYQFKNMIQCTVPNRSWWHFANYGCYC
GR.G 
          1015.7131 4 R.GGSGTPVDDLDRCCQIHDNCYGEAEKISG
CWPYIK.T 




Naja sputatrix 2399 17034 622.2471 3 R.SWWHFADYGCYCGR.G 





419 14262 454.7229 2 R.VAANCFAR.A 
          607.2232 2 K.CAASVCDCDR.V 
          856.3667 2 K.TYTYESCQGTLTCK.D 
          673.6379 3 K.CYDEAEKISGCWPYIK.T 
          701.6238 3 K.CAASVCDCDRVAANCFAR.A 
          740.8244 4 R.CCQIHDKCYDEAEKISGCWPYIK.T 















m/z z Peptide sequence  











131 13673 823.8873 2 -.NLYQFGGMIQCANK.G 
          595.2321 3 R.CCQIHDNCYGEAEK.K 
  PA2A4_NAJ
SG 





68 13816 1069.5065 2 K.LTLYSWDCTGNVPICNPK.S 
CRISP CRVP1_NA
JAT 





280 27764 748.2969 2 K.SKCPASCFCHNK.I 
          611.6387 3 R.AWTEIIQLWHDEYK.N 
  CRVP2_NA
JKA 
Naja kaouthia 193 27111 516.1959 2 K.CAASCFCR.T 





174 27944 933.4592 3 K.NFVYGVGANPPGSMIGHYTQIVWYK.S 





166 27310 1276.125 2 K.YLYVCQYCPAGNIIGSIATPYK.S 






166 27311 726.8194 2 K.QTGCQNTWIQSK.C 















m/z z Peptide sequence  
 CRISP CRVPB_NA
JHA 
Naja annulifera 50 3608 584.7634 2 -.NVDFNSESTR.R 
          442.2125 3 -.NVDFNSESTRR.K 
          662.8157 2 -.NVDFNSESTRR.K 
          560.6417 3 K.EIVDLHNSLRRNVD.- 
SVMP VM3H_NAJ
AT 
Naja atra 136 71416 578.2184 2 K.CGDGMVCSNR.Q 
          848.3706 2 K.VYEMINTMNMIYR.R 




Naja kaouthia 76 69841 578.2184 2 K.CGDGMVCSNR.Q 
          848.3706 2 K.VYEMINTMNMIYR.R 




Naja kaouthia 44 46174 641.3285 2 R.VYEMINAVNTK.F 
          560.643 3 K.FEVKPAASVTLKSFR.E 




Naja kaouthia 76 18594
0 
527.8106 2 R.IDVPLQIEK.A 
          669.327 2 K.VNDDYLIWGSR.S 







1027.5355 2 R.VDMNPAGGMLVTPTIKIPAK.E 
          1111.549 2 R.IEEKDGNDIYVMDVLEVIK.G 
          976.2033 3 R.KNIVTVIELDPSVKGVGGTQEQTVVANK.L 















m/z z Peptide sequence  
VESP VESP_NAJ
KA 
Naja kaouthia 165 12087 457.23 2 -.SPPGNWQK.A 
          360.194 3 R.SGKHFFEVK.Y 
          670.7029 3 R.LVPEERIWQKGLWWLG.- 
          757.7111 3 K.ADVTFDSNTAFESLVVSPDKK.T 






28 68601 834.0909 3 R.VGAFGFLGLPGSPEAPGNMGLLDQR.L 
WAP WAPN_NAJ
NG 

















 m/z z Peptide sequence 
DIS  VM2D3_BITAR Bitis arietans  3150 9856 492.688 2 R.CCNAATCK.L 
          501.69 2 K.SSDCPWNH.- 
          684.267 3 K.LTPGSQCSYGECCDQCK.F 
          1041.09 3 -.SPPVCGNELLEEGEECDCGSPANCQDR.C 
          1349.88 3 -.SPPVCGNELLEEGEECDCGSPANCQDRCCNAATC
K.L 
  DIDB_CERVI Cerastes 
vipera 
194 7584 496.878 3 K.RGEHCISGPCCR.N 
          590.929 3 -.NSAHPCCDPVTCKPK.R 
  VM2_BITAR Bitis arietans  179 9796 332.166 2 K.AGTVCR.I 
          429.71 2 -.SPPVCGNK.I 
          492.688 2 R.CCNAATCK.L 
          501.69 2 K.SSDCPWNH.- 
  DID5B_ECHOC Echis 
ocellatus  
162 7707 590.929 3 -.NSAHPCCDPVTCQPK.K 
  DID2_BITGA Bitis gabonica 64 14404 496.88 3 K.RGEHCISGPCCR.N 
          729.303 3 K.TMLDGLNDYCTGVTPDCPR.N 
CTL SLB2_MACLB Macrovipera 
lebetina 
160 16969 367.215 2 K.VFDKPK.S 
          914.396 2 K.AWAEESYCVYFSSTK.K 
          967.5 2 K.LVSQTLESQILWMGLSK.V 
  SLA_BITAR Bitis arietans  127 15324 431.255 2 K.LASQTLTK.F 
          890.951 2 K.EEADFVTKLASQTLTK.F 













m/z z Peptide sequence  
 CTL SLA1_MACLB Macrovipera 
lebetina 
80 18226 439.698 2 K.TWEDAEK.F 
          846.427 2 K.KEANFVAELVSQNIK.E 
  SLB_BITAR Bitis arietans  76 15188 375.231 2 K.VFKVEK.T 
          410.695 2 K.TWADAEK.F 
          728.805 2 -.DEGCLPDWSSYK.G 
  SL3_BITGA Bitis gabonica 57 18483 439.698 2 K.TWEDAEK.F 
          777.809 2 K.EQQCSSEWNDGSK.V 
  SL2_BITGA Bitis gabonica 48 18602 353.673 2 R.AFDEPK.R 
          846.427 2 K.EEADFVAQLISDNIK.S 
CRISP CRVP_PROMU Protobothrops 
mucrosquamat
us 
1374 27583 993.931 2 R.YFYVCQYCPAGNMIGK.T 
  CRVP_VIPBE Vipera berus  69 27404 993.931 2 K.YFYVCQYCPAGNMQGK.T 
SVSP VSPP_CERCE Cerastes 
cerastes  
257 28583 607.796 2 K.VFDYTDWIR.N 
  VSP2_MACLB Macrovipera 
lebetina 
114 29559 797.384 2 R.TLCAGILQGGIDSCK.V 
  VSP1_BITGA Bitis gabonica 109 29648 696.353 3 R.FHCAGTLLNKEWVLTAAR.C 
  VSP13_TRIST Trimeresurus 
stejnegeri 
44 29118 557.946 3 K.NHTQWNKDIMLIR.L 
  VSP2_PROEL Protobothrops 
elegans 
37 26259 424.487 4 K.NYTKWNKDIMLIR.L 
SVMP VM3H_NAJAT Naja atra  84 71416 578.219 2 K.CGDGMVCSNR.Q 
























35 70832 402.699 2 K.GMVDPGTK.C 
          983.694 4 R.LYCFDNLPEHKNPCQIYYTPSDENKGMVDPGTK.
C 
VEGF TXVE_BITAR Bitis arietans  2821 17126 439.919 3 K.IFRPSCVAVLR.C 
          686.878 2 R.TVELQVMQVTPK.T 
          768.394 2 R.ETLVSILEEYPDK.I 
          405.438 4 K.FREHTACECRPR.S 
          622 3 R.ETLVSILEEYPDKISK.I 
          791.436 4 R.ETLVSILEEYPDKISKIFRPSCVAVLR.C 
LAAO OXLA_DABRR Daboia 
russelii 
43 57251 979.951 2 R.FDEIVGGMDQLPTSMYR.A 
          1008.99 2 K.LNEFVQETENGWYFIK.N 
  OXLA_GLOBL Gloydius 
blomhoffii 
40 57455 979.951 2 R.FDEIVGGMDKLPTSMYR.A 
CYS CYT_BITAR Bitis arietans  3452 12841 665.874 2 R.VVEAQSQVVSGVK.Y 
          902.932 2 R.DVTDPDVQEAAAFAVEK.Y 
          645.341 3 R.FEVWSRPWLPSTSLTK.- 
          1546.73 3 K.GYQEIQNCNLPPENQQEEITCRFEVWSRPWLPSTS
LTK.- 
PLA2 PA2BA_PSEAU Pseudechis 
australis  
80 13816 1069.5 2 K.LTLYSWDCTGNVPICNPK.S 
  PA2A3_PSEAU Pseudechis 
australis 
32 13941 825.906 2 -.NLIQFGNMIQCANK.G 
KUN VKT3_BITGA Bitis gabonica  171 17763 973.928 2 K.CEVFIYGGCPGNANNFK.T 
          1008.43 3 R.FYYDSASNKCEVFIYGGCPGNANNFK.T 
 
